Conditions: Multiple System Atrophy
Keywords: Multiple System Atrophy (MSA)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 421
Healthy volunteers: no

Brief summary:
The purpose of this study is to compare the efficacy of verdiperstat (BHV-3241) versus placebo in participants with Multiple System Atrophy

Detailed description:

Arms:
arm 1: Participants received verdiperstat 300 mg tablet orally once daily for 1 week, followed by 300 mg twice daily for 1 week, and then 600 mg twice daily for the remaining 46 weeks of the double-blind phase.

Participants who completed the double-blind phase were offered the opportunity to enroll in an open-label extension (OLE) phase to continue verdiperstat 600 mg twice daily for 48 weeks. arm 2: Participants received placebo matching with verdiperstat for 48 weeks. Participants who completed the double-blind phase were offered the opportunity to enroll in an OLE phase to receive verdiperstat 600 mg tablet orally twice daily for 48 weeks.

Interventions: intervention 1: Verdiperstat intervention 2: Placebo
Intervention descriptions: intervention 1: 300mg 2 oral tablets, twice daily intervention 2: Matching placebo

Protocol document:
Prot_000.pdf: 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa g e 1 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
D R U G:
B H V- 3 2 4 1
S T U D Y N U M B E R:
B H V 3 2 4 1- 3 0 1
P R O T O C O L TI T L E:
Ra n d o mize d, D o u ble- Bli n d, Plac e b o- C o ntr olle d, 
Parallel- Gr o u p St u d y t o E val uat e t he Efficac y a n d S afet y 
of B H V- 3 2 4 1 i n S u bjects wit h M ulti ple S yste m Atr o p h y 
( M- S T A R St u d y)
I N D N U M B E R:
E u dr a C T N U M B E R:
1 0 7, 3 9 8
2 0 1 9- 0 0 1 1 0 0- 3 8
S P O N S O R:
Bi o ha ve n P har m ace uticals, I nc
2 1 5 C h urc h Street
Ne w Ha ve n, C T 0 6 5 1 0
U S A
O RI GI N A L P R O T O C O L 
D A T E:
1 9 Dec 2 0 1 8
V E R SI O N N U M B E R:
V 0 7
V E R SI O N D A T E:
2 0 J a n 2 0 2 1


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa g e 2 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
S U M M A R Y O F C H A N G E S
V ersi o n N u m ber
Brief des cri pti o n s u m m ar y of c h a n ges
D ate
Versi o n 0 1 
Ori gi nal Draft
N ot A p plic a ble
1 9 De c 2 0 1 8
Versi o n 0 2
A d mi nistrati ve u p dates, refi ne me nt of i ncl usi o n criteri a, a n d 
assess me nt s c he d ule pri or t o E C s u b missi o n.
1 5 Ja n 2 0 1 9
Versi o n 0 3
M o dific ati o n of Pri mar y a n d Sec o n d ar y O bjecti ves a n d 
E n d p oi nts, a d diti o n of P GI- S, refi ne me nt of eli gi bilit y 
criteria a n d d ose m o dific ati o n g ui deli nes, a d diti o n of W ee k 
4 8 p h o n e c all, a d diti o n of B e n efit/ Ris k se cti o n, 
a d mi nistrati ve clarifi cati o ns/ u p dates.
1 8 A pr 2 0 1 9
Versi o n 0 3. 1
U K c o u ntr y s pe cific a me n d me nt- m o dificati o ns p er re q uest 
of M H R A
2 2 N o v 2 0 1 9
Versi o n 0 3. 2
Fra n ce c o u ntr y s pe cific a me n d me nt- m o dificati o ns per 
re q uest of A N S M
0 2 D ec 2 0 1 9
Versi o n 0 3. 3
Ger ma n y c o u ntr y s p ecific a m e n d me nt- m o dificati o ns p er 
re q uest of Bf Ar M
1 8 D ec 2 0 1 9
Versi o n 0 4
O nl y s u b mitt e d t o U S sites -M o dific ati o n of U M S A R S 
a nal ysis per F D A, f urt her refi ne me nt of eli gi bilit y criteria 
a n d clarifi cati o n of pr o hi bite d/restricte d c o nc o mita nt 
me dicati o ns /ti mi n g of re q uire d w as h o ut f or pr o hi bit e d 
me dicati o ns t o a d dress li mitati o ns i n t his rare dise as e 
p o p ulati o n of ver y ill patie nts wit h m ulti ple c o m or bi dities, 
s pecificati o n of o pti o n t o R es cre e n patie nts, i nc or p orati o n of 
A d mi nistrati ve Letter s 1, 2 a n d 3 t o u p d ate 
 me dic al 
m o nit or i nf or mati o n a n d clarif y I P st ora ge te m perat ure a n d 
e xc ursi o n re p orti n g, a n d a d mi nistrati ve 
clarificati o ns/ u p dates.
2 0 N o v 2 0 1 9
Versi o n 0 5
C o ns oli dati o n of c o u ntr y s pecific pr ot oc ol versi o ns 3. 1, 3. 2, 
a n d 3. 3 wit h v ersi o n 4. 0.
3 1 Ja n 2 0 2 0
Versi o n 0 6
1 6 J ul 2 0 2 0
Versi o n 0 7
2 0 Ja n 2 0 2 1
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa g e 3  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
B H V 3 2 4 1- 3 0 1 
R A N D O MI Z E D, D O U B L E- B LI N D, P L A C E B O- C O N T R O L L E D, 
P A R A L L E L- G R O U P S T U D Y T O E V A L U A T E T H E E F FI C A C Y A N D 
S A F E T Y O F B H V- 3 2 4 1 I N S U B J E C T S WI T H M U L TI P L E S Y S T E M 
A T R O P H Y ( M- S T A R S T U D Y)
C O N FI D E N TI A LI T Y A N D I N V E S TI G A T O R S T A T E M E N T 
T he i nf or m ati o n c o ntai ne d i n t his pr ot oc ol a n d all ot her i nf or mati o n rele va nt t o B H V- 3 2 4 1 are 
t he c o nfi d e nti al a n d pr o pri etar y i nf or mati o n of Bi o h a ve n P har ma ce uticals, I nc., a n d e xc e pt as 
ma y be re q uire d b y fe der al, state or l o cal la ws or re g ulati o n, ma y n ot b e dis cl ose d t o ot hers 
wit h o ut pri or writte n per missi o n of Bi o ha v e n P har m ace uticals, I nc.
I ha ve rea d t he pr ot oc ol, i ncl u di n g all a p p e n dic es, a n d I a gree t h at it c o ntai ns all of t he 
necessar y i nf or m ati o n f or m e a n d m y st aff t o c o n d u ct t his st u d y as des cri b e d. I will c o n d uct 
t his st u d y as o utli n e d herei n, i n acc or da nce wit h t h e re g ulati o ns state d i n t he Fe d eral C o de of 
Re g ulati o ns f or G o o d Cli nic al Practices a n d I nter nati o nal C o nfere n ce o n Har m o ni zati o n 
g ui deli n es, a n d will ma ke a reas o na bl e eff ort t o c o m plete t he st u d y wit hi n t he ti m e desi g nate d.  
I will pr o vi de all st u d y p ers o n nel u n der m y s u per visi o n c o pies of t he pr ot oc ol a n d a n y 
a me n d m e nts, a n d access t o all i nf or m ati o n pr o vi de d b y Bi o ha ve n P har m ace uticals, I nc. or 
s pecifie d d esi g nees. I will disc uss t he materi al wit h t he m t o e ns ure t hat t he y are f ull y i nf or me d 
a b o ut B H V- 3 2 4 1 a n d t he st u d y. 
 
 
 
 
 
 
 
 
 
 
 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa g e 4 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
S T U D Y S U M M A R Y ( S Y N O P SI S)
 
M ulti ple-s yste m atr o p h y ( M S A) is a n a d ult- o ns et, fat al ne ur o de g e nerati ve 
dis eas e t hat is c har acterize d p at h ol o gicall y b y oli v o p o nt ocere b ell ar a n d 
striat o ni gr al atr o p h y, ne ur o de ge n erati ve c h a n ges affe cti n g t h e ce ntral 
a ut o n o mi c ner v o us s yste m, a n d t he prese nc e of glial c yt o plas mic i n cl usi o ns 
-s y n ucl ei n pr ot ei n i n oli g o de n dr oc yt es. T h e
f or mati o n of G CIs is ass ociate d wit h o xi dati ve stress, ne ur oi nfla m mati o n, l oss 
of ne ur otr o p hic s u p p ort, a n d ulti matel y ne ur o n al c ell deat h.
M yel o per o xi das e ( M P O) is a n e nz y me t hat ge ner ates c yt ot o xi c o xi da nts a n d 
acts as a ke y dri ver of o xi dati ve a n d ne ur oi nfla m mat or y pr ocesses t hat 
u n derlie n e ur o de ge ner ati o n. T he l e vels of M P O are si g nific a ntl y i ncre as e d i n 
acti v ate d i m m u n e cells, s uc h as micr o glia, i n brai ns fr o m M S A patie nts, a n d 
t hese el e vati o ns i n M P O are belie v e d t o pr o m ote ne ur o de ge nerati o n. B y 
i n hi biti n g M P O acti vit y, t her e b y re d uci n g t he ge n erati o n of c yt ot o xic 
o xi dizi n g s pecies, B H V- 3 2 4 1 has t he p ot e ntial t o sl o w t he pr o gressi o n of 
ne ur o de ge nerati o n i n M S A.
I n a m o us e m o del of M S A, treat m e nt wit h B H V- 3 2 4 1 was f o u n d t o ha ve 
ne ur o pr otecti ve effects, i n cl u di n g t he f oll o wi n g: s u p pressi o n of micr o glial 
acti v ati o n ( n e ur oi nfla m mati o n); r e d ucti o n of al p h a-s y n uclei n p at h ol o g y; 
ne ur o pr otecti o n i n s e v eral brai n re gi o ns aff ect e d i n M S A, i ncl u di n g s u bsta ntia 
ni gra a n d stri atal pr ojecti o n ne ur o ns; a n d be nefici al effects o n m ot or f u n cti o n.
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa g e 5  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
 
 
 
 
 
 
 
 T o e val u ate t he effi cac y of B H V- 3 2 4 1, c o m p are d t o place b o, as meas ure d 
b y a c ha n ge fr o m bas eli n e i n a m o difi e d U nifie d M S A Rati n g Scal e 
( U M S A R S), c o nsisti n g of a s u bset of ite ms fr o m Part I a n d P art II, at 
Wee k 4 8. 
 T o assess t he safet y a n d t olera bilit y of B H V- 3 2 4 1, relati v e t o pl ace b o, i n 
s u bjects wit h M S A. 
 
 T o e val u ate t he effi cac y of B H V- 3 2 4 1, c o m p are d t o place b o, as meas ure d 
b y t he Cli nical Gl o bal I m pressi o n of I m pr o ve m e nt ( C GI-I) s c ore at Wee k 
4 8. 
 T o e val u ate t he i m pact of B H V- 3 2 4 1 o n q ualit y of life, c o m par e d t o 
place b o, as meas ure d b y a c ha n ge fr o m baseli ne i n t he m ot or s u bs cal e of 
t he M S A- Q ualit y of Lif e ( M S A- Q o L) s cale at W ee k 4 8. 
 T o e val u ate t he i m pact of B H V- 3 2 4 1 o n q ualit y of life, c o m par e d t o 
place b o, as meas ure d b y a c ha n ge fr o m baseli ne i n t he n o n- m ot or s u bs cal e 
of  t he M S A- Q o L s cale at Wee k 4 8. 
 T o e val u ate t he effi cac y of B H V- 3 2 4 1, c o m p are d t o place b o, as meas ure d 
b y a c ha n ge fr o m bas eli n e i n t h e U M S A R S P art I a n d Part II t otal s c ore at 
Wee k 4 8. 
 
 T o ass ess t he i m pa ct of B H V- 3 2 4 1, relati ve t o plac e b o, as meas ure d b y a 
c ha n ge fr o m b as eli ne at W ee k 4 8 i n t he f oll o wi n g i nstr u me nts: 
 Patie nt Gl o b al I m pr essi o n of S e verit y ( P GI- S), 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa g e 6 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
Cli nic al Gl o bal I m pressi o n of Se verit y ( C GI- S),
U M S A R S Part III,
U M S A R S Part I V.
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa g e 7 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
Fi g ur e 1:
St u d y S c h e m ati c
 
 
 
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa g e 8 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
T A B L E O F C O N T E N T S
 
S U M M A R Y O F C H A N G E S  ..................................................................................................... 2 
C O N FI D E N TI A LI T Y A N D I N V E S TI G A T O R S T A T E M E N T  ............................................ 3 
S T U D Y S U M M A R Y ( S Y N O P SI S)  ........................................................................................... 4 
T A B L E O F C O N T E N T S  ........................................................................................................... 8 
LI S T O F T A B L E S  ................................................................................................................... 1 0 
LI S T O F FI G U R E S  ................................................................................................................. 1 0 
LI S T O F A B B R E VI A TI O N S  .................................................................................................. 1 1 
1  
I N T R O D U C TI O N A N D R A TI O N A L E .......................................................................... 1 5 
1. 1  
B ac k gr o u n d  ................................................................................................................... 1 5 
1. 1. 1  
M ulti ple S yste m Atr o p h y ( M S A)  .......................................................................... 1 5 
 
1. 1. 3  
B H V- 3 2 4 1  ................................................................................................................ 1 6 
 
1. 1. 5  
Cli nic al A d vers e E ve nt P r ofil e  .............................................................................. 2 9 
1. 1. 6  
P ote nti al Ris k t o Fet al De v el o p me nt  .................................................................... 3 5 
1. 2  
St u d y R ati o n ale ............................................................................................................. 3 5 
1. 2. 1  
St u d y D esi g n R ati o n ale  .......................................................................................... 3 5 
1. 3  
D ose Selecti o n  ............................................................................................................... 3 6 
1. 4  
Be n efit- Ris k ................................................................................................................... 3 7 
2  
S T U D Y O B J E C TI V E S  ..................................................................................................... 4 0 
2. 1  
Pri m ar y  ......................................................................................................................... 4 0 
2. 2  
Sec o n d ar y  ...................................................................................................................... 4 0 
 
3  
S T U D Y E N D P OI N T S  ....................................................................................................... 4 2 
3. 1  
Pri m ar y  ......................................................................................................................... 4 2 
3. 2  
Sec o n d ar y  ...................................................................................................................... 4 2 
4  
S T U D Y P L A N  ................................................................................................................... 4 3 
4. 1  
St u d y D esi g n a n d D ur ati o n  ......................................................................................... 4 3 
4. 2  
St u d y Sc he m atic  ........................................................................................................... 4 3 
4. 3  
Sc he d ule of Assess me nts  .............................................................................................. 4 4 
4. 3. 1  
C O VI D- 1 9 P u blic He alt h E mer ge nc y  .................................................................. 4 4 
4. 3. 2  
Scree ni n g P h as e  ...................................................................................................... 5 4 
4. 3. 3  
R a n d o miz ati o n P h as e  ............................................................................................. 5 4 
4. 4  
E n d of Tre at me nt  ......................................................................................................... 5 5 
4. 5  
P ost St u d y A ccess t o T her a p y/ O pe n- L a bel E xte nsi o n P h ase  ................................... 5 6 
4. 5. 1  
O pe n- L a bel E xte nsi o n P h ase Eli gi bilit y Crite ri a  ................................................ 5 6 
4. 5. 2  
O pe n- L a bel E xte nsi o n P h ase Pr oce d ures  ............................................................ 5 7 
5  
P O P U L A TI O N  .................................................................................................................. 5 8 
5. 1  
N u m ber of S u bjects  ...................................................................................................... 5 8 
5. 2  
I ncl usi o n Criteri a ......................................................................................................... 5 8 
5. 3  
E xcl usi o n Criteri a  ........................................................................................................ 6 0 
5. 4  
Pr o hi bite d a n d R estricte d C o n c o mit a nt Me dic ati o n  ................................................ 6 5 
5. 4. 1  
Ot h er R estricti o ns a n d Prec a uti o ns ...................................................................... 6 7 
5. 5  
W o m a n of C hil d be ari n g P ote nti al ( W O C B P)  ........................................................... 6 8 
C CI
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa g e 9 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
5. 6
D e vi ati o n fr o m I ncl usi o n/ E xcl usi o n Criteri a ............................................................. 6 9
6  
S T U D Y C O N D U C T A N D D E S C RI P TI O N O F S T U D Y P R O C E D U R E S  .................. 6 9 
6. 1  
St u d y M ateri als  ............................................................................................................ 6 9 
6. 2  
Eli gi bilit y a n d S afet y Ass ess me nts  .............................................................................. 6 9 
6. 2. 1  
Me dic al a n d Ps yc hi atric Hist or y ........................................................................... 6 9 
6. 2. 2  
S afet y Assess me nts  ................................................................................................. 6 9 
6. 2. 3  
Cli nic al O utc o m e Assess me nts  .............................................................................. 7 3 
6. 3  
Ot h er Ass ess me nts ........................................................................................................ 7 6 
 
6. 3. 2  
P h ar m ac o ki netic Assess me nts ............................................................................... 7 7 
 
6. 3. 5  
C S F C ollecti o n ( O pti o n al)  ..................................................................................... 7 9 
6. 4  
E arl y Dis c o nti n u ati o n fr o m t he St u d y  ....................................................................... 7 9 
7  
S T U D Y D R U G M A N A G E M E N T  ................................................................................... 8 1 
7. 1  
D es cri pti o n of St u d y D r u g  ........................................................................................... 8 1 
7. 1. 1  
I n vesti g ati o n al Pr o d uct .......................................................................................... 8 1 
7. 1. 2  
P ac k a gi n g, S hi p me nt a n d St or a ge  ........................................................................ 8 1 
7. 2  
D ose a n d A d mi nistr ati o n  ............................................................................................. 8 2 
7. 2. 1  
Met h o d of Assi g ni n g P atie nt I d e ntific ati o n  ......................................................... 8 2 
7. 2. 2  
Selecti o n a n d Ti mi n g of D ose a n d A d mi nistr ati o n  ............................................. 8 3 
7. 2. 3  
D ose M o dific ati o ns  ................................................................................................. 8 4 
7. 3  
Bli n di n g a n d U n bli n di n g ............................................................................................. 8 5 
7. 4  
Tre at me nt C o m pli a n ce  ................................................................................................ 8 6 
7. 5  
D estr ucti o n a n d R et ur n of St u d y Dr u g  ...................................................................... 8 6 
8  
A D V E R S E E V E N T S  ......................................................................................................... 8 6 
8. 1  
Seri o us A d verse E ve nts  ................................................................................................ 8 7 
8. 1. 1  
D efi niti o n of Seri o us A d verse E ve nt ( S A E)  ......................................................... 8 7 
8. 1. 2  
D efi niti o n of Ter ms  ................................................................................................ 8 7 
8. 1. 3  
Cl assific ati o n of A d vers e E ve nts  ........................................................................... 8 8 
8. 1. 4  
C ollecti o n a n d R e p orti n g S eri o us A d vers e E ve nts .............................................. 8 9 
8. 1. 5  
O ver d ose  .................................................................................................................. 9 1 
8. 1. 6  
Pre g n a nc y  ................................................................................................................ 9 1 
8. 1. 7  
P ote nti al D r u g I n d uce d Li ver I nj ur y ( DI LI)  ....................................................... 9 2 
8. 1. 8  
A d vers e E ve nt of S peci al I nterest- T h yr oi d F u n cti o n  ......................................... 9 2 
8. 2  
N o n-s eri o us A d vers e E ve nts  ........................................................................................ 9 3 
8. 2. 1  
C ollecti o n a n d R e p orti n g of N o n- Seri o us A d verse E ve nts  ................................. 9 3 
8. 2. 2  
L a b or at or y Test A b n or m alities  ............................................................................ 9 3 
9  
S T A TI S TI C S  ..................................................................................................................... 9 4 
9. 1  
Ge ner al Pr oce d ures  ...................................................................................................... 9 4 
9. 2  
S a m ple Size  ................................................................................................................... 9 4 
9. 3  
P o p ul ati o ns f or A n al ysis  .............................................................................................. 9 4 
9. 4  
St atistic al Met h o ds  ....................................................................................................... 9 5 
9. 4. 1  
D e m o gr a p hic a n d B aseli n e C h ar acteristi cs  ......................................................... 9 5 
9. 4. 2  
Pri m ar y E n d p oi nt(s)  .............................................................................................. 9 5 
9. 4. 3  
Sec o n d ar y E n d p oi nt(s)  ........................................................................................... 9 6 
C CI
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 1 0  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
9. 4. 4
E xte nsi o n P h as e A n al ysis ....................................................................................... 9 6
9. 4. 5  
A dj ust me nt f or M ulti plicit y  .................................................................................. 9 6 
9. 4. 6  
Missi n g D at a  ........................................................................................................... 9 6 
9. 4. 7  
A n al ysis of S afet y  ................................................................................................... 9 7 
9. 5  
Sc he d ule of A n al ys es  .................................................................................................... 9 7 
1 0  E T HI C S A N D R E S P O N SI BI LI TI E S  ............................................................................. 9 7 
1 0. 1  
G o o d Cli nic al P r acti ce  ................................................................................................. 9 7 
1 0. 2  
D at a M o nit ori n g C o m mittee  ....................................................................................... 9 8 
1 0. 3  
I nstit uti o n al R e vie w B o ar d/I n d e pe n d e nt Et hics C o m mittee  ................................... 9 8 
1 0. 4  
I nf or me d C o ns e nt ......................................................................................................... 9 9 
1 0. 5  
C ase R e p ort F or ms ..................................................................................................... 1 0 0 
1 0. 6
R ec or ds M a n a ge me nt a n d Rete nti o n ....................................................................... 1 0 0
1 0. 7  
S o urce D oc u me nt ati o n  ............................................................................................... 1 0 1 
1 0. 8  
St u d y Files a n d R ec or d R ete nti o n  ............................................................................ 1 0 1 
1 1  A M E N D M E N T S  ............................................................................................................. 1 0 1 
1 2  S T U D Y R E P O R T A N D P U B LI C A TI O N S  .................................................................. 1 0 2 
1 3  S T U D Y DI S C O N TI N U A TI O N  ..................................................................................... 1 0 2 
1 4  C O N FI D E N TI A LI T Y  .................................................................................................... 1 0 2 
1 5  A P P E N DI C E S  ................................................................................................................. 1 0 3 
1 5. 1  
A P P E N DI X I - N a mes of St u d y Pers o n nel ............................................................... 1 0 3 
1 6  R E F E R E N C E S CI T E D  .................................................................................................. 1 0 4 
C LI NI C A L P R O T O C O L A P P R O V A L F O R M .................................................................. 1 0 6 
 
LI S T O F T A B L E S 
T a ble 1:  
Sc he d ule of Assess me nts a n d E ve nts - R a n d o mize d D o u ble- bli n d P h as e  ... 4 7 
T a ble 2:  
Sc he d ule of Assess me nts a n d E ve nts - O pe n- L a bel E xte nsi o n P h ase  ......... 5 1 
 
LI S T O F FI G U R E S 
Fi g u re 1: 
St u d y Sc he m atic ................................................................................................. 7
Fi g u re 2:  
St u d y Sc he m atic  ............................................................................................... 4 3 
 
 
 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 1 1 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
LI S T O F A B B R E VI A TI O N S
C CI
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 1 2  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 1 3 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
C CI
C CI
C CI
C CI
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 1 4 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
 
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 1 5  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
1 I N T R O D U C TI O N A N D R A TI O N A L E 
1. 1 
B a c k gr o u n d 
Bi o ha ve n P har m ace uticals, I nc [ Bi o ha v e n] is de vel o pi n g a ne w dr u g, B H V- 3 2 4 1, als o k n o w n 
as V er di perstat, f or t he tre at m e nt of m ulti ple s yste m atr o p h y ( M S A). B H V- 3 2 4 1 is a n 
irre versi bl e i n hi bit or of t h e m yel o p er o xi das e ( M P O) e nz y me t hat g e nerat es c yt ot o xic o xi dizi n g 
a n d nitr os ylati n g c o m p o u n ds.  T he pr o p os e d st u d y is bas e d o n c u m ul ati v e precli nic al, cli ni cal, 
a n d ne ur oi m a gi n g st u di es t hat i m plicate M P O acti vit y i n t he o ns et a n d pr o gressi o n of 
ne ur o de ge nerati ve dis eas es, i ncl u di n g M S A, s u g gesti n g treat me nt wit h B H V- 3 2 4 1 has t he 
p ote nti al t o sl o w ne ur o d e ge nerati o n i n M S A. T he hi g h u n met nee d f or a n effecti v e tre at m e nt, 
t o get her wit h t he a vaila ble d ata, pr o vi de a c o m pelli n g rati o nale f or t h e de vel o p me nt of B H V-
3 2 4 1 as a treat me nt f or M S A.  
1. 1. 1
M ulti pl e S y st e m Atr o p h y ( M S A) 
M S A is a n or p ha n diseas e ( Or p ha n n u m ber: O R P H A 1 0 2 [ w w w. or p ha. net]) t hat is a n a d ult-
o ns et, fatal ne ur o de ge n erati ve dise as e 1. O nset of M S A us uall y occ urs d uri n g t he si xt h dec a de 
of life, a n d i n vari a bl y le a ds t o deat h aft er a n a v era ge of 6 t o 1 0 years fr o m s y m pt o m o nset, wit h 
t he ca us es of de at h c o m m o nl y bei n g br o nc h o p ne u m o nia, ur ose psis, a n d s u d de n deat h. N o 
dis eas e m o dif yi n g tre at m e nt c urre ntl y e xists, o nl y s y m pt o matic a n d palliati ve a p pr o ac hes ar e 
a vail a ble 1. 
T he defi ni n g ne ur o pat h ol o g y of M S A o n p ost- m orte m e xa mi nati o n i ncl u des varia ble de gr ees 
of oli v o p o nt ocere bellar atr o p h y a n d stri at o ni gr al de g e nerati o n, w hic h refl ect t he prese n ce of 
ata xi a a n d par ki ns o nis m, res pecti vel y, d uri n g lif e. I n a d diti o n, n e ur o de ge n erati v e c ha n g es 
affect t he ce ntral a ut o n o mic ner v o us s yste m, i ncl u di n g t he h y p ot hala m us, n ora dr e ner gic a n d 
s er ot o ni ner gi c brai n-st e m n ucl ei, d ors al n u cle us of t h e va g us ner ve, n ucle us a m bi g u us, 
i nter m e di ol ater al c ol u m ns of t he s pi nal c or d, a n d O n uf n ucle us. T he d efi ni n g m olec ular a n d 
cell ular ne ur o pat h ol o g y of M S A is t he wi des prea d pr es e nce of glial c yt o plas mi c i ncl usi o ns 
( G CIs) c o ntai ni n g fi brili ze
-s y n ucl ei n pr ot ei n i n oli g o de n dr oc yt es 2- 4. M S A is t h us 
-s y n uclei n o p at h y, 
eas e a n d de m e nti a wit h Le w y b o di es, 
alt h o u g h it has ver y disti nct p at h ol o gical a n d cli nic al feat ures. 
M S A is a s p ora dic dis eas e of u n k n o w n eti ol o g y. Alt h o u g h t he pat h o p h ysi ol o gic al m ec ha nis ms 
u n derl yi n g M S A re mai n u n cle ar, e vi de n ce fr o m pr ecli nic al m o d els a n d p ost- m orte m st u dies 
s u g gests t hat t he f or mati o n of G CIs is ass oci ate d wit h o xi dati v e stress, ne ur oi nfl a m m ati o n, l oss 
of ne ur otr o p hic s u p p ort, a n d ulti matel y ne ur o n al c ell deat h.  
M S A is c haracteri ze d cli nic all y b y pr o gr essi ve a ut o n o mic fail ure, p ar ki ns o nia n fe at ures, a n d 
cere bellar a n d p yr a mi d al fe at ures i n v ari o us c o m bi nati o ns 1. Patie nts wit h M S A are di vi de d 
i nt o 2 s u bt y pes base d o n t h eir pre d o mi na nt s y m pt o ms: 1) M S A- P patie nts ha ve pre d o mi na ntl y 
par ki ns o nia n feat ures; a n d 2) M S A- C pati e nts ha ve cere bellar ata xia as t he pre d o mi na nt 
s y m pt o m. Bas e d o n t h e re vis e d crit eria f or t h e dia g n osis of M S A t hat were esta blis he d at a 
c o nse ns us c o nfere nce i n 2 0 0 7 5, t he di a g n osis of M S A i ncl u des 3 cate g ori es: 1) Defi nit e M S A; 
2) Pr o ba ble M S A; a n d 3) P ossi ble M S A. As t he pre d o mi na nt f eat ur es of M S A ma y c ha n ge 
o ver ti m e, t he d esi g nati o n of M S A- P or M S A- C f or a gi ve n patie nt ma y c ha n ge d uri n g t he 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 1 6 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
c o urs e of t he dis e as e. A p pr o xi mat el y 6 0- 8 0 % of M S A patie nts i n E ur o pe a n d N ort h A m erica 
ha ve t he M S A- P s u bt y pe 6, w hereas 6 5- 8 5 % of M S A patie nts i n Ja pa n a n d K orea h a ve t h e 
M S A- C s u bt y pe 
7, 8.
M S A has a n esti mate d p oi nt pre v ale nc e of 3. 4 t o 4. 9 cas es per 1 0 0, 0 0 0, i ncre asi n g t o 7. 8 per 
1 0 0, 0 0 0 a m o n g pers o ns ol der t h a n 4 0 years of a g e 9. Cas es of M S A- P o ut n u m ber cases of 
M S A- C b y 2: 1 t o 4: 1 i n m ost c o u ntries
1 0- 1 2, wit h M S A- C bei n g m ore pre vale nt i n J a pa n 1 3 a n d 
li kel y i nfl ue n ce d b y ge netic a n d e pi g e netic fa ct ors.
1. 1. 3
B H V- 3 2 4 1
B H V- 3 2 4 1 is a n irre versi ble, mec ha nis m- base d M P O i n hi bit or t h at is h y p ot h esize d t o s u p press 
t he ge ner ati o n of c yt ot o xic o xi di zi n g a n d nitr os ylati n g c o m p o u n ds, t here b y sl o wi n g t he 
pr o gressi o n of M S A-ass ociate d ne ur o de ge ner ati o n. T he e nz y me, M P O, is a n o xi dati ve he m e 
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 1 7 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
pr otei n release d pri maril y b y acti vate d ne utr o p hils, b ut is als o e x presse d i n p h a g oc ytic cells, 
i ncl u di n g micr o glia, a n d le a ds t o t he pr o d ucti o n of h y p oc hl oric aci d, a p ote nt o xi da nt. M P O 
o xi dizes nitrit e t o re acti ve nitr o g e n s peci es a n d c o n v erts t yr osi ne t o t yr os yl ra di cal, a r eacti ve 
i nter
- dit yr osi ne f or mati o n a n d i nitiat es li pi d p er o xi dati o n. 
1. 1. 3. 1
Pr e- Cli ni c al St u di e s
S u m maries of rele va nt fi n di n gs fr o m pre- cli nical st u dies c o n d uct e d wit h B H V- 3 2 4 1 are 
pr o vi de d. Please r efer t o t h e I n vesti g at or Br oc h ur e f or a d diti o n al i nf or mati o n. 
1. 1. 3. 1. 1
Pri m ar y P h ar m a c o d y n a mi c s
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 1 8 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 1 9 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 2 0 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 2 1 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 2 2 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
1. 1. 3. 2
Cli ni c al E x p eri e n c e
T o date, se v e n cli nical st u dies (f o ur P hase 1 st u di es i n healt h y s u bj ects; t w o P hase 2 st u dies i n 
s u bject
s u bjects wit h M S A) ha ve be e n 
c o n d ucte d wit h B H V- 3 2 4 1, wit h a p pr o xi m atel y 2 3 4 s u bjects ha vi n g r ecei ve d B H V- 3 2 4 1 i n 
t hese cli nic al st u di es. Refer t o t h e I n vesti g at or Br oc h ure f or detaile d i nf or mati o n o n t hese 
st u dies. 
1. 1. 3. 2. 1
B H V- 3 2 4 1 P h a s e I 
Refer t o t h e I n vesti g at or Br oc h ure f or d etaile d i nf or mati o n o n t he P has e 1 st u di es. 
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 2 3 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 2 4 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 2 5 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 2 6 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
1. 1. 3. 2. 2. 3
St u d y D 0 4 9 0 C 0 0 0 2 3
T his P hase 2 1 2- w ee k, m ultice nter, ra n d o miz e d, parallel- gr o u p st u d y i n patie nts wit h M S A was 
desi g ne d t o ass ess t he eff ect o n s afet y, t ol era bilit y, p har mac o ki netics, mi cr o glial acti vati o n 
(assess e d b y P E T i ma gi n g), bi o mar k er effects, a n d efficac y of t w o d osa ges of B H V- 3 2 4 1 ( 3 0 0 
m g a n d 6 0 0 m g BI D). Recr uite d s u bj ects were m ale a n d fe male, 3 0 t o 8 0 y ears of a ge, 
i ncl usi ve, at Scre e ni n g, w h o met t he criteria f or di a g n osis of pr o ba ble or p ossi ble M S A 
acc or di n g t o c o ns e ns us cli nical crit eria. 5 9 s u bj ects were act u all y ra n d o miz e d a n d tr eat e d ( 1 9,
B H V- 3 2 4 1 3 0 0 m g BI D; 2 0, B H V- 3 2 4 1 6 0 0 m g BI D; a n d 2 0, plac e b o BI D); a n d 4 6 s u bjects 
c o m plete d t h e st u d y ( 1 4, B H V- 3 2 4 1 3 0 0 m g BI D; 1 7 B H V- 3 2 4 1 6 0 0 m g BI D; a n d 1 5 place b o 
BI D). 
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 2 7 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
P E T i ma gi n g: B H V- 3 2 4 1 treat me nt at eit her d osa g e ( 3 0 0 m g or 6 0 0 m g) ha d n o statisti call y 
si g nifica nt effe ct o n micr o gli al a cti v ati o n, b as e d o n c ha n ge i n t h e re gi o n al t otal distri b uti o n 
T ) meas ure d b y P E T i ma gi n g of ra di oli ga n d [1 1C]
P B R 2 8 bi n di n g t o tra nsl o cat or pr otei n. I m p orta ntl y, t he lac k of st atisticall y si g nifica nt 
differe nce bet w ee n B H V- 3 2 4 1 tre at m e nt ar ms a n d pl ace b o ar ms o n [ 1 1C] P B R 2 8 bi n di n g t o 
T S P O is n ot i nc o nsiste nt wit h a p ote ntial tre at m e nt effect i n M S A. T he relati vel y l ar ge 
treat me nt effect si ze i n St u d y D 0 4 9 0 C 0 0 0 0 4
was us e d t o 
deter mi ne t h e s a m pl e size f or t his st u d y i n patie nts wit h M S A, a n d ma y ha ve b ee n a n 
o veresti m ate. I n a d diti o n, t here are k n o w n iss ues wit h t his P E T i m a gi n g t ec h ni q u e, i ncl u di n g 
heter o ge n e o us a n d n o n-s pecifi c bi n di n g a n d si g nal-t o- n ois e rati o.
Plas ma M P O acti vit y: B H V- 3 2 4 1 treat me nt f or 1 2 wee ks (at d os es of eit her 3 0 0 m g BI D or 
6 0 0 m g BI D) s h o w e d statistic all y si g nific a nt re d ucti o ns i n meas ures of M P O acti vit y i n 
plas ma. F or s pecific M P O acti vit y ( M P O acti vit y/ M P O pr otei n), t here were statisticall y 
si g nifica nt re d ucti o ns of a p pr o xi matel y 1 0 % bet we e n bas eli ne a n d p ost- d os e ass ess me nts at 
Wee k 1 2, f or t h e B H V- 3 2 4 1 3 0 0 m g BI D a n d B H V- 3 2 4 1 6 0 0 m g BI D treat e d gr o u ps 
( p = 0. 0 1 3 8 a n d p = 0. 0 0 0 3, res pecti vel y). Pair wise c o m paris o ns bet wee n t he B H V- 3 2 4 1 treat e d 
gr o u ps a n d place b o w ere st atisticall y si g nifica nt ( p = 0. 0 1 6 6 a n d p = 0. 0 0 2 6 f or t he 3 0 0 m g BI D 
a n d 6 0 0 m g BI D gr o u ps, res pecti v el y). T hes e cli nical trial res ults s u p p ort t h e i nt e n de d 
mec ha nis m of acti o n of B H V- 3 2 4 1.
P K:
M S A s u bjects treate d wit h B H V- 3 2 4 1 3 0 0 m g BI D f or 1 2 wee ks ha d t he f oll o wi n g st ea d y 
ma x of 2. 3 8 
( C V: 4 6. 4 %). M S A s u bjects treate d wit h B H V- 3 2 4 1 6 0 0 m g BI D f or 1 2 wee ks ha d t he 
f oll o wi n g stea d y st ate, g e o metric m ea n e x p os ures: A U C of 3
C V: 4 3. 8 %) a n d 
C ma x o
V: 4 1. 6 %).
Safet y/ T olera bilit y: B H V- 3 2 4 1 treat me nt was ge n erall y safe a n d well-t olerat e d i n M S A 
s u bjects at d os es of 3 0 0 m g a n d 6 0 0 m g BI D.
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 2 8 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 2 9 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
1. 1. 5
Cli ni c al A d v er s e E v e nt Pr ofil e
T o date, a p pr o xi m atel y 2 3 4 s u bjects ha v e rec ei ve d B H V- 3 2 4 1 i n s e ve n cli ni cal st u dies: f o ur 
P hase 1 st u dies i n healt h y s u bje cts, a P hase 2 P E T i ma gi n g st u d y i n 
dis eas e ( St u d y D 0 4 9 0 C 0 0 0 0 4), a P has e 2 safet y a n d t olera bilit y st u d y i n s u bje cts wit h 
dis eas e ( St u d y D 0 4 9 0 C 0 0 0 0 5), a n d a P has e 2 P E T i m a gi n g st u d y i n s u bj ects wit h 
M S A ( St u d y D 0 4 9 0 C 0 0 0 2 3). I n t he P hase 1 st u dies, treat me nt wit h m ulti pl e d os es of u p t o 9 0 0 
m g B H V- 3 2 4 1 BI D w as ge nerall y safe a n d well t ol erate d. I n t h e P hase 2 st u dies i n s u bj ects 
dis eas e a n d M S A, treat me nt wit h B H V- 3 2 4 1 at d oses of u p t o 6 0 0 m g BI D
f or 8- 1 2 w ee ks w as ge nerall y s afe a n d well t oler ate d.
1. 1. 5. 1
B H V- 3 2 4 1 P h a s e 1 St u di e s
T o date, 4 P hase 1 st u dies ha ve b ee n c o n d ucte d wit h B H V- 3 2 4 1. Ke y safet y-relate d fi n di n gs 
fr o m t hes e st u di es are pres e nt e d bel o w.
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 3 0 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 3 1 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
1. 1. 5. 2
B H V- 3 2 4 1:  P h a s e 2 Cli ni c al A d v er s e E v e nt Pr ofil e
T o date, 3 P hase 2 st u dies ha ve b ee n c o n d ucte d wit h B H V- 3 2 4 1 . Ke y safet y-relate d fi n di n gs 
fr o m t hes e st u di es are pres e nt e d bel o w.
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 3 2 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
1. 1. 5. 2. 3
St u d y D 0 4 9 0 C 0 0 0 2 3
I n t his st u d y i n M S A patie nts, tr eat me nt wit h B H V- 3 2 4 1 ( 6 0 0 m g BI D a n d 3 0 0 m g BI D) f or 1 2 
w ee ks w as ge nerall y safe a n d w ell t oler ate d. T here were 2 deat hs i n t his st u d y d ue t o A Es of 
M S A disease pr o gressi o n ( B H V- 3 2 4 1 6 0 0 m g) a n d c h o ki n g o n f o o d ( plac e b o); b ot h e ve nts 
w ere c o nsi dere d se ver e a n d j u d g e d n ot relat e d t o B H V- 3 2 4 1. T hree s u bjects e x perie n ce d 
S A Es. O ne s u bject i n t he B H V- 3 2 4 1 3 0 0 m g tr eat e d gr o u p ha d a n S A E of fract ure d ri g ht hi p 
t hat w as c o nsi der e d se vere, j u d g e d n ot relat e d t o st u d y dr u g, a n d le d t o dis c o nti n u ati o n. T w o 
s u bjects ha d S A Es of M S A dis eas e pr o gressi o n a n d c h o ki n g w hic h l e d t o deat h (see a b o v e). 
F o ur s u bjects, 3 recei vi n g B H V- 3 2 4 1 3 0 0 m g a n d 1 recei vi n g place b o, disc o nti n ue d t h e st u d y 
d ue t o A Es. T he A Es t hat le d t o dis c o nti n uati o n of tr eat m e nt wit h B H V- 3 2 4 1 3 0 0 m g i n cl u de d 
mil d-t o- m o derate bala nce dis or der, s y nc o pe, fe eli n g jitt er y, a n d e pista xis i n 1 s u bj ect; fract ur e d 
ri g ht hi p (se v er e) i n a sec o n d s u bj ect; a n d d ys p ha gi a (se vere) i n a t hir d s u bject. T he s u bj ect 
recei vi n g place b o dis c o nti n ue d fr o m t he st u d y d ue t o ge neral disc o mf ort ( m o derat e) a n d 
hea dac h e ( mil d). All of t he e ve nts l ea di n g t o dis c o nti n uati o n, e x ce pt f or e pista xis a n d hi p 
fract ure, w ere c o nsi dere d b y t he I n vesti gat or- t o be r elat e d t o st u d y dr u g a d mi nistr ati o n. T he 
o verall i nci d e nce of T E A Es w as si milar acr oss t he tr eat m e nt gr o u ps, ra n gi n g fr o m 7 8. 9 % t o 
8 4. 2 %. T he m ost c o m m o n A E w as uri nar y tract i nfe cti o n, re p orte d wit h a hi g her i n ci de n ce i n 
t he B H V- 3 2 4 1 3 0 0- m g gr o u p ( 2 6. 3 %) t ha n i n t he B H V- 3 2 4 1 6 0 0 m g ( 1 5. 0 %) or place b o 
( 1 5. 8 %) gr o u ps. Fati g u e w as re p orte d wit h a si milar i nci de n ce i n t he B H V- 3 2 4 1 3 0 0 m g 
( 1 5. 8 %) a n d 6 0 0 m g ( 1 5. 0 %) gr o u ps, b ut wit h a l o wer i nci d e nce i n t he pl ace b o gr o u p ( 5. 3 %).
Ort h ostatic h y p ote nsi o n w as m ore fre q u e nt a m o n g s u bjects i n t he B H V- 3 2 4 1 6 0 0 m g gr o u p 
( 1 5. 0 %) t ha n i n t h e B H V- 3 2 4 1 3 0 0 m g ( 5. 3 %) a n d place b o ( 0) gr o u ps. Si milarl y, falls a n d 
pres y nc o pe e ve nts w ere m ore fre q u e nt a m o n g s u bjects i n t he B H V- 3 2 4 1 6 0 0 m g gr o u p ( 2 0. 0 % 
a n d 1 0. 0 %, res pecti vel y) t ha n i n t h e B H V- 3 2 4 1 3 0 0 m g ( 5. 3 % f or b ot h e ve nts) a n d plac e b o 
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 3 3 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
( 5. 3 % a n d 0, res pecti vel y) gr o u ps. T he maj orit y of A Es re p orte d i n t his st u d y were mil d 
( 6 3. 2 % of e ve nts i n b ot h t he pl ace b o a n d B H V- 3 2 4 1 3 0 0 m g gr o u ps a n d 6 0. 0 % of e ve nts i n t he 
B H V- 3 2 4 1 6 0 0 m g gr o u p). Se vere T E A Es were re p orte d i n 1 s u bje ct e ac h i n t he B H V- 3 2 4 1
6 0 0 m g ( 5. 0 %) a n d pla ce b o ( 5. 3 %) gr o u ps a n d i n 4 s u bjects i n t he B H V- 3 2 4 1 3 0 0 m g gr o u p 
( 2 1. 1 %). T he s e vere T E A Es i n t he B H V- 3 2 4 1 3 0 0 m g gr o u p were d ys p ha gia, t h er mal b ur n, hi p 
fract ure, a n d hea da c he; a n d t he s e v ere A E i n t he B H V- 3 2 4 1 6 0 0 m g gr o u p was M S A 
( w ors e ni n g). C h o ki n g w as t he se vere A E i n t he pl ace b o gr o u p. T he maj orit y of A Es were 
j u d ge d u nrel ate d t o st u d y treat me nt b y t he I n v esti gat ors, ra n gi n g fr o m 7 0. 0 % t o 7 3. 7 % a cr oss 
t he tre at m e nt gr o u ps. Treat me nt-rel ate d A Es were r e p orte d i n 6 ( 3 1. 6 %) s u bjects i n t h e B H V-
3 2 4 1 3 0 0 m g gr o u p, 5 ( 2 5. 0 %) s u bjects i n t he B H V- 3 2 4 1 6 0 0 m g gr o u p, a n d 4 ( 2 1. 1 %) 
s u bjects i n t h e place b o gr o u p.
La b orat or y v al ues t h at met p ote ntiall y cli ni call y si g nifica nt ( P C S) criteria were i nfr e q ue nt i n 
t his st u d y. Of 1 7 s u bjects wit h P C S la b orat or y val u es, 7 recei ve d place b o, 6 r ecei ve d B H V-
3 2 4 1 3 0 0 m g BI D, a n d 4 recei ve d B H V- 3 2 4 1 6 0 0 m g BI D. T hree ( 1 6. 7 %) s u bjects i n t he 
B H V- 3 2 4 1 3 0 0 m g gr o u p ha d p ote nti all y cli nicall y si g nific a nt T S H le v els: 1 s u bject ha d l o w 
T S H at t he e arl y t er mi nati o n ( 0. 1 8 uI U/ m L) a n d f oll o w- u p ( 0. 3 3 uI U/ m L; refere n ce ra n g e: 
0. 3 4- 5. 6) visits; 1 ot her s u bj ect h a d hi g h T S H at Wee ks 2, 3, 4, 8, a n d 1 2 (ra n gi n g fr o m 6. 5 8 t o 
9. 3 3 uI U/ m L); a n d t he t hir d s u bject ha d hi g h T S H be gi n ni n g at Wee k 4 ( 9. 1 1 uI U/ m L) a n d 
decreasi n g at We e k 8 ( 7. 4 3 uI U/ m L) a n d We e k 1 2 ( 6. 2 8 uI U/ m L). O ne ( 5. 3 %) s u bject i n t he 
B H V- 3 2 4 1 6 0 0 m g BI D gr o u p ha d hi g h T S H at Wee k 1 2 ( 9. 3 1 uI U/ m L) a n d t h e F oll o w- u p
visit ( 7. 2 5 uI U/ m L). T w o ( 1 1. 1 %) s u bjects i n t he B H V- 3 2 4 1 3 0 0 m g BI D gr o u p a n d 1 ( 5. 3 %) 
s u bject i n t he B H V- 3 2 4 1 6 0 0 m g BI D gr o u p ha d hi g h uri ne pr otei n.
T here w ere n o cli ni call y si g nifi ca nt differe n ces i n E C G res ults bet wee n eit her of t he B H V-
3 2 4 1 gr o u ps a n d place b o.
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 3 4 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 3 5 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
1. 1. 6
P ot e nti al Ri s k t o F et al D e v el o p m e nt
O n t he basis of t he re pr o d u cti ve a n d de vel o p me ntal t o xicit y st u dies des cri b e d a b o ve, w o me n of 
c hil d be ari n g p ot e nti al ( W O C B P) ma y be i ncl u d e d i n t he cli nical trials pr o vi d e d t he y ar e n ot 
pre g na nt or l act ati n g at a d missi o n a n d s uffici e nt c o ntrace pti ve pr ot ecti o n is use d. T here is a 
p ote nti al ris k of dr u g- dr u g i nteracti o ns wit h h or m o n al c o ntr ace pti ve m et h o ds s e nsiti v e t o 
i n d ucti o n of C Y P 3 A 4 wit h B H V- 3 2 4 1. C o nse q ue ntl y, st u d y I n vesti gat ors s h o ul d ke e p t his 
p ote nti al of re d u ce d h or m o nal c o ntr ace pti ve effecti v e ness i n mi n d f or w o me n usi n g 
c o ntrac e pti v e c o ntr ol me di ci nes a n d d e vices c o ntai ni n g estr o ge n/ pr o gest er o ne. Estr o ge n a n d 
pr o gester o ne h or m o n al c o ntrace pti ves as a s ol e met h o d of c o ntrac e pti o n are pr o hi bite d. 
1. 2
St u d y R ati o n al e
1. 2. 1
St u d y D e si g n R ati o n al e
T he p ur p os e of t his P has e 3 st u d y is t o d e m o nstrate t he efficac y of B H V- 3 2 4 1 i n t he tr eat me nt 
of M S A a n d c haracteri ze its s afet y/t oler a bilit y pr ofil e.
T he st u d y is a ra n d o miz e d, d o u ble- bli n d, 2-ar m, plac e b o-c o ntr olle d, parallel- gr o u p st u d y i n 
s u bjects wit h M S A treat e d wit h B H V- 3 2 4 1 f or 4 8 wee ks. If a bs ol utel y necessar y d ue t o t he 
C O VI D- 1 9 p u blic healt h e mer ge n c y, tre at m e nt d urati o n ma y be l o n ger, wit h a n e x pa n de d
Wee k 4 8 visit wi n d o w u p t o a m a xi m u m treat me nt d urati o n of 6 0 wee ks, as detaile d i n t h e 
Sc he d ule of Ass ess me nts a n d E ve nts ta bl es ( Ta ble 1 , Ta ble 2 ). U n der t hese cir c u msta n ces, t he 
s p o ns or me dical m o nit or ( or d esi g nee) s h o ul d be c o ns ulte d a n d m ust a p pr o ve t h e re q uest t o 
e xte n d t h e treat me nt d urati o n. 
D uri n g t he ra n d o mize d d o u ble- bli n d treat me nt p hase, t he use of pla ce b o c o ntr ol will f acilit ate 
t he i de ntifi cati o n of a tre at m e nt eff ect r elate d t o a d mi nistrati o n of B H V- 3 2 4 1. T he us e of 
place b o is j ustifi e d beca use t here is n o c urre nt st a n dar d t hera p y f or M S A a n d s u bjects i n t his 
st u d y will be all o w e d t o c o nti n u e t heir bac k gr o u n d s y m pt o matic treat me nts f or M S A ( wit h t he 
e xce pti o n of e xcl u de d me dicati o ns). T he p o p ulati o n i ncl u des s u bje cts wit h M S A ( M S A- P a n d 
M S A- C).  B ot h ha ve t he s a me u n d erl yi n g diseas e pr ocess a n d t he sa m e rate of dis eas e 
pr o gressi o n as meas ure d b y cli nic al rati n g scales (i.e., U M S A R S).  M ore o ver, b ot h s u bt y pes 
are e q uall y li kel y t o be nefit fr o m M P O i n hi biti o n b y B H V- 3 2 4 1 a n d de m o nstrate d t he p ot e ntial 
t o be res p o nsi ve t o treat me nt wit h B H V- 3 2 4 1 i n t he pre vi o us P hase 2 st u d y i n M S A s u bjects 
( St u d y D 0 4 9 0 C 0 0 0 2 3). 
S u bjects w h o are c o m pleti n g or ha ve c o m pl ete d Wee k 4 8 of t he ra n d o mize d d o u ble- bli n d 
treat me nt p h ase ma y be off ere d t h e o p p ort u nit y t o e nr oll i n a n O pe n- La bel E xte nsi o n ( O L E) 
p hase, i n w hic h s u bje cts will r ecei v e o pe n-l a bel treat me nt wit h B H V- 3 2 4 1 f or a p pr o xi mat el y 
4 8 w ee ks. E nr oll m e nt i nt o t he O L E
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 3 6 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
j u d ge me nt t hat o pe n-l a bel treat me nt off ers a n ac ce pt a ble ris k- be n efit pr ofile f or e ac h 
i n di vi d ual. 
T he pri m ar y o utc o me vari a ble i n t his st u d y is a m o difie d U M S A R S s c ore c o m prise d of a
s u bset of ite ms fr o m t he U M S A R S ( U M S A R S I: Acti viti es of Dail y Li vi n g & U M S A R S II: 
M ot or E xa mi n ati o n). T he U M S A R S is a cli nic al rati n g scale t h at has bee n de vel o p e d a n d 
vali date d f or m eas uri n g f u ncti o nal i m pair me nt i n M S A o ver 4 8 wee ks. It is t he sta n dar d 
o utc o me v ar ia ble use d i n l o n git u di nal nat ural hist or y st u dies a n d i nt er ve nti o nal st u dies. T he 
ke y s ec o n dar y o ut c o me varia bl es are t h e Cli nical Gl o bal I m pressi o n of I m pr o v e me nt ( C GI-I)
a n d M S A -Q ualit y of Life ( M S A -Q o L) m ot or a n d n o n -m ot or s u b s cales, w hic h ass ess 
c o m ple me nt ar y as pects of dis a bilit y i n M S A a n d ha v e als o pre vi o usl y b ee n vali dat e d i n M S A 
st u dies t o m o nit or disease pr o gr essi o n, as well as t he U M S A R S Part I a n d P art II t otal s c ore at 
Wee k 4 8 .
 P har mac o ki netic par a meters a n d P D effects, s uc h as M P O acti vit y, are 
als o i ncl u d e d.
1. 3
D o s e S el e cti o n
T he d os e s electe d f or e v al uati o n i n t his P hase 3 B H V- 3 2 4 1- 3 0 1 st u d y is 6 0 0 m g BI D. T his 
d os e s electi o n w as base d o n c u m ulati v e cli nical a n d n o ncli ni cal e x perie n ce wit h B H V- 3 2 4 1,
i ncl u di n g n o n cli nical t o xi c ol o g y a n d s afet y a n d effic ac y dat a i n M S A s u bjects.
T he n o ncli nic al t o xic ol o g y pr o gra m f or B H V- 3 2 4 1 is c o m pre he nsi ve a n d s u p p orts oral 
a d mi nistr ati o n i n t he cli nic f or c hr o ni c tre at m e nt.  I n cl u de d i n t he t o xic ol o g y pr o gr a m are: 
si n gle a n d re p eat- d os e t o xicit y st u dies i n r ats a n d d o gs, ge n ot o xicit y st u dies, re pr o d u cti v e 
t o xicit y st u dies, p h ot ot o xicit y st u di es, a n d safet y p h ar mac ol o g y st u dies.  B H V- 3 2 4 1 d os es i n 
t he prese nt st u d y are pre di cte d t o pr o d uce p h ar ma c o ki neti c e x p os ures bel o w t h e e x p os ure 
li mits s et o n t he b asis of n o ncli nical t o xi c ol o g y data.
T o date, a p pr o xi m atel y 2 3 4 s u bjects ha v e rec ei ve d B H V- 3 2 4 1 i n s e ve n cli ni cal st u dies: f o ur 
D 0 4 9 0 C 0 0 0 0 4), a P hase 2 safet y
( St u d y D 0 4 9 0 C 0 0 0 0 5), a n d a P hase 2 P E T i m a gi n g st u d y i n s u bjects wit h M S A ( St u d y 
D 0 4 9 0 C 0 0 0 2 3). I n t he P hase 1 st u dies, tre at m e nt wit h m ulti ple d os es of u p t o 9 0 0 m g B H V-
3 2 4 1 BI D w as ge nerall y safe a n d w ell t olerate d. I n t he P hase 2 st u dies i n s u bjects wit h 
- 3 2 4 1 at d oses of u p t o 6 0 0 m g BI D f or 8-
1 2 w ee ks w as ge nerall y s afe a n d w ell t oler ate d.
T he s ele cte d d ose of B H V -3 2 4 1 a d mi nistere d 6 0 0 m g BI D is b ase d o n t he fi n di n gs i n t he P hase 
1 a n d 2 st u dies re gar di n g safet y a n d t oler a bilit y of B H V -3 2 4 1 at 6 0 0 m g BI D; 
 
 a n d t h e d ose-
de pe n de nt f a v ora ble tre n ds o n cli nical effica c y me as ures i n t he P has e 2 st u d y i n M S A. Ta ke n 
t o get her, t he safet y, t oler a bilit y, P K, a n d P D data ge nerate d i n cli nical st u dies wit h B H V-3 2 4 1,
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 3 7  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
al o n g wit h t h e precli ni cal p har mac ol o g y, P K, a n d s afet y dat a, s u p p ort t he f urt her e val uati o n of 
B H V- 3 2 4 1 i n M S A patie nts i n a P hase 3 st u d y. 
 
1. 4 
B e n efit- Ri s k 
Be n efit- Ris k Assess me nt  
T he c urre nt be nefit-ris k a nal ysis is base d o n t he a vaila ble d ata wit h B H V- 3 2 4 1 fr o m precli nical 
a n d M S A s u bjects). It is c o nsi dere d t hat t he be nefits of e val uati n g B H V- 3 2 4 1 as a p ote ntial 
treat me nt f or M S A o ut w ei g h t h e ris ks. 
Precli ni cal st u dies s afet y a n d t o xic ol o g y st u dies ar e descri be d i n Se cti o n 1. 1. 3. 1. 3 a n d Secti o n 
1. 1. 3. 1. 5, res pecti v el y. Safet y p har ma c ol o g y st u di es were perf or me d assessi n g t he ce ntr al 
ner v o us, res pirat or y, car di o vas c ul ar a n d gastr oi ntesti nal s yste ms. A c o m pre h e nsi ve t o xic ol o g y 
data pac ka ge has bee n de vel o pe d o n B H V- 3 2 4 1 i ncl u di n g si n gle d os e t o xicit y, re pe at- d os e 
t o xicit y (i ncl u di n g c hr o nic t o xicit y i n rats a n d d o gs), ge neti c t o xi cit y, r e pr o d ucti v e a n d 
de vel o p m e ntal t o xi cit y, a n d s pecial t o xi cit y. 
T he cli nic al e x perie nc e wit h B H V- 3 2 4 1 is des cri be d i n detail i n S e cti o n 1. 1. 3. 2. T he a d v erse 
e ve nt pr ofile o bser ve d i n t hes e cli ni cal st u dies wit h B H V- 3 2 4 1 is des cri be d i n Secti o n 1. 1. 5. 
T o date, se v e n cli nical st u dies (f o ur P hase 1 st u di es i n healt h y s u bj ects; t w o P has e 2 st u dies i n 
ha ve be e n 
c o n d ucte d wit h B H V- 3 2 4 1, wit h a p pr o xi m atel y 2 3 4 s u bjects ha vi n g r ecei ve d B H V- 3 2 4 1 i n 
t hese cli nic al st u di es.  
E x p os u re 
T he e x p os ure li mits f or B H V- 3 2 4 1 i n cli ni cal st u dies ha ve pre vi o usl y b ee n a C ma x  of 4 0 
µ m ol/ L a n d a n A U C( 0-
 base d o n t he hist o pat h ol o gi cal fi n di n gs i n t h e 
t h yr oi d gla n d i n t he r at 6- m o nt h st u d y. I n t he P hase 2 b st u d y ( D 0 4 9 0 C 0 0 0 2 3), M S A s u bjects 
treat e d wit h B H V- 3 2 4 1 6 0 0 m g BI D f or 1 2 wee ks ha d t he f oll o wi n g st ea d y state, ge o metri c 
mea n e x p os ures: A U C of 3 9. 5 µ m
ma x  
T h us, t he e x p os ures of B H V- 3 2 4 1 i n pla n ne d cli nical trials are pr oj ecte d t o be bel o w t he 
N O A E L. 
S afet y a n d T oler a bilit y i n Cli ni c al St u dies 
I n t he P has e 1 st u dies, B H V- 3 2 4 1 has bee n ge ner all y well t ol erat e d w he n a d mi nistere d t hr o u g h 
titrati o n as m ulti ple d os es u p t o 9 0 0 m g BI D. I n t h e P hase 2 st u dies i n s u bjects wit h 
- 3 2 4 1 at d oses of u p t o 6 0 0 m g BI D f or 8 t o 
1 2 w ee ks w as ge nerall y s afe a n d w ell t oler ate d. 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 3 8  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
P ote nti al Be nefits
T he rati o nal e f or t he pr o p ose d st u d y is base d o n c u m ulati v e precli ni cal a n d cli nical st u dies t h at 
i m pli cat e M P O acti vit y i n t h e o nset a n d pr o gressi o n of M S A a n d s u g gest treat me nt wit h B H V-
3 2 4 1 has t he p ote ntial t o sl o w ne ur o de ge n erati o n i n M S A. 
I n partic ular, i n a P has e 2 b st u d y, s u bjects wit h M S A were ra n d o mi ze d t o re cei v e B H V- 3 2 4 1 
3 0 0 m g BI D, B H V- 3 2 4 1 6 0 0 m g BI D, or place b o f or 1 2 wee ks. T he B H V- 3 2 4 1 gr o u ps 
e x hi bit e d n u merical, b ut n ot st atisticall y si g nifi ca nt, i m pr o ve m e nts c o m p are d t o t he pla ce b o 
gr o u p t hat w ere d ose-relat e d, bas e d o n c h a n ges i n t h e U nifie d M S A Rati n g Scale sc ores fr o m 
baseli ne t o Wee k 1 2. Place b o-treate d s u bje cts w ors e ne d b y 4. 6 p oi nts, w hile B H V- 3 2 4 1 tre ate d 
s u bjects s h o w e d less w orse ni n g of 3. 7 p oi nts at t he 3 0 0- m g d os e a n d 2. 6 p oi nts at t he 6 0 0- m g 
d os e, s u g gesti n g a d ose-res p o nse relati o ns hi p. B H V- 3 2 4 1 treat me nt f or 1 2 wee ks (at d os es of 
3 0 0 m g BI D a n d 6 0 0 m g BI D) s h o we d statisti call y si g nifica nt re d ucti o ns i n m eas ures of M P O 
acti vit y i n plas ma. T hes e res ults s u p p ort t he i nt e n de d mec ha nis m of acti o n of B H V- 3 2 4 1 a n d 
p ote nti al f or efficac y i n M S A. 
P ote nti al Ris ks
Precli ni cal a n d cli nical st u dies ha v e de m o nstr ate d a n acce pta bl e safet y a n d t oler a bilit y pr ofile 
f or B H V- 3 2 4 1 b ut d o s u g gest s pecific p ot e nti al ris ks. T he pres e nt st u d y i ncl u d es ge neral a n d 
s pecific s af et y pr oce d ur es a nti ci pate d t o mi ni miz e a n y p ote nti al ris ks. 
Ge ner al pr oce d ur es will i n cl u de fr e q ue nt s af et y assess me nts b y I n vesti gat ors, t h or o u g h 
e val uati o ns a n d re vie w of A Es a n d S A Es o n a n o n g oi n g basis t o m o nit or f or a n y safet y si g nals 
or tre n ds b y t he S p o ns or a n d Me dic al M o nit or, a n d D M C re vie w of t he be nefit-ris k of t he 
st u d y f or s u bjects. 
T h yr oi d 
I n precli nical st u dies, re versi ble hist o p at h ol o gical c h a n ges i n t he t h yr oi d gl a n d a n d re versi ble 
t h yr oi d h or m o ne c ha n ges w ere o bser ve d. I n cli nical st u dies, B H V- 3 2 4 1 has bee n ass ociat e d 
wit h la b orat or y c ha n g es i n dicati ve of d ecre ase d t h yr oi d f u ncti o n. S pe cifi call y, t here h a ve be e n 
i ncreases o ver ti m e i n mea n T S H le vels a n d s o me de creases o ver ti me i n mea n fr ee T 4 a n d 
mea n fre e T 3 le v els rel ati v e t o pl ace b o. M ost s u bje cts di d n ot ha ve t h yr oi d f u ncti o n test v al ues 
o utsi de t he n or mal r a n ge, a n d t h e a b n or m alities t h at occ urre d were mil d. C ha n g es i n t h yr oi d 
f u ncti o n t ests ass ociat e d wit h B H V- 3 2 4 1 ret ur n e d t o war d baseli ne le vels d uri n g t he peri o d of 
o bs er vati o n f oll o wi n g disc o nti n uati o n of B H V- 3 2 4 1. 
T he pres e nt st u d y will i n v ol ve m o nit ori n g of t h yr oi d f u ncti o n. T h yr oi d f u ncti o n test 
a b n or maliti es i n dicati n g cli nicall y si g nifi ca nt t h yr oi d h or m o ne defi cie n c y ar e re a dil y treata bl e 
wit h t h yr oi d h or m o n e re pl ace m e nt. 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 3 9  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
R e n al
Re versi ble r e nal fi n di n gs were o bs er ve d i n t he 1- m o nt h precli nic al st u di es i n fe male rats at 
hi g h d os es, a n d n o re nal c ha n ges w ere n ot e d i n t h e 6- m o nt h st u d y. I n cli nic al st u di es, B H V-
3 2 4 1 has bee n ass ociate d wit h de creas es i n mea n uri c aci d le vels o ver ti me rel ati v e t o pl ace b o. 
A varia ble pr o p orti o n of s u bjects recei vi n g B H V- 3 2 4 1 ha ve ha d pl as ma uri c aci d le vels bel o w 
t he l o w er li mit of n or mal. D ecreases i n uric aci d l e vels ass ociate d wit h B H V- 3 2 4 1 ha ve te n de d 
t o ret ur n t o war d b as eli n e f oll o wi n g t h e disc o nti n uati o n of d osi n g. I n dices of re nal f u ncti o n 
ha ve n ot s h o w n a n y a b n or m alities ass ociate d wit h B H V- 3 2 4 1. T he mec ha nis m of t he c h a n ges 
i n uric a ci d l e vels is u nclear b ut c o ul d i n cl u de d ecre ase d uric aci d pr o d ucti o n or decreas e d 
re nal t u b ular rea bs or pti o n. H y p o urice mia is t h o u g ht t o be a bi oc h e mi call y defi ne d dis or der 
wit h n o k n o w n cli ni cal si g nific a nce.  
T he pres e nt st u d y will i n v ol ve m o nit ori n g of uric aci d le vels a n d i n dices of re nal f u ncti o n.
C ar di o v as c ul ar 
I ncreases i n heart rat e w ere o bser ve d i n d o gs d uri n g t he precli ni cal st u dies. H o we ver, B H V-
3 2 4 1 ha d n o effect o n bl o o d press ure or o n E C G par a met ers at a n y d ose. T w o st u dies 
e val uati n g c ar di o vasc ul ar res p o nse t o ort h ost ati c tilt i n d o gs were als o perf or me d; n o 
i nci de n ces of ort h ostatic h y p ote nsi o n were o bser ve d f oll o wi n g a d mi nistrati o n of B H V- 3 2 4 1. 
T he first S A D cli ni cal st u d y ( D 0 4 9 0 C 0 0 0 0 1) was dis c o nti n ue d o n t he basis of A Es t hat 
i ncl u de d s y nc o p e ass ociate d wit h bri ef si n us pa uses detecte d o n c ar diac tel e metr y. T w o of t he 
cas es of s y nc o pe w ere ass ociate d wit h ort h ostatic t esti n g. T her e was n ot a relati o ns hi p b et wee n 
t hese e ve nts a n d B H V- 3 2 4 1 c o nce ntrati o ns. T her e was n o e vi de nce of direct pr oarr h yt h mic or 
ot her car di ot o xi c effects. It was c o nsi dere d t hat e ve nts of s y nc o pe ma y ha v e re pres e nt e d a n 
e xa g gerate d p h ysi ol o gical r es p o nse t o st u d y pr oce d ures, i n v ol vi n g s y nc o pe of 
ne ur ocar di o g e nic ori gi n. H o we ver, a n eff ect of B H V- 3 2 4 1 c o ul d n ot be r ule d o ut. A sec o n d 
S A D st u d y w as c o n d ucte d wit h 2 m o difi cati o ns desi g ne d t o re d uc e t he ris k of s y nc o pe: ( 1) t he 
e xcl usi o n of s u bje cts wit h a hist or y of rec urre nt pres y nc o pe a n d/ or s y nc o p e i n c o n ne cti o n wit h 
ort h ostati c c halle n g e, a n d ( 2) fracti o nate d d osi n g. I n t his s ec o n d S A D st u d y, t here were n o 
e pis o des of pres y nc o pe or s y nc o pe, a n d n o cli nicall y rele va nt fi n di n gs i n v ol vi n g vital si g ns or 
E C G par a meters. S u bs e q ue nt cli nic al st u di es ha ve us e d E R f or m ul ati o ns a n d t here ha v e bee n 
n o cas es of s y nc o pe i n s u bje cts recei vi n g B H V- 3 2 4 1. T here ha v e bee n s o me A Es p ot e nti all y 
relat e d t o s y nc o pe (e. g., dizzi ness, ort h ostatic h y p ot e nsi o n). O verall, t h ere ha ve b ee n n o 
cli ni call y rel e va nt fi n di n gs i n v ol vi n g vital si g ns or E C Gs, wit h t he e xce pti o n of s o me d ecreas es 
i n t he m ea n R R i nter val o bser ve d i n t he B H V- 3 2 4 1 6 0 0- m g BI D gr o u p i n t he s afet y/t olera bilit y 
I n a g gre gat e, t he cli ni cal d ata d o n ot s h o w clear e vi d e nce of si g nifica nt car di o v asc ular 
a b n or maliti es ass ociat e d wit h a d mi nistrati o n of B H V- 3 2 4 1 E R f or m ulati o ns at t he d oses us e d. 
T he pres e nt st u d y will i n v ol ve m o nit ori n g of vital si g ns, i ncl u di n g ort h ost ati c me as ure me nts, 
a n d E C Gs. 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 4 0  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
Li ver
Mi ni mall y n o n-a d verse, i ncreas e d ala ni ne a mi n otr a nsferase a n d sli g ht ( a da pti ve) 
hist o pat h ol o gical effects i n t he li ver w er e o bser ve d i n rats d uri n g t he pr ecli nical st u dies; t hes e 
are li k el y relate d t o e nz y me i n d u cti o n ( e. g., C Y P 2 B 1 i n d ucti o n). I n t he M A D st u d y 
( D 0 4 9 0 C 0 0 0 0 2), s e veral s u bjects, i ncl u di n g t h ose re cei vi n g B H V- 3 2 4 1 a n d pl ace b o, ha d 
i ncreases i n h e patic tra nsa mi n ases. H o we ver, i n s u bs e q ue nt st u di es t here h a ve bee n n o 
cli ni call y rel e va nt fi n di n gs i n v ol vi n g he patic f u ncti o n.  
I n a g gre gat e, t he cli ni cal d ata d o n ot s h o w a cle ar ass ociati o n of he patic a b n or maliti es wit h 
B H V- 3 2 4 1. T he pres e nt st u d y will i n v ol ve m o nit ori n g of li ver f u ncti o n t ests. 
O ver all Be nefit- Ris k Assess me nt 
M S A is a n a d ult- o ns et, fat al ne ur o d e ge nerati ve dis eas e. N o diseas e m o dif yi n g treat me nt 
c urre ntl y e xists, o nl y s y m pt o matic a n d p alliati v e a p pr oac hes are a v ail a ble. B H V- 3 2 4 1 is a n 
irre versi bl e i n hi bit or of t h e M P O e nz y me t hat pr o m otes o xi dati ve stress a n d 
ne ur oi nfla m mati o n. T h e hi g h u n m et nee d f or a n effe cti ve treat me nt f or M S A, t o get her wit h t h e 
a vail a ble pr ecli nical a n d cli ni cal d ata wit h B H V- 3 2 4 1, pr o vi de a c o m pelli n g a n d fa v or a ble 
o verall b e nefit-ris k ass ess me nt f or t he d e vel o p me nt of B H V- 3 2 4 1 at t he 6 0 0 m g BI D d os e as a 
treat me nt f or M S A. T he s afet y m o nit ori n g i n t h e pla n ne d cli nical st u d y will mi ni miz e t he 
p ote nti al ris ks t o st u d y s u bjects. 
2 
S T U D Y O B J E C TI V E S 
2. 1 
Pri m ar y 
 T o e val u ate t he effi cac y of B H V- 3 2 4 1, c o m p are d t o place b o, as meas ure d b y a c ha n ge 
fr o m bas eli n e i n a m o difi e d U nifie d M S A Rati n g Sc ale ( U M S A R S), c o nsisti n g of a s u bset 
of ite ms fr o m Part I a n d P art II, at Wee k 4 8. 
 T o assess t he safet y a n d t olera bilit y of B H V- 3 2 4 1, relati v e t o pl ace b o, i n s u bjects wit h 
M S A. 
2. 2 
S e c o n d ar y 
Ke y Sec o n d ar y  
 T o e val u ate t he effi cac y of B H V- 3 2 4 1, c o m p are d t o place b o, as meas ure d b y t h e Cli nical 
Gl o bal I m pressi o n of I m pr o v e me nt ( C GI-I) s c ore at Wee k 4 8. 
 T o e val u ate t he i m pact of B H V- 3 2 4 1 o n q ualit y of life, c o m par e d t o pl ace b o, as m eas ure d 
b y a c ha n ge fr o m bas eli n e i n t h e m ot or s u bs cale of t he M S A- Q ualit y of Life ( M S A- Q o L) 
s cale at Wee k 4 8. 
 T o e val u ate t he i m pact of B H V- 3 2 4 1 o n q ualit y of life, c o m par e d t o pl ace b o, as m eas ure d 
b y a c ha n g e fr o m bas eli n e i n t h e n o n- m ot or s u bs cale of t he M S A- Q o L s cale at Wee k 4 8. 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 4 1 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
T o e val u ate t he effi cac y of B H V- 3 2 4 1, c o m p are d t o place b o, as meas ure d b y a c ha n ge 
fr o m bas eli n e i n t h e U M S A R S Part I a n d Part II t otal sc ore at W ee k 4 8.
Ot h er Sec o n d ar y
T o ass ess t he i m pa ct of B H V- 3 2 4 1, relati ve t o plac e b o, as meas ure d b y a c ha n ge fr o m 
baseli ne at W ee k 4 8 i n t h e f oll o wi n g i nstr u me nts:
Patie nt Gl o b al I m pr essi o n of Se verit y ( P GI- S),
Cli nic al Gl o bal I m pressi o n of Se verit y ( C GI- S),
U M S A R S Part III,
U M S A R S Part I V.
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 4 2 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
3
S T U D Y E N D P OI N T S
3. 1
Pri m ar y
C ha n ge fr o m baseli ne i n a m o difie d U M S A R S s c ore, base d o n a s u bs et of it e ms fr o m Part I 
a n d II, at W ee k 4 8 (s ee S ecti o n 9. 4. 2).
T he fre q ue n c y of u ni q ue s u bjects wit h: seri o us a d vers e e ve nts; a d v ers e e ve nts l ea di n g t o 
dis c o nti n uati o n; a d vers e e ve nts j u d ge d t o b e rel ate d t o st u d y me dic ati o n; cli nic all y 
si g nifica nt E C G a b n or m alities a n d cli ni call y si g nifi c a nt la b or at or y a b n or malities.
3. 2
S e c o n d ar y
Ke y Sec o n d ar y
T he C GI-I s c or e at W ee k 4 8
C ha n ge fr o m bas eli ne i n t he M S A- Q o L m ot or s u bs cale at Wee k 4 8 
C ha n ge fr o m bas eli ne i n t he M S A- Q o L n o n- m ot or s u bs cale at Wee k 4 8
C ha n ge fr o m bas eli ne i n U M S A R S Part I a n d II t otal s c ore at W ee k 4 8 
Ot h er Sec o n d ar y
C ha n ge fr o m baseli ne at We e k 4 8 o n t he f oll o wi n g i nstr u me nts:
P GI- S,
C GI- S,
U M S A R S Part III,
U M S A R S Part I V.
 
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 4 3  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
4 
S T U D Y P L A N 
4. 1 
St u d y D e si g n a n d D ur ati o n 
B H V 3 2 4 1- 3 0 1 is a P has e 3, m ultic e nter, r a n d o miz e d, d o u ble- bli n d, 2- ar m pl ace b o-c o ntr oll e d 
parall el- gr o u p st u d y desi g n e d t o e val uat e t he effic ac y a n d s afet y of B H V- 3 2 4 1 i n a p o p ul ati o n 
of patie nts wit h M S A ( M S A- C a n d M S A- P). T he st u d y is pla n ne d t o c o nsist of a Scre e ni n g 
p hase lasti n g a ma xi m u m of a p pr o xi matel y 6 we e ks a n d a ra n d o mize d d o u ble- bli n d treat me nt 
p hase of a p pr o xi m atel y 4 8 w ee ks, per  Fi g ure 2. It is a ntici pat e d t hat t he R a n d o miz ati o n p h ase 
will i ncl u de a d os e titr ati o n p eri o d of a p pr o xi mat el y 2 wee ks f oll o we d b y a f ull d os e peri o d of 
a p pr o xi matel y 4 6 w ee ks. A p pr o xi matel y 3 2 5 s u bjects i n t otal are pl a n ne d t o b e ra n d o mi ze d i n 
a 1: 1 rati o t o re cei ve eit h er B H V- 3 2 4 1 6 0 0 m g BI D, or matc hi n g pla ce b o BI D. It is a ntici p ate d 
t hat s u bje cts will b e ass esse d at cli nic visits, per t h e Sc he d ule of Ass ess me nts & E ve nts ( Ta bl e 
1 ).  I n a d diti o n, s u bj ects w h o are c o m pleti n g or ha v e c o m plete d W ee k 4 8 of t he d o u ble- bli n d 
treat me nt p h ase ma y be off ere d t h e o p p ort u nit y t o e nr oll i n a n O pe n- La bel E xte nsi o n p h as e, i n 
w hic h s u bjects will rec ei ve o pe n-la bel tre at m e nt wit h B H V- 3 2 4 1 f or a p pr o xi matel y 4 8 wee ks. 
(Ta ble 2 ) 
4. 2 
St u d y S c h e m ati c 
Fi g ur e 2:  
St u d y S c h e m ati c 
 
 
 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 4 4 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
4. 3
S c h e d ul e of A s s e s s m e nt s
4. 3. 1
C O VI D- 1 9 P u bli c H e alt h E m er g e n c y
I n b ot h t he d o u bl e- bli n d p h ase a n d O L E p has e of t he st u d y, e ver y eff ort s h o ul d b e ma de t o 
c o n d uct pr ot o c ol-s pecifie d i n- p ers o n st u d y visits as pla n ne d a n d as cl ose t o t he dat e of t he 
s c he d ule d visit as p ossi ble.  H o w e ver, d ue t o t he C O VI D- 1 9 p u blic healt h e m er ge nc y, i n or d er 
t o mi ni mize p ote ntial ris ks t o t he s af et y of st u d y partici pa nts a n d st u d y site p ers o n nel a n d t o 
c o m pl y wit h g o v er n me nt a n d l o cal he alt h care i nstit uti o n g ui da n ce a n d r estricti o ns, st u d y 
partici pa nts m a y be u na ble t o atte n d st u d y sc h e d ule d pr ot oc ol re q uire d visits i n pers o n (e. g., 
s helter i n plac e restricti o ns, st u d y site p olic y t hat cli nical r esearc h visits m ust be dela ye d). 
U n der t hese cir c u msta nc es, if a st u d y partici pa nt is u na ble t o att e n d a n i n p ers o n pr ot oc ol-
re q uire d e v al uati o n at t he st u d y sit e at t he s c he d ule d ti me, t he sit e I n vesti g at or s h o ul d disc uss 
t he a p pr o pri ate c o urse of acti o n a n d s pecific r e q uire me nts f or re m ote safet y visits o n a c ase b y 
cas e basis wit h t h e S p o ns or M e dical M o nit or ( or desi g nee), base d o n t he s pecific st u d y visit, 
t he cli nic al stat us of t he partici p a nt, c o nsi d erati o n of t heir c o m pli a nce t o st u d y me dicati o n, 
pre vi o us la b res ults a n d ot her ris k fact ors.  
P ote ntial c o urs es of acti o n i n cl u de e x p a nsi o n of t he visit wi n d o w, c o n d uct of a re m ote [ via 
p h o ne or te l e me dici ne vi de o] visit, f oc usi n g o n s afet y assess me nts d uri n g re m ot e visits ,
i ncl u di n g st u d y dr u g c o m plia nce, c o nc o mita nt me dic ati o n re vie w, a d vers e e v e nt m o nit ori n g, 
S hee ha n S uici d alit y Tra c ki n g Scal e, U M S A R S Part I a n d Ti m e t o E v e nt M eas ures , perf or mi n g 
s afet y la bs vi a l ocal la bs or i n-h o me p hle b ot o m y ve n d ors, a n d s hi p pi n g st u d y me di cati o n t o 
st u d y partici pa nts, if n ee de d. Vital si g ns, p h ysical e xa ms , a n d cli nicia n-rat e d o utc o me 
meas ures (e. g., U M S A R S Part II, C GI -I/ S) will n ot b e c o n d uct e d re m otel y.  E C Gs ma y b e 
c o n d ucte d at a l ocal h ealt h facilit y ot her t ha n t h e st u d y site, w it h s u bse q ue nt s u b missi o n t o 
 (ce ntral E C G v e n d or). S cree ni n g, B as eli n e a n d Wee k 4 8 visits m ust be c o n d u cte d i n 
pers o n a n d la b a n al ys es s h o ul d be c o n d ucte d b y 
 ce ntral la b .
F or o n -tre at m e nt st u d y visits ( n ot Scree ni n g, Baseli n e or Wee k 4 8) , if t he C O VI D-1 9 p u blic 
healt h e mer g e nc y pre ve nts st u d y s u bjects fr o m b ei n g a ble t o h a ve bl o o d a n d uri ne l a b sa m pl es 
c olle cte d at t h e st u d y site f or s hi p me nt t o 
 ce ntral la b f or a nal ysis, t h e s a m ples m a y be 
c olle cte d at l o cati o ns ot her t ha n t he st u d y sit e (l oc al l a b, pri mar y care pra cti ce, i n-h o me 
p hle b ot o m y s er vice) a n d ma y be a nal y ze d b y a l ocal la b.  T he st u d y site will c ollect a n y l oc al 
la b res ults f or re vie w a n d e ntr y i nt o t h e e D C e C R F. T he s afet y la b s a m ples c oll ect e d a n d 
a nal yze d i n t h ese cas es of re m ote ass ess me nts will b e li mite d t o safet y la bs specifie d b y t he 
S p o ns or (s ee Secti o n 6. 2. 2. 4 ).  P har ma c o ki netic a n d 
will n ot be c oll ect e d.  
 
C CI
C CI
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 4 5 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
4. 3. 1. 1
Crit eri a f or T e m p or ar y I nt err u pti o n of I n v e sti g ati o n al Pr o d u ct (I P)
T he visit wi n d o ws f or c ollecti o n of B H V 3 2 4 1- 3 0 1 pr ot oc ol-re q uire d s afet y la bs d uri n g t h e 
C O VI D- 1 9 e mer ge nc y, a n d t he crit eria f or te m p or ar y i nterr u pti o n of I P d ue t o i n a bilit y t o 
m o nit or patie nt s afet y via l a b a nal yses ar e as f oll o ws:
Wee k 4 or W ee k 4- E xt e nsi o n s afet y la bs- nee d t o be c o n d ucte d wit hi n a 1 0 d a y wi n d o w of 
Wee k 4 or W ee k 4- E xt e nsi o n. If n ot, nee d t o t e m p or aril y i nterr u pt I P u ntil l a bs are 
c o n d ucte d.
Wee k 1 2 or W ee k 1 2- E xt e nsi o n s afet y la bs- nee d t o be c o n d uct e d wit hi n a 8- wee k wi n d o w 
of Wee k 1 2- E xte nsi o n (ass u mi n g n o cli ni call y si g nifica nt la b a b n or maliti es at Wee k 8 or
Wee k 8- E xte nsi o n). F or s u bjects w h o di d n ot ha ve Wee k 8 or W ee k 8 - E xt e nsi o n la bs 
c o n d ucte d, b ut w h o ha d Wee k 4 or Wee k 4- E xte nsi o n la bs c o n d uct e d wit h n o cli ni call y 
si g nifica nt la b a b n or malities, t he n Wee k 1 2 or W ee k 1 2- E xte nsi o n l a bs nee d t o b e 
c o n d ucte d wit hi n a 4 w e e k wi n d o w of Wee k 1 2 or Wee k 1 2- E xte nsi o n. If n ot, nee d t o 
te m p oraril y i nterr u pt I P u ntil l a bs are c o n d ucte d.
Wee k 2 4 or W ee k 2 4- E xt e nsi o n s afet y la bs- nee d t o be c o n d uct e d wit hi n a 1 2- wee k wi n d o w 
of Wee k 2 4 or
Wee k 2 4- E xt e nsi o n (ass u mi n g n o cli nicall y si g nifi ca nt la b a b n or malities at 
Wee k 1 2 or W ee k 1 2- E xt e nsi o n). If n ot, ne e d t o t e m p oraril y i nterr u pt I P u ntil l a bs are 
c o n d ucte d.
4. 3. 1. 2
W e e k 1 8 A s s e s s m e nt
If a s u bject h as n ot bee n ass ess e d at a n i n pers o n visit at W ee k 1 2 or We e k 1 2 -E xt e nsi o n ,
c hec ki n g i n wit h t h e s u bject re m ot el y ( b y p h o ne or vi de o) bet we e n Wee k 1 2 or Wee k 1 2 -
E xte nsi o n a n d Wee k 2 4 or W ee k 2 4 -E xte nsi o n (at a p pr o xi mat el y t h e Wee k 1 8 or Wee k 1 8 -
E xte nsi o n ti me p oi nt) a n d o btai ni n g s afet y la bs is str o n gl y e nc o ura g e d.  T hes e l a bs ma y be 
c o n d ucte d usi n g t he 
 ce ntral la b U nsc he d ule d Visit la b kit or t he y ma y be c oll ecte d at a 
visiti n g p hl e b ot o m y s er v ice) a n d ma y be a nal y ze d b y a l ocal la b.
4. 3. 1. 3
S hi p m e nt of St u d y M e di c ati o n t o St u d y P arti ci p a nt s
I n t hes e cases of re m ote assess me nts, w he n a n i n- pers o n st u d y visit is n ot p ossi ble d ue t o t he 
C O VI D- 1 9 p u blic healt h e mer ge n c y, o ver ni g ht s hi p me nt of st u d y m e dic ati o n fr o m t he site t o 
t he st u d y partici p a nt vi a certifie d a n d tra c ka bl e c o uri er u n der a m bie nt c o n diti o ns (f oll o wi n g 
Re m ote Visit W or kar o u n d G ui d eli n es pr o vi de d t o sit es), is per missi ble, if ac ce pta ble t o t he 
C o nfir mati o n t h at t h e st u d y dr u g s hi p me nt was rec ei ve d b y t he st u d y 
partici pa nt s h o ul d b e retai n e d as d oc u me nt ati o n, e. g., trac ki n g c o nfir m ati o n pri nt o ut fr o m t he 
c o urier, writte n d oc u me ntati o n of c o ntact wit h t h e s u bject ( b y p h o n e, e m ail, te xt), s u bject 
si g nat ure o n pac ki n g list, et c.
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 4 6 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
4. 3. 1. 4
R e m ot e M o nit ori n g/ S o ur c e D at a V erifi c ati o n
T he o n -site r e vie w a n d verific ati o n of st u d y s o urc e d oc u me nts b y t h e S p o ns or a n d its 
re pres e ntati ves m a y be affe cte d b y C O VI D-1 9 p u bli c healt h e m er ge nc y restricti o ns li miti n g 
access t o t h e st u d y site.  If it is s pecificall y all o we d a cc or di n g t o h ealt h a ut h orit y, I R B/ E C a n d 
data pr ot ecti o n a ge nc y r e g ulati o ns, re m ote s o urce d ata verificati o n m a y be c o n d ucte d t hr o u g h 
Re m ote M o nit ori n g, wit h st u d y d o c u me nts access e d electr o nic all y wit h o ut brea ki n g st u d y
o perati n g pr oce d ure.  
 
 
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
 
Pa ge 4 7  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
T a bl e 1:  
S c h e d ul e of A s s e s s m e nt s a n d E v e nt s - R a n d o mi z e d D o u bl e- bli n d P h a s e  
Visit 
Scr ee ni n g 
B as eli ne 
( Pre- d os e) 
2 a 
3 
3- 1 
4 
5
6 
7 9 
 
D a y ( Visit pr oc e d ures c o n d ucte d wit hi n a +/- 
3 d a y wi n d o w, u nl ess ot her wis e s pecifie d)
M a xi m u m 
of 4 2 d a ys 
(- 4 2 t o - 1)
1
1 4
2 9
5 7
8 5
1 6 9
2 5 3
3 3 7 ( +/- 7 
d a ys)
 
We e k 
 
0 
2 
4 
8 
1 2 
2 4 
3 6 
4 8 
( E a rl y D/ C) 9 
We e k 4 8 
P h o ne C all 
(if a p plic a ble)1 0  
Eli gi bilit y Ass ess m e nts 
 
 
 
 
 
 
 
 
 
 
I nf or me d C o ns e nt (s u bje ct a n d c are gi v er) 
X 
 
 
 
 
 
 
 
 
 
I ncl usi o n/ E x cl usi o n Criteria 
X 
X 
 
 
 
 
 
 
 
 
M e dical Hist or y 
X 
 
 
 
 
 
 
 
 
 
De m o gra p hic Dat a 
X 
 
 
 
 
 
 
 
 
 
C o n c o mita nt M e dicati o n re vie w 
X 
X 
X 
X 
 
X 
X 
X 
X 
X 
S af et y Assess m e nts 
 
 
 
 
 
 
 
 
 
 
P h ysi cal E xa mi nati o n * 
X 
X 
X 
X 
 
X 
X 
X 
X 
 
P h ysi cal M eas ure me nts 1 
X 
X 
 
 
X 
 
Vital Si g ns 2  
X 
X 
X 
X 
 
X 
X 
X 
X 
 
E C G ( 1 2-lea d) 
X 
X 
X 
X 
 
X 
X 
X 
X 
 
La b orat or y T ests 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Pre g n a n c y T est 3 
X 
X 
 
X 
 
X 
X 
X 
X 
 
S h ee h a n S uici dalit y Trac ki n g Scale 
X 
X 
X 
X 
 
X 
X 
X 
X 
 
A d verse E ve nt Re p orti n g 
 
 
 
 
 
 
 
 
 
 
M o nit or f or N o ns eri o us A Es 
 
X 
X 
X 
 
X 
X 
X 
X 
X 
M o nit or f or S A Es 
X 
X 
X 
X 
 
X 
X 
X 
X 
X 
 
 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 4 8 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
Visit
Scr ee ni n g
B as eli ne
( Pre- d ose)
2 a
3
3- 1
4
5
6
7 9
D a y ( Visit pr oce d ur es c o n d ucte d wit hi n a +/-
3 d a y wi n d o w, u nless ot her wise s pecifi e d)
M a xi m u m 
of 4 2 d a ys 
(- 4 2 t o - 1)
1
1 4
2 9
5 7
8 5
1 6 9
2 5 3
3 3 7 ( +/- 7
d a ys)
We e k
0
2
4
8
1 2
2 4
3 6
4 8
( E a rl y 
D/ C) 9
We e k 4 8 
P h o ne C all
(if a p plic a ble)1 0
Effic ac y Ass ess m e nts
U nifie d M S A Rati n g Sc ale Parts I-I V *
X
X
X
X
X
X
X
Cli nical Gl o bal I m pressi o n of Se v erit y ( C GI- S)
X
X
X
X
X
X
Cli nical Gl o bal I m pressi o n of I m pr o ve me nt 
( C GI-I)
X
X
X
X
X
Patie nt Gl o bal I m pressi o n of Se v erit y ( P GI- S)
X
X
X
X
X
X
M S A Q ualit y of Life
X
X
X
Ti me-t o-e v e nt meas ures of dise ase pr o gressi o n 
X
X
X
X
X
X
X 1 0
Ot he r Ass ess m e nts
L u m b ar P u nct ure 5
X
X
P h ar m ac o ki neti c Ass ess m e nts
Bl o o d P K Sa m pli n g 6
X
X
X
X
X
X
C CI
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 4 9 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
Visit
Scr ee ni n g
B as eli ne
( Pre- d ose)
2 a
3
3- 1
4
5
6
7 9
D a y ( Visit pr oce d ur es c o n d ucte d wit hi n a +/-
3 d a y wi n d o w, u nless ot her wise s pecifi e d)
M a xi m u m 
of 4 2 d a ys 
(- 4 2 t o - 1)
1
1 4
2 9
5 7
8 5
1 6 9
2 5 3
3 3 7 ( +/- 7
d a ys)
We e k
0
2
4
8
1 2
2 4
3 6
4 8
( E a rl y 
D/ C) 9
We e k 4 8 
P h o ne C all
(if a p plic a ble)1 0
 
  
  
 
  
 
  
  
  
  
 
Ra n d o mize
X
Dis pe ns e St u d y Dr u g
X
X
X
X
X
St u d y Dr u g C o m plia nce Ass ess me nt 8
X
X a
X
X
X
X
X
U n der re g ular circ u msta n ces, visits are t o b e c o m plet e d i n- p ers o n, u nless ot h er wis e s p ecifie d. S o me visits ca n b e c o n d uct e d re m otel y, as n ee de d, d ue t o 
C O VI D- 1 9 restricti o ns. See Pr ot o c ol Secti o n 4. 3. 1, C O VI D- 1 9 P u blic H ealt h E mer ge nc y, f or f urt her details a n d re q uire me nts re g ar di n g c o n d uct of re m ote 
visits d ue t o C O VI D- 1 9.
a T he Wee k 2 ass ess me nt s h o ul d ge nerall y be c o n d ucte d at t he st u d y site. Per I n vesti g at or j u d g e m e nt, a d diti o n al e val uati o ns/ pr oc e d ures ma y be c o n d ucte d at 
t his ti me p oi nt as a p pr o priate.
*I ncl u di n g n e ur ol o gic e xa m as a c o m p o n e nt of g e n eral p h ysical e xa m a n d U M S A R S
1 Hei g ht at Scre e ni n g a n d We e k 4 8; wei g ht at Scree ni n g, Baseli ne, a n d Wee k 4 8.
2 S u bje cts s h o ul d be seate d a n d resti n g f or a p pr o xi matel y 5 mi n utes pri or t o vital si g n me as ure me nts - te m p erat ure, bl o o d press ure, a n d he art rate. Tilt ta ble 
ma y be use d, if a v aila ble.
3 Ser u m pre g na n c y test will be c o n d ucte d i n W O C B P (s e e s ecti o n 5. 5) at all s c h e d ule d visits.  Uri n e pre g na nc y test will be p erf or me d o n W O C B P (i n 
a d diti o n t o ser u m) at Bas eli ne ( wit hi n 2 4 h o urs pri or t o first d ose).
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 5 0 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
6 O n e P K s a m ple s h o ul d b e c ollecte d pre- d os e a n d o n e P K s a m ple s h o ul d be c ollecte d p ost- d os e. T he ti me of t h e last B H V- 3 2 4 1/ place b o d os e pri or t o t h e 
s a m ple c ollecti o n a n d ti me of t he P K sa m ple c ollecti o n a n d ti me of m ost rec e nt me al s h o ul d be re p ort e d o n t he C R F. At W ee ks 4, 1 2, 2 4, 3 6 a n d 4 8, t h e 
m or ni n g d os e of st u d y dr u g s h o ul d be h el d a n d a d mi nistere d i n t he cli nic/ offi ce d uri n g t he st u d y visit, s o t hat o ne pre- d os e (tr o u g h) a n d o ne p ost- d os e P K 
s a m ple c a n b e c ollecte d. T he p ost- d ose s a m ple s h o ul d be c ollecte d wit hi n a ti me wi n d o w of a p pr o xi m atel y 2 t o 4 h o urs. C ollecti o n of P K s a m ples is n ot 
re q uire d at t h e Earl y Dis c o nti n uati o n visit.
8 S u bje cts s h o ul d ta ke t he first d os e of i n vesti g ati o n al pr o d u ct (I P) w hile i n t h e offic e/cli nic o n t h e d a y of t h e B aseli n e visit a n d sta y at t h e cli nic f or ~ 4 h o urs 
f or o bs er vati o n. Fr o m st art t o e n d of
We e k 1, s u bje cts will i n gest eit her 3 0 0 m g Q D of B H V- 3 2 4 1 or matc hi n g plac e b o Q D.  Fr o m st art t o e n d of
Wee k 2, 
s u bjects will i n gest eit h er 3 0 0 m g BI D of B H V- 3 2 4 1 or matc hi n g plac e b o BI D.  Starti n g wit h We e k 3 a n d f or t h e re mai n der of t he d o u ble- bli n d p orti o n of 
t he st u d y, s u bje cts will i n gest eit h er 6 0 0 m g BI D of B H V- 3 2 4 1 or matc hi n g place b o BI D. 
9 T he Wee k 4 8 ass ess me nts/ pr oc e d ures s h o ul d b e c o n d u ct e d as a n i n p ers o n visit at t he st u d y site.
E v er y eff ort s h o ul d b e ma d e t o c o n d uct t he Wee k 4 8 visit 
a n d mai ntai n a +/- 7 da y wi n d o w. H o we ver, d u e t o t he C O VI D- 1 9 p u blic h ealt h e mer ge nc y, if a bs ol utel y necess ar y, i n or der t o mi ni mize p ote ntial ris ks t o 
st u d y p artici pa nt safet y a n d t o c o m pl y wit h g o v er n me ntal a n d l ocal i nstit uti o n al g ui da n ce (e. g., st u d y site h as a p olic y t hat a n i n p ers o n cli nical res earc h visit 
m ust be d ela ye d), t h e Wee k 4 8 visit wi n d o w ma y b e e x pa n de d u p t o a n a d diti o nal 1 2 we e ks ( ma xi m u m treat me nt d urati o n of 6 0 wee ks).  H o we ver, e ver y 
atte m pt s h o ul d b e ma de t o c o n d u ct t he visit as cl os e as p ossi ble t o t he d at e t hat t he visit is d u e. U n der t h es e circ u msta nces, t he I n v esti gat or s h o ul d dis c uss t h e 
s pecific circ u msta nces of t hese c ases wit h t he s p o ns or me dic al m o nit or ( or desi g nee), w h o m ust a p pr o v e t h e re q uest t o e xte n d t h e treat me nt d urati o n, pri or t o 
a n y m o difi cati o n of t he visit wi n d o w. If t he We e k 4 8 visit wi n d o w is m o difie d, partici pa nts s h o ul d ha ve s afet y ass ess me nts e v al uate d re m otel y (e. g., via 
p h o ne) a n d safet y la bs c o n d ucte d (at a l ocal la b) at t h e ti me of t he s c he d ule d Wee k 4 8 visit. 
S u bje cts w h o dis c o nti n ue fr o m st u d y me dicati o n pri or t o W ee k 4 8 will h a v e a n Earl y Dis c o nti n uati o n visit.  De pe n di n g o n t he r eas o n f or t he earl y 
dis c o nti n uati o n (e. g., d e cli ni n g patie nt stat us), s o me pr oce d ures, f or e x a m ple, P K s a m ples, P D s a m ples, l u m b ar p u nct ure, m a y n ot be c o n d u ct e d at t his visit.  
C o n d u ct of all pr o ce d ures, if p ossi ble, is e nc o ura g e d.
1 0 F or s u bjects w h o dis c o nti n ue st u d y me di cati o n earl y ( pri or t o Wee k 4 8), t h e site s h o ul d c o ntact t h e s u bject b y p h o n e call at a p pr o xi matel y We e k 4 8 t o 
c ollect i nf or mati o n o n cli nical stat us (i n cl u di n g Ti me t o E ve nt meas ures of dis ease pr o gressi o n, a n d if a p plica ble, A Es, S A Es).
 
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
 
Pa ge 5 1  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
T a bl e 2: 
S c h e d ul e of A s s e s s m e nt s a n d E v e nt s - O p e n- L a b el E xt e n si o n P h a s e  
Visit 
B as eli ne 
E xt 1 
( Pre- d ose) 
A b bre vi ate d 
Dr u g 
Dis pe ns ati o n 
Visit 2 
2 E xt 
( p h o ne) 
3 E xt 7 
(c a n be 
re m ote) 
4 E xt 7 
(c a n be 
re m ote) 
5 E xt 
6 E xt 
7 E xt 
8 E xt 8 
D a y ( Visit pr oc e d ures c o n d ucte d 
wit hi n a +/- 7 d a y wi n d o w, u nl ess 
ot her wis e s pe cifie d) 
1 
 
1 4 
2 9 
5 7 
8 5 
1 6 9 
2 5 3 
3 3 7 
We e k 
0 
 
2 E xt 
4 E xt 
8 E xt 
1 2 
E xt 
2 4 
E xt 
3 6 
E xt 
4 8 E xt / E a rl y 
Dis c o nti n u ati o n 8  
Eli gi bilit y Ass ess me nts 
  
 
  
 
  
  
  
  
 
I nf or me d C o ns e nt (s u bject) 
X  
X 
  
 
  
 
 
  
 
M e dical Hist or y 
X  
 
  
 
  
 
 
  
 
C o n c o mita nt M e dicati o n re vie w 
X 
X 
 
 
 
X 
X 
X 
X 
S af et y Assess m e nts 
  
 
  
 
  
  
  
  
 
P h ysi cal E xa mi nati o n 3 
X 
 
 
 
 
X 
X 
X 
X 
P h ysi cal M eas ure me nts 4 
X 
 
  
 
  
 
 
 
X 
Vital Si g ns 5  
X 
X 
 
 
 
X 
X 
X 
X 
E C G ( 1 2-lea d) 
X 
 
 
X 
if visit is 
c o n d u cte d 
i n p ers o n 
X 
 if visit is 
c o n d u cte d 
i n p ers o n 
X 
X 
X 
X 
La b orat or y T ests 
X 
 
 
X 
X 
X 
X 
X 
X 
Pre g n a n c y T est 6 
X 
 
 
X 
X 
X 
X 
X 
X 
S h ee h a n S uici dalit y Trac ki n g Scale 
X 
 
X 
 
 
X 
X 
X 
X 
A d verse E ve nt Re p orti n g
M o nit or f or N o ns eri o us A Es a n d S A Es
X
X
X
X
X
X
X
X
X
 
 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
 
Pa ge 5 2  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
Visit 
B as eli ne 
E xt 1 
( Pre- d ose) 
A b bre vi ate d 
Dr u g 
Dis pe ns ati o n 
Visit 2 
2 E xt 
( p h o ne) 
3 E xt 7 
(c a n be 
re m ote) 
4 E xt 7 
(c a n be 
re m ote) 
5 E xt 
6 E xt 
7 E xt 
8 E xt 8 
D a y ( Visit pr oc e d ures c o n d ucte d 
wit hi n a +/- 7 d a y wi n d o w, u nl ess 
ot her wis e s pe cifie d) 
1 
 
1 4 
2 9 
5 7 
8 5 
1 6 9 
2 5 3 
3 3 7 
We e k 
0 
 
2 E xt 
4 E xt 
8 E xt 
1 2 
E xt 
2 4 
E xt 
3 6 E xt 
4 8 E xt / E a rl y 
Dis c o nti n u ati o n 8  
Effic ac y Ass ess m e nts 
  
 
  
 
  
  
  
  
 
U nifie d M S A Rati n g Sc ale Parts I-I V 3 
(if visit is c o n d ucte d re m otel y [ b y 
p h o ne], o nl y c o n d uct Part I) 
X 
 
 
 
 
X 
X 
X 
X 
M S A Q ualit y of Life 
X 
 
 
 
 
X 
X 
X 
X 
Ti me-t o-e v e nt meas ures of dise ase 
pr o gressi o n  
X 
 
 
 
 
X 
X 
X 
X 
Dis pe ns e St u d y Dr u g 
X 
X 
 
 
 
X 
X 
X 
 
St u d y Dr u g C o m plia nce Assess me nt 
X 
 
X 
 
 
X 
X 
X 
X 
U n der re g ular circ u msta n ces, visits are t o b e c o m plet e d i n- p ers o n, u nless ot h er wis e s p ecifie d.  S o me visits ca n b e c o n d uct e d re m otel y, as n ee de d, d ue t o 
C O VI D- 1 9 restricti o ns.  See Pr ot o c ol Secti o n 4. 3. 1, C O VI D- 1 9 P u blic H ealt h E mer ge nc y, f or f urt her d et ails a n d re q uire me nts re gar di n g c o n d uct of re m ote 
visits d ue t o C O VI D- 1 9. 
1 Baseli ne visit f or t h e O L E P hase is o nl y re q uire d if t here is a n e xte n d e d bre a k (
4 wee ks) i n d osi n g bet wee n t he d o u ble- bli n d a n d O L E P has es.  Ot her wis e, 
t he d o u ble- bli n d Wee k 4 8 visit will ta ke t h e place of t h e B aseli ne- E xte nsi o n visit. S u bjects s h o ul d ta k e t he first d ose of I P w hile i n t h e office/cli nic o n t he da y 
of t h e Bas eli ne- E xte nsi o n visit a n d sta y at t he cli nic f or ~ 4 h o urs f or o bs er vati o n. Fr o m st art t o e n d of We e k 1- E xte nsi o n, s u bje cts will i n gest 3 0 0 m g Q D of 
B H V- 3 2 4 1.  Fr o m st art t o e n d of W ee k 2- E xte nsi o n, s u bje cts will i n gest 3 0 0 m g BI D of B H V- 3 2 4 1.  Starti n g wit h W ee k 3- E xt e nsi o n a n d f or t h e re mai n d er of 
t he O L E, s u bje cts will i n gest 6 0 0 m g BI D of B H V- 3 2 4 1.  
2 A b bre viate d visit o nl y n ee de d f or p atie nts w h o c o m plete d d osi n g i n t h e d o u ble- bli n d p has e < 4 w ee ks pri or t o e nteri n g t he O L E P h as e. T he d o u ble- bli n d 
We e k 4 8 Visit ser ves as t h e B as eli ne- E xte nsi o n visit. T his visit is pri maril y t o dis pe ns e st u d y dr u g. S u bjects s h o ul d ta k e t he first d os e of I P w hile i n t h e 
office/cli nic o n t he da y of t he Bas eli ne- E xte nsi o n visit a n d sta y at t h e cli nic f or ~ 4 h o urs f or o bs er v ati o n. Fr o m start t o e n d of Wee k 1, s u bjects will i n gest 3 0 0 
m g Q D of B H V- 3 2 4 1.  Fr o m st art t o e n d of We e k 2, s u bje cts will i n gest 3 0 0 m g BI D of B H V- 3 2 4 1.  Starti n g wit h We e k 3 a n d f or t he re m ai n der of t he O L E, 
s u bjects will i n gest 6 0 0 m g BI D of B H V- 3 2 4 1.  
3I ncl u di n g n e ur ol o gic e xa m as a c o m p o ne nt of ge n eral p h ysical e x a m a n d U M S A R S. 
4 Hei g ht a n d wei g ht. 
5 S u bje cts s h o ul d be seate d a n d resti n g f or a p pr o xi matel y 5 mi n utes pri or t o vital si g n meas ure me nts - te m p erat ure, bl o o d press ure, a n d heart rate. Tilt ta ble 
ma y be use d, if a v aila ble. 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
 
Pa ge 5 3  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
6 Ser u m pre g n a n c y test will b e c o n d ucte d i n W O C B P (se e secti o n 5. 5) at all s c he d ule d visits.  Uri n e pre g na nc y test will be perf or m e d o n W O C B P (i n a d diti o n 
t o s er u m) at B as eli ne- E xte nsi o n ( wit hi n 2 4 h o urs pri or t o first d os e of o pe n-la b el B H V- 3 2 4 1). 
7 W ee k 4- E xte nsi o n a n d W ee k 8- E xte nsi o n are pri maril y t o c oll ect la b tests a n d, if c o n d u cte d i n t he cli nic/st u d y site, t o c o n d uct a n E C G. If t h e patie nt atte n ds 
t he visit at t h e cli nic/st u d y site, a n ass ess me nt of a d v ers e e ve nts, c o n d uct of a n E C G a n d c ollecti o n of s a m ples f or la b a n al yses will b e c o m plete d.  If a 
p artici pa nt prefers t o n ot atte n d t he visit at t he cli nic/st u d y site, t he la b s a m ples ca n b e c ollecte d/c o n d u ct e d at a l o cal la b orat or y/l o cati o n a n d a tele p h o ne call 
t o c o nfir m t h es e were c ollecte d, as well t o ass ess a n y a d vers e e v e nts, will ta k e plac e. 
8 S u bje cts w h o dis c o nti n ue fr o m st u d y me dic ati o n pri or t o Wee k 4 8- E xte nsi o n will h a v e a n Earl y Dis c o nti n u ati o n visit 
 
 
 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 5 4  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
4. 3. 2
S cr e e ni n g P h a s e
T he p ur p os e of t he Scr ee ni n g p hase is t o e ns ure t h at t he a p pr o pri ate s u bj ects are e nter e d i nt o 
t he tri al a n d r e mai n sta ble d uri n g t he pr e-tre at m e nt p eri o d. It is esti mate d t h at a p pr o xi matel y 
3 6 0 s u bjects will e nter t he S cree ni n g p hase of t h e tri al. T he I n v esti gat or will d eter mi ne t h at t h e 
s u bject m eets eli gi bilit y criteria a n d will c oll ect d e m o gra p hic a n d me di cal data prese nti n g a f ull 
c haracteriz ati o n of t he s u bject. All att e m pts s h o ul d b e ma de t o o btai n me dical a n d p har m ac y 
rec or ds t o c o nfir m t he s u bj ect s me dical a n d m e dic ati o n treat me nt hist or y. D uri n g Scree ni n g, 
Bi o ha ve n ( or desi g n ee) ma y r e vie w rele va nt cli nic al i nf or mati o n t o c o nfir m t h e dia g n osis a n d 
s u bt y pe of M S A, f or st u d y eli gi bilit y a n d str atificati o n pri or t o ra n d o mizati o n. 
Scree ni n g will ra n ge fr o m a mi ni m u m of 1 d a y t o a ma xi m u m of 4 2 da ys. Please r efer t o t h e 
Sc he d ule of Ass ess me nts  & E ve nts ( Ta bl e 1 ) f or Scree ni n g pr oc e d ure det ails.  
If i niti al Scre e ni n g l a b s a m ple r es ults d o n ot m eet pr ot oc ol-s pecifie d eli gi bilit y criteri a a n d t h e 
I n vesti gat or d eter mi nes t hat a re p eat s a m ple ma y m e et t he r a n ge re q uire d f or eli gi bilit y, a 
re peat la b s a m ple ma y b e c ollecte d ( o ne r e peat c olle cti o n/ a nal ysis all o we d).  
R escree ni n g:  After o btai ni n g S p o ns or a p pr o val, a s u bject w h o d o es n ot meet pr ot oc ol re q uire d 
eli gi bilit y criteri a d uri n g Scree ni n g b ut w h o ma y p ot e ntiall y bec o me eli gi ble (e. g., l o gisti cal 
reas o ns s uc h as e xcee di n g s cr ee ni n g wi n d o w t o acc o m m o dat e ti me re q uire d f or 
a dj ust me nt/sta bilit y of c o nc o mit a nt m e dicati o n, was h o ut of pr o hi bit e d me dicati o n or re peat 
pr oce d ures t o all o w f or rec hec k/c o nfir mati o n of a n a b n or malit y t hat ma y meet t he re q uire d 
ra n ge i n a r eas o na ble a m o u nt of ti m e), ma y b e e nt ere d as a Scree n Fail ure i n I W R S a n d t he n 
rescree ne d o ne ti m e (e nt ere d as a Scr ee n Fail ure a n d Res cree n i n I W R S a n d e C R F).  If t he 
S p o ns or a p pr o ves Rescree ni n g f or a s u bje ct, i nstr u cti o ns will be pr o vi de d t o t he site re g ar di n g 
t he s pecific Scree ni n g pr oce d ur es/e val uati o ns t hat will nee d t o be re p eate d f or R escree ni n g, as 
t his is de pe n de nt o n t he a m o u nt of ti m e ela pse d. 
4. 3. 3
R a n d o mi z ati o n P h a s e 
S u bjects w h o are deter mi ne d t o be eli gi ble f or t he st u d y will be ra n d o miz e d i nt o t he trial. It is 
esti mate d t h at a p pr o xi matel y 3 2 5 s u bjects will b e ra n d o mize d a n d assi g ne d t o r ecei v e B H V-
3 2 4 1 ( 6 0 0 m g BI D) or matc hi n g pla ce b o ( BI D) i n a 1: 1 rati o, wit h ra n d o mizati o n stratifie d b y 
dis eas e s u bt y pe of eit her M S A- P vs. M S A- C, dia g n ostic cate g or y of eit her p ossi ble M S A vs. 
pr o ba ble M S A, a n d c o u ntr y. 
S u bjects s h o ul d be a d mi nistere d t he D a y 1/first d os e of st u d y me dic ati o n ( 3 0 0 m g Q D or 
m atc hi n g pl ace b o Q D) w hil e i n t he offic e/cli nic o n t he d a y of t he B as eli ne visit. S u bjects 
s h o ul d st a y at t he office/cli nic f o r m o nit ori n g f or a p pr o xi m atel y 4 h o urs. 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 5 5  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
D ose titrati o n peri o d: F or t he rest of W ee k 1, s u bjects will i n gest eit her 3 0 0 m g Q D of B H V-
3 2 4 1 or matc hi n g pla ce b o Q D. Fr o m st art t o e n d of Wee k 2, s u bjects will i n gest eit her 3 0 0 m g 
BI D of B H V- 3 2 4 1 or matc hi n g pla ce b o BI D.  S u bje cts s h o ul d ta ke t he st u d y dr u g t wi ce a da y; 
d osi n g i n t he m or ni n g a n d e v e ni n g a p pr o xi matel y 1 2 h o urs a part.  If t here is a del a y i n d osi n g, 
t he i nt er val b et wee n t w o d oses s h o ul d be n o l ess t ha n 6 h o urs. 
A n e n d of Wee k 2 ass ess me nt of c o m pli a nce a n d t ol era nce t o t his d ose titrati o n sc he d ul e will 
be c o n d uct e d.  Per I n vesti gat or j u d ge me nt, a d diti o nal e val u ati o ns/ pr o ce d ures ma y b e 
c o n d ucte d at t his ti m e p oi nt as a p pr o priat e.  If t ol era bilit y iss ues are e x perie nce d wit h 3 0 0 m g 
Q D or 3 0 0 m g BI D d osi n g, t he titrati o n sc he d ule m a y be m o difi e d (s ee Secti o n  7. 2. 3). 
F ull d os e p eri o d: St arti n g wit h We e k 3 a n d f or t he r e mai n der of t he st u d y, s u bje cts will i n gest 
eit her 6 0 0 m g BI D of B H V- 3 2 4 1 or matc hi n g place b o BI D. S u bjects s h o ul d ta ke t he st u d y 
dr u g t wice a d a y; d osi n g i n t he m or ni n gs a n d e ve ni n gs a p pr o xi mat el y 1 2 h o urs a part.  
At Wee ks 4, 1 2, 2 4, 3 6 a n d 4 8, t h e m or ni n g d os e of st u d y me dicati o n s h o ul d n ot be t a ke n o n 
t he da y of t h e st u d y visit u ntil it is a d mi nist ere d b y site pers o n nel d uri n g t he st u d y visit, s o t hat 
o ne pre- d os e (tr o u g h) a n d o ne p ost- d os e P K s a m pl e ca n be c olle cte d a p pr o xi matel y 2- 4 h o urs 
p ost- d os e (s ee Secti o n 6. 3. 2).  
T he t a blets s h o ul d be s w all o we d w h ol e wit h a dri n k of w ater. T he t a blets s h o ul d n ot be 
s plit, c he we d, or cr us he d. 
St u d y me dic ati o n ca n be ta ke n wit h o ut re gar d t o meals, h o we ver, t he last m ealti me pri or t o 
c olle cti o n of P K sa m pl es s h o ul d be o btai ne d. 
If s u bjects ha ve diffic ult y t olerati n g B H V- 3 2 4 1 6 0 0 m g BI D, t he n t he d os e ma y be a dj uste d 
(s ee Secti o n 7. 2. 3).  
T here is a +/- 3 da y visit a n d pr oc e d ure wi n d o w d uri n g t he st u d y, u nless ot her wise s pecifi e d. 
Please refer t o t he Sc he d ule of Assess me nts & E ve nts ( Ta ble 1 ) f or details o n pr oce d ures.  
4. 4 
E n d of Tr e at m e nt 
Patie nts will ha ve a Wee k 4 8/ Earl y Disc o nti n u ati o n visit w he n t he y eit h er c o m plete t he st u d y 
at Wee k 4 8 or dis c o nti n ue fr o m st u d y m e dic ati o n earl y ( pri or t o Wee k 4 8).  T he Wee k 
4 8/ Earl y Dis c o nti n uati o n ass ess me nts/ pr o ce d ures s h o ul d be c o n d ucte d as a n i n pers o n visit at 
t he st u d y site.  E ver y eff ort s h o ul d be ma d e t o c o n d u ct t he Wee k 4 8 visit a n d mai ntai n a +/- 7 
da y wi n d o w. H o w e ver, d ue t o t he C O VI D- 1 9 p u blic healt h e mer g e nc y, if a bs ol utel y n ecess ar y, 
i n or der t o mi ni mize p ote ntial ris ks t o st u d y partici pa nt safet y a n d t o c o m pl y wit h 
g o ver n me nt al a n d l ocal i nstit uti o nal g ui da n ce (e. g., st u d y site has a p olic y t hat a n i n pers o n 
cli ni cal r es earc h visit m ust be d ela y e d), t he Wee k 4 8 visit wi n d o w ma y be e x pa n de d b e y o n d 
t he +/- 7 da y wi n d o w u p t o a n a d diti o nal 1 2 wee ks ( ma xi m u m tre at m e nt d urati o n of 6 0 wee ks).  
H o w e ver, e ver y att e m pt s h o ul d b e ma d e t o c o n d u ct t he visit as cl ose as p ossi ble t o t he date t hat 
t he visit is d ue. U n der t hese circ u msta nces, t h e I n vesti gat or s h o ul d dis c uss t he s pecific 
circ u mst a nces of t h ese cas es wit h t h e s p o ns or me dic al m o nit or ( or desi g ne e), w h o m ust 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 5 6  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
a p pr o ve t he r e q uest t o e xte n d t h e tre at m e nt d urati o n, pri or t o a n y m o dific ati o n of t he visit 
wi n d o w. 
If t he Wee k 4 8 visit wi n d o w is m o difie d, partici pa nts s h o ul d ha ve s afet y ass ess me nts e v al uat e d 
re m otel y (e. g., vi a p h o ne) a n d safet y la bs c o n d u cte d (at a l o cal la b) at t he ti me of t he sc he d ule d 
Wee k 4 8 visit. 
F or s u bjects w h o dis c o nti n ue earl y, d e pe n di n g o n t h e reas o n f or earl y dis c o nti n u ati o n ( e. g., 
decli ni n g patie nt st at us), s o me pr oce d ur es (f or e xa m ple, P K sa m ples, P D sa m ples, l u m b ar 
p u nct ure), m a y n ot be c o n d ucte d at t his visit.  C o n d u ct of all pr oce d ures, if p ossi ble, is 
e nc o ura ge d.  If p ossi bl e, t he s u bje cts w h o dis c o nti n u e fr o m st u d y me dicati o n pri or t o Wee k 4 8 
s h o ul d be c o nta cte d b y a f oll o w u p p h o ne c all at t h e a p pr o xi mate ti me of t heir W ee k 4 8 visit, 
t o c oll ect i nf or mati o n o n cli nic al stat us (i ncl u di n g Ti me t o E v e nt m eas ures of dis ease 
pr o gressi o n, a n d if a p plica ble, A Es, S A E S). 
4. 5 
P o st St u d y A c c e s s t o T h er a p y/ O p e n- L a b el E xt e n si o n P h a s e  
T he O L E P hase is a n o pti o nal 4 8 w ee k o pe n-l a bel tr eat m e nt p has e f oll o wi n g t h e d o u ble- bli n d 
p hase of t he st u d y.  
4. 5. 1  
O pe n- L a bel E xte nsi o n P h ase Eli gi bilit y Crite ri a 
ris k- be nefit pr ofile, t he c o ns e nt of t he partici pa nt a n d t he i nt e grit y of t he trial, t o deter mi ne 
w het her a st u d y partici pa nt is a p pr o priat e a n d eli gi bl e t o c o nti n ue partici pati o n i n t he o pti o nal 
O L E P has e, bas e d o n cli nical j u d ge me nt, t he restrict e d a n d pr o hi bite d m e dicati o n criteria 
s pecifie d i n pr ot oc ol s ecti o n 5. 4, t he disc o nti n uati o n criteria g ui d a nce s pecifie d i n pr ot oc ol 
s ecti o n 6. 4  a n d r e vie w of t he f oll o wi n g criteria:  
 C o m pleti o n of t he 4 8 w ee k D o u ble- Bli n d ra n d o mize d p has e of t he st u d y. Partici p a nts w h o 
earl y-t er mi n ate d fr o m t he d o u bl e- bli n d p h ase of t he trial or w h o disc o nti n ue d t h e st u d y 
me dic ati o n f or a n y reas o n will n ot eli gi bl e f or e nr oll me nt i n t he O L E p h as e. All 
partici pa nts m ust h a ve t h eir We e k 4 8 visit i n- pers o n pri or t o e nr olli n g i n t he O L E p h ase. 
D ue t o C O VI D- 1 9, t he ti mi n g of t his visit ma y be d ela ye d.  
 St u d y partici pa nts m ust b e:  
o  a ble t o c o nti n u e t o s w all o w w h ole st u d y me dic ati o n ta blets  
o  willi n g a n d a ble t o c o nti n ue t o  
 a d here t o t he st u d y dr u g re gi me n  
 t o parti ci pate i n all pr ot oc ol s pecific ass ess me nts, a n d 
 t o c o m pl y wit h t he st u d y visit s c he d ule. 
 Pr o vi de i nf or me d c o ns e nt t o p artici pat e i n t h e O L E p hase.  All s u bjects w h o e nter t h e O L E 
p hase will si g n a n e w i nf or me d c o ns e nt f or m.  


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 5 7  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
4. 5. 2
O pe n- L a bel E xte nsi o n P h ase Pr oce d ures
W he n a sit e is o pe n f or recr uit m e nt t o t he O L E P has e, parti ci pa nts c o m pl eti n g t he d o u ble- bli n d 
treat me nt p h ase w h o c h o os e t o partici p ate i n t he O L E p has e a n d ar e eli gi ble t o c o nti n ue, m ust 
c o nse nt t o t h e O L E p has e a n d directl y e nter t h e O L E p has e starti n g at W ee k 4 8 visit of t he 
d o u ble- bli n d treat me nt p hase. T he Wee k 4 8 visit will s er ve as t he B aseli n e- E xte nsi o n visit i n 
t he O L E p has e f or p artici pa nts w h o m o ve directl y fr o m t he d o u bl e- bli n d treat me nt p hase t o t h e 
O L E. T here after, partici pa nts will u n der g o visits at Wee k 2- E xte nsi o n, Wee k 4- E xt e nsi o n, 
Wee k 8- E xte nsi o n, Wee k 1 2- E xt e nsi o n, a n d t h e n e v er y 1 2 wee ks of t he O L E p has e as o utli n e d 
i n Ta bl e 2  ( Sc he d ul e of Ass ess me nts & E ve nts- E xt e nsi o n P hase).  
A partici p a nt w h o has c o m plete d t he d o u bl e- bli n d tr eat m e nt p hase of t he st u d y pri or t o t he 
O L E p hase of t he st u d y b ei n g a p pr o ve d a n d o pe n f or recr uit me nt at t h e st u d y ce nt er w here t h e y 
are partici p ati n g, c a n rec o ns e nt a n d start t he O L E p h as e as l o n g as t he i n vesti g at or det er mi n es 
t hat o pe n-la bel treat me nt offers a n a cce pta bl e ris k- be nefit pr ofile f or t h e parti ci pa nt. O nce t h e 
st u d y site is o pe n f or recr uit me nt f or t h e O L E, st u d y partici pa nts w h o pre vi o usl y c o m pl ete d t h e 
d o u ble- bli n d p h ase of t he st u d y will ha v e u p t o a p pr o xi mat el y 1 2 wee ks (fr o m t he dat e of O L E 
o pe ni n g at t he sit e) t o e nr oll a n d c o m plete t h e O L E B aseli ne- E xte nsi o n Visit, re gar dless of 
t heir date of d o u bl e- bli n d p hase c o m pl eti o n.  
F or partici p a nts w h o ha ve bee n off of t he st u d y dr u g f or less t ha n 4 wee ks, t he s u bj ect s h o ul d 
atte n d a n A b bre viate d Dr u g Dis pe ns ati o n Visit at t h e i n vesti gati ve site, w he n m e dical a n d/ or 
me dic ati o n c ha n ges will be re vi e w e d pri or t o dis pe nsi n g o pe n-la b el B H V- 3 2 4 1.  I n t his cas e, 
f or t hes e partici p a nts, t he Wee k 4 8 visit will als o s er ve as t he Baseli ne- E xte nsi o n visit i n t he 
O L E P has e.  T here after, partici pa nts will u n der g o visits at We e k 2- E xt e nsi o n, Wee k 4-
E xte nsi o n, W ee k 8- E xte nsi o n, Wee k 1 2- E xt e nsi o n, a n d t he n e ver y 1 2 we e ks of t he E xt e nsi o n 
P hase as o utli ne d i n Ta ble 2  ( Sc he d ule of Ass ess me nts & E ve nts- E xte nsi o n P hase). 
F or partici p a nts w h o will ha v e bee n off of t h e st u d y dr u g f or greater t ha n or e q ual t o 4 wee ks, 
t hese partici p a nts s h o ul d be re-ass esse d a n d re- c o nse nte d b y t he I n v esti gat or d uri n g a n O L E 
Bas eli ne- E xte nsi o n Visit. Fr o m t he d ate t hat t he O L E is o pe n f or recr uit m e nt at t heir 
i n vesti gati ve site, t h es e partici pa nts will ha v e u p t o a p pr o xi mat el y 1 2 wee ks t o c o m pl ete t h e 
O L E Bas eli n e- E xt e nsi o n Visit. T h ereaft er, partici p a nts will u n der g o visits at W ee k 2-
E xte nsi o n, Wee k 4- E xte nsi o n, We e k 8- E xt e nsi o n, W ee k 1 2- E xt e nsi o n, a n d t h e n e ver y 1 2 
w ee ks of t he E xt e nsi o n P hase as o utli ne d i n T a ble 2  ( Sc he d ule of Ass ess me nts & E ve nts- 
E xte nsi o n P hase).
D ose Titr ati o n:  S u bjects e nteri n g t he O L E p has e of t he st u d y will r ecei ve o pe n-l a bel acti ve 
B H V- 3 2 4 1 a n d will f oll o w t he s a me d os e titrati o n sc he d ule as t h e titrati o n i n t h e d o u ble- bli n d 
p hase of t he st u d y, t o e ns ure t hat all p arti ci pa nts s afel y c o nti n u e fr o m eit her a cti v e B H V- 3 2 4 1 
or place b o t o o pe n-l a bel B H V- 3 2 4 1. 
S u bjects s h o ul d be a d mi nistere d t he D a y 1/first d os e of o pe n-l a bel B H V- 3 2 4 1 ( 3 0 0 m g 
Q D) w hile i n t he office/cli nic o n t h e d a y of t he B aseli ne- E xte nsi o n visit.  S u bjects s h o ul d 
st a y at t h e office/cli nic f or m o nit ori n g f or a p pr o xi m atel y 4 h o urs. 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 5 8  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
F or t he r est of We e k 1- E xte nsi o n of t he O L E p h as e, s u bjects will i n gest o ne ta bl et of B H V-
3 2 4 1 ( 3 0 0 m g) per da y i n t he m or ni n g f or o ne wee k.  Fr o m start t o e n d of Wee k 2- E xte nsi o n, 
s u bjects will i n gest 3 0 0 m g BI D of B H V- 3 2 4 1.  S u bjects s h o ul d ta k e o ne 3 0 0 m g ta bl et of 
B H V- 3 2 4 1 t wice a da y ( 6 0 0 m g p er da y); i n t he m or ni n gs a n d e ve ni n gs, a p pr o xi matel y 1 2 
h o urs a part.  If t here is a del a y i n d osi n g, t h e i nt er val bet wee n t w o d os es s h o ul d be n o l ess t ha n 
6 h o urs.
A n e n d of Wee k 2- E xte nsi o n ass ess me nt of c o m pli a nce a n d t olera nce t o t his d ose titr ati o n 
s c he d ule will be c o n d u cte d.  Per I n vesti gat or j u d ge m e nt, a d diti o nal e val uati o ns/ pr oce d ures 
ma y be c o n d u cte d at t his ti m e p oi nt as a p pr o priat e.  If t olera bilit y iss ues are e x perie nc e d wit h 
3 0 0 m g Q D or 3 0 0 m g BI D d osi n g, t he titr ati o n sc h e d ule ma y b e m o difi e d (s ee Secti o n  7. 2. 3). 
Starti n g wit h Wee k 3- E xte nsi o n a n d f or t he re mai n d er of t he O L E p h as e of t he st u d y 
(a d diti o n al 4 6 w ee ks), s u bjects will i n gest 6 0 0 m g BI D of B H V- 3 2 4 1. S u bjects s h o ul d ta ke t w o 
3 0 0 m g ta bl ets of B H V- 3 2 4 1 t wice a d a y ( 1 2 0 0 m g per da y); i n t he m or ni n gs a n d e ve ni n gs, 
a p pr o xi matel y 1 2 h o urs a p art.  
S u bjects w h o w ere ta ki n g a re d uc e d d ose of 3 0 0 m g BI D ( o ne ta blet t wic e a da y) of t h e bli n d e d 
st u d y me dicati o n d u e t o t olera bilit y iss ues w he n t he y c o m plete d t h e d o u ble- bli n d p hase of t h e 
pr ot oc ol, m a y c o nti n ue t a ki n g 3 0 0 m g BI D d uri n g t h e O L E. 
5 
P O P U L A TI O N 
5. 1 
N u m b er of S u bj e ct s 
A p pr o xi matel y 3 2 5 s u bjects are e x pe cte d t o be ra n d o mize d i n t his st u d y.  
5. 2 
I n cl u si o n Crit eri a 
1.  I nf or me d C o nse nt 
a. S u bjects m ust pr o vi d e a writte n si g ne d a n d date d i nf or me d c o ns e nt f or m/f or ms 
(I R B/ E C s pecific) i n acc or da n ce wit h r e g ulat or y a n d i nstit uti o nal g ui deli nes, pri or t o 
t he i nitiati o n of a n y pr ot oc ol r e q uire d pr oc e d ures.  O nl y pati e nts wit h t h e ca p acit y t o 
u n dersta n d t he n at ure, si g nifica n ce a n d sc o p e of t he cli ni cal trial i nt er ve nti o ns a n d t o 
e x press t heir wis hes acc or di n gl y m a y pr o vi de c o nse nt t o partici p ate i n t he st u d y. 
b.  Care gi vers m ust b e willi n g t o si g n a n d d ate a n I R B/ E C-a p pr o ve d writte n i nf or me d 
c o nse nt f or m t h at o utli nes t h e care gi ver e x p ect ati o ns a n d res p o nsi bilities i n t his st u d y 
(s ee I ncl usi o n criteri o n 3 k), i n acc or da nc e wit h re g ul at or y a n d i nstit uti o nal g ui deli nes, 
as a p pr o priat e. 
2.  A ge a n d Se x 
a. M ale a n d fe mal e s u bjects bet wee n t h e a ges of > 4 0 t o < 8 0 years at ti me of Scr ee ni n g. 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 5 9  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
3.
T ar get P o p ul ati o n
a. Dia g n osis of pr o ba ble or p ossi ble M S A acc or di n g t o c o ns e ns us cli nical criteri a ( Gil m a n 
et al 2 0 0 8), i ncl u di n g s u bjects wit h M S A of eit her s u bt y pe ( M S A- P or M S A- C).
b.  A ble t o a m b ulat e wit h o ut t he assista n ce of a n ot h er p ers o n, defi ne d as t h e a bilit y t o ta ke 
at le ast 1 0 ste ps. Use of assisti ve de vices (e. g., wal k er or ca ne) is all o we d.
c. A ntici pate d s ur vi val of at least 3 ye ars at t h e ti me of S cree ni n g, as j u d g e d b y t he 
I n vesti gat or.
d.  A brai n M RI s ca n (c o n d ucte d wit hi n t he 1 4 da ys pri or t o Bas eli n e/ Da y 1, 
a p pr o xi matel y) t hat d o es n ot r ule o ut a dia g n osis of M S A.  
e. A ble t o t ol erat e M RI. 
f. B o d y mass i n de x ( B MI) < 4 0 k g/ m 2 at Scree ni n g. 
g.  A ble t o s w all o w ta blets w h ole a n d a ntici pate d t o b e a ble t o d o s o t hr o u g h o ut t he 
d urati o n of t h e st u d y. 
h.  Willi n g a n d a ble t o a d here t o t he st u d y dr u g re gi me n. 
i. Willi n g a n d a ble t o p erf or m all pr ot oc ol-s pecifie d ass ess me nts a n d c o m pl y wit h t he 
st u d y visit s c he d ul e.  
j. A ble t o rea d, u n d ersta n d, a n d s pea k l ocal la n g u a ge fl ue ntl y t o e ns ure c o m pr e he nsi o n of 
i nf or me d c o ns e nt a n d pr ot o c ol-s pecifie d ass ess me nts. 
k.  M ust ha ve reli a ble care gi v er t o a cc o m p a n y s u bject t o st u d y visits, wit h t he sa me 
care gi v er c o m pleti n g care gi ver ass ess me nts at Bas eli ne, Wee k 2 4 a n d Wee k 4 8/ Earl y 
Disc o nti n uati o n, w he n p ossi ble. Car e gi ver m ust be a ble t o re a d, u n dersta n d, a n d s pe a k 
l ocal la n g ua g e fl ue ntl y t o e ns ure c o m pre h e nsi o n of i nf or me d c o ns e nt a n d pr ot oc ol-
s pecifie d ass ess me nts. Care gi ver m ust als o ha v e fre q ue nt c o nt act wit h s u bject (at l east 3 
h o urs per w ee k at o ne ti me or differe nt ti mes) a n d be willi n g t o m o nit or t he s u bje ct's 
healt h a n d c o nc o mit a nt me dicati o ns t hr o u g h o ut t he st u d y. 
l. If s u bject is recei vi n g treat me nt f or M S A, t he d oses m ust ha ve bee n sta bl e f or at l east 
3 0 da ys pri or t o Bas eli ne/ R a n d o mi zati o n a n d me dicati o ns pres e nt at Baseli ne e x pecte d 
t o re mai n rel ati v el y sta ble d uri n g t h e st u d y peri o d. T his ma y i ncl u de m e dic ati o ns 
c o m m o nl y us e d f or Par ki ns o n's disease (e. g., c oe nz y me Q 1 0, le v o d o pa/car bi d o pa, 
le v o d o pa/ b e ns erazi de, fa va b ea n e xtract, a d o pa mi ne a g o nist, catec h ol- 0-
met h yltra nsferase i n hi bit or, a ma nta di n e) or t h ose f or a ut o n o mi c d ysf u ncti o n ( e. g., 
e p he dri ne, mi d o dri n e, fl u dr oc ortis o ne, octr e oti d e, des m o pressi n, o x y b ut y ni ne, 
dr o xi d o pa). 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 6 0 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
m. Sta ble o n ot h er c hr o ni c me dicati o ns a n d s u p ple m e nts f or at least 3 0 d a ys pri or t o
Bas eli ne/ Ra n d o mizati o n a n d e x pect e d t o re mai n r elati vel y st a ble d uri n g t he st u d y 
peri o d.
n.
W o me n of c hil d beari n g p ote ntial ( W O C B P) [s ee pr ot oc ol secti o n 5. 5] a n d f ertile me n 
(i ncl u di n g t h os e vas ect o mi ze d f or less t ha n 6 m o nt hs) wit h fe male part ners w h o are 
W O C B P ( n ot s ur gicall y st eril e a n d n ot p ost me n o pa us al) [s ee pr ot oc ol s ecti o n 5. 5] m ust 
a gree t o use hi g hl y effe cti v e birt h c o ntr ol, i ncl u di n g t w o met h o ds of c o ntr ace pti o n, f or 
t he d urati o n of t he st u d y (i.e., be gi n ni n g 3 0 da ys pri or t o Bas eli n e/ Ra n d o mizati o n a n d 
e xte n di n g t o 3 0 da ys f or w o me n a n d 9 0 da ys f or m e n after t he last d os e of st u d y dr u g). 
T he t w o met h o ds of c o ntra ce pti o n s h o ul d i ncl u d e:
i.
o ne barrier met h o d (e. g. dia p hra g m wit h s per mici d e, c o n d o m wit h s per mici d al gel, 
cer vical ca p); 
ii.
a n d o ne ot her met h o d t hat c o ul d i ncl u de h or m o n al c o ntrace pti ves (e. g. oral 
c o ntrac e pti v es, i njecta bl e c o ntr ace pti ves, c o ntrace pti ve i m pl a nt, patc h) use d f or at 
least 4 w ee ks pri or t o se x ual i nterc o urse ( Se cti o n 5. 5); 
o.
W O C B P m ust ha ve a ne g ati v e s er u m pre g na n c y test at S cree ni n g a n d a ne g ati v e uri ne 
pre g na nc y t est wit hi n a p pr o xi matel y 2 4 h o urs pri or t o d osi n g at 
Bas eli ne/ Ra n d o mizati o n.
5. 3
E x cl u si o n Crit eri a
1.
T ar get Dis e ase E xce pti o ns
a.
S u bjects ha vi n g a d va nc e d disease, defi ne d b y t h e prese nce of o ne or m ore of t he 
f oll o wi n g o n t he U M S A R S Part I:
i.
S peec h i m p air m e nt, as assesse d b y a sc ore gre ater t h a n or e q ual t o 3, Q uesti o n 1;
ii.
S w all o wi n g i m pair me nt, as ass ess e d b y a s c ore of gr eater t ha n or e q ual t o 3 o n 
Q uesti o n 2;
iii. Falli n g m or e fre q ue ntl y t h a n o nce per wee k, as ass ess e d b y a s c ore of great er t ha n 
or e q ual t o 3 o n Q uesti o n 8; or 
2.
Me dic al Hist or y E xcl usi o ns
a.
i nstr ucti o ns, pl ace t he s u bje ct at u n acc e pta ble ris k, a n d/ or c o nf o u n d t he i nter pr etati o n of 
s afet y or effi cac y data fr o m t he st u d y, as j u d g e d b y t he I n vesti gat or.
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 6 1  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
b.
Dia g n osis of ne ur ol o gic al dis or ders, ot h er t ha n M S A, i ncl u di n g ( b ut n ot li mite d t o) t he 
f oll o wi n g:
i. I di o pat hi c Par ki ns o n's dis eas e or a n ot her f or m of par ki ns o nis m (e. g., de m e nti a wit h 
Le w y b o dies, dr u g-i n d uc e d, p ost-e nce p h alitic, v asc ular), w hic h has n ot 
s u bse q ue ntl y re vise d t o a di a g n osis of M S A, 
ii. A n y ot her ne ur o de ge ner ati v e dis eas e ( e. g., Alz hei mer's dis ease, fr o nt ote m p oral 
de me ntia, a m y otr o p hi c lateral s cler osis, pri o n dis eas e),
iii. A n y ot her cli nicall y si g nifica nt ne ur ol o gi cal dis or der (e. g., hist or y of str o ke, hist or y 
of hea d i nj ur y wit h l oss of c o nsci o us ness f or at least 1 5 mi n utes wit hi n t he p ast 2 0 
years, hist or y of s eiz ur e dis or der, brai n t u m or, or ot h er s pace- occ u p yi n g lesi o n). 
c. Hist or y of or S cree ni n g brai n M RI sca n i n dicati v e of si g nifica nt a b n or m alit y, i ncl u di n g 
( b ut n ot li mit e d t o) t h e f oll o wi n g: pri or he m orr ha ge or i nfarct gr eater t ha n 1 c m 3; 3 or 
m ore la c u nar i nfar cts; cere bral c o nt usi o n; e nc e p hal o malacia; a ne ur ys m; vasc ular 
malf or m ati o n; s u b d ural he mat o ma; h y dr oc e p hal us; s pace- oc c u p yi n g lesi o n (e. g., 
a bscess or brai n t u m or). 
d.  C o ntrai n di cati o n t o M RI e xa mi nati o n f or a n y re as o n. 
e. F or t h ose partici pati n g i n t h e o pti o n al C S F s u b-st u d y, c o ntrai n dicati o n t o u n d er g oi n g a n 
L P i ncl u di n g, b ut n ot li mite d t o: i na bilit y t o t olerate a n a p pr o priatel y fle xe d p ositi o n f or 
t he ti me ne cess ar y t o perf or m a n L P; i nf ecti o n at t he desire d L P site; ta ki n g 
a nti pl atelet/a ntic oa g ul a nt m e dicati o ns t h at ca n n ot be disc o nti n ue d f or a s h ort peri o d of 
ti me pri or t o perf or mi n g t h e L P; de ge n erati ve art hritis of t he l u m bar s pi n e; s us pect e d 
n o n-c o m m u ni cati n g h y dr oce p hal us or i ntra cra ni al m ass; pri or hist or y of s pi nal mass or 
tra u ma. 
f. Pres e nce of cli nicall y si g nifica nt t h yr oi d disease wit h a b n or mal fr ee T 4 le vels a n d T S H 
> 1 0 mI U/ L ( des pit e tre at m e nt) at Scree ni n g, c o nfir m e d b y re peat .   
g.  Wit hi n 1 y ear pri or t o S cree ni n g or b et wee n S cr ee ni n g a n d Bas eli n e ( Da y - 1), a n y of 
t he f oll o wi n g: m y oc ar dial i nfarcti o n; h os pitalizati o n f or c o n gesti ve h eart fail ure; 
h os pitali zati o n f or, or s y m pt o ms of, u nsta ble a n gi na; or s y nc o pe n ot rel ate d t o M S A. 
h.  Dia g n osis of cli ni call y si g nifi ca nt ps yc hiatri c dis or d er i ncl u di n g ( b ut n ot li mite d t o) t he 
f oll o wi n g: a n y ps yc h otic dis or der, s e vere bi p olar or u ni p olar de pr essi o n, pri or hist or y 
of s uici dal t h o u g hts or be ha vi or t hat are belie v e d t o r e prese nt a c urre nt safet y ris k.  
i. Hist or y of s u bsta nce us e dis or der ( dr u g or al c o h ol) i n t he last 1 2 m o nt hs, wit h t h e 
e xce pti o n of nic oti ne, as defi ne d b y D S M- V criteri a. 
j. Hist or y or pres e nce of gastr oi ntesti n al or ot h er disease k n o w n t o i nterfer e wit h 
a bs or pti o n, distri b uti o n, m eta b olis m, or e x creti o n of dr u gs, or a hist or y of s ur ger y 
k n o w n t o i nterfer e wit h a bs or pti o n or e xcreti o n of dr u gs (i.e., gastric b y p ass). 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 6 2  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
k.
Hist or y of a n y ot her cli ni call y si g nifica nt dis e as e (e. g., a ut oi m m u ne, c ar di o vasc ular, 
e n d ocri ne, g astr oi nt esti nal, he mat ol o gi cal, h e patic, i m m u n ol o gi cal, i nfecti o us, 
ne ur ol o gic al, p ul m o nar y, ps yc hiatric, or r e nal) t hat, bas e d o n t he j u d g me nt of t he 
I n vesti gat or, is cli nicall y u nsta ble, is li kel y t o deteri orate d uri n g t he c o urse of t h e st u d y, 
c o ul d p ut t h e patie nt at ris k bec a us e of partici p ati o n i n t he st u d y, c o ul d affect t he 
 
l. Hist or y of h u ma n i m m u n o defi cie n c y vir us i nfecti o n. 
m.  H e mat ol o gic or s oli d mali g na nc y dia g n osis wit hi n 5 years pri or t o Scre e ni n g. [ N ote: 
S u bjects wit h a hist or y of l oc ali ze d s ki n ca n cer, bas al cell or s q ua m o us cell car ci n o m a, 
ma y be e nr olle d i n t he st u d y as l o n g as t he y ar e ca n c er free pri or t o ra n d o mi zati o n. 
S u bjects wit h ot h er l oc ali ze d ca n cers ( wit h o ut met astati c s prea d) w h o ha ve pre vi o usl y 
c o m plete d t h eir c o urse of tr eat me nt m ore t h a n 5 years pri or t o Scree ni n g, are n ot 
c urre ntl y r ecei vi n g tre at m e nt a n d h a ve be e n i n re missi o n ma y be e nr olle d o nl y if, i n t he 
o pi ni o n of t he I n v esti gat or, t here is n o e x pectati o n f or rec urre nce or f urt her c a ncer 
treat me nt d uri n g t he st u d y p eri o d. A nti h or m o nal t h er a p y (e. g., ta m o xife n) is all o we d if 
t he s u bject's c a ncer is i n r e missi o n a n d t he s u bje ct is o n sta ble m ai nt e na nce t hera p y t o 
re d uce t h eir ris k of rec urr e nce.] 
n.  A n y maj or s ur ger y wit hi n 4 we e ks of Scree ni n g. 
o.  Bl o o d tra nsf usi o n wit hi n 4 we e ks of Scree ni n g. 
p.  Hist or y of brai n s ur ger y f or Par ki ns o nis m (i. e., dee p- brai n sti m ulati o n).
q.  Hist or y of ste m-cell tr eat me nt. 
r. W o me n w h o are pre g n a nt or breastfee di n g. 
s. S u bjects or pris o ners w h o are i n v ol u ntaril y det ai ne d or i ncarcerate d f or treat me nt of 
eit her a ps yc hiatric or p h ysical ill ness m ust n ot b e e nr olle d i nt o t he st u d y. 
t. A n y me dical c o n diti o n, base d o n t he j u d ge me nt of t h e I n vesti gat or, t hat w o ul d 
c o nf o u n d t he a bilit y t o a d e q uatel y ass ess s afet y a n d efficac y o utc o me meas ures 
3.  P h ysic al a n d L a b or at o r y Test Fi n di n gs 
a. E vi de nc e of or ga n d ysf u ncti o n or a n y cli nicall y si g nifica nt d e viati o n fr o m n or mal i n 
p h ysical e x a mi n ati o n, vital si g ns, E C G, or cli nical la b orat or y det er mi n ati o ns be y o n d 
w hat is c o nsiste nt wit h t he tar get p o p ulati o n. 
b.  Cli nic all y si g nifica nt a b n or malit y o n 1 2-le a d E C G pri or t o st u d y dr u g a d mi nistrati o n 
be y o n d w hat is c o nsiste nt wit h t h e tar g et p o p ulati o n, c o nfir me d b y r e peat. 
c. 
 Scr ee ni n g/ B as eli n e peri o d or 
u nc o ntr oll e d arr h yt h mia or fre q u e nt pre mat ur e ve ntri c ular c o ntracti o n ( P V Cs) ( > 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 6 3  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
5/ mi n ut e) or M o bitz T y pe II sec o n d or t hir d de gre e atri o ve ntric ul ar ( A V) bl oc k or left 
b u n dle bra nc h bl oc k, or ri g ht b u n dle bra n c h bl oc k wit h a Q R S 
or s u b-ac ute m y o car dial i nfar cti o n or isc he mia or ot h er E C G fi n di n gs t hat, i n t h e 
d y. 
d.  A b n or mal free T 4 le vels a n d T S H > 1 0 mI U/ L ( des pite tr eat me nt) at Scree ni n g, 
c o nfir me d b y r e peat. 
e. T otal bilir u bi n, al a ni ne a mi n otra nsferas e ( A L T) or as partat e a mi n otra nsferas e ( A S T) 
greater t ha n 2 ti mes t he u p p er li mit of n or mal ( U L N), c o nfir me d b y r e p eat.  If t he 
M e dical M o nit or. 
f. Pat h ol o gic r e nal fi n di n gs at S cr ee ni n g as defi ne d b y t he pres e nc e of eit h er of t he 
f oll o wi n g criteri a: 
i. Esti mate d gl o mer ul ar filtrati o n r ate ( e G F R) acc or di n g t o t he re- e x press e d 
a b bre viate d (f o ur- vari a ble) M o dificati o n of Diet i n R e nal Disease ( M D R D) St u d y 
e q uati o n < 3 0 ml/ mi n/ 1. 7 3 m 2; T h e M D R D esti mati o n is calc ulat e d as f oll o ws: 
e G F R ( m L/ mi n/ 1. 7 3 m 2) = 1 7 5 x (sta n d ar diz e d S cr)- 1. 1 5 4 x ( A ge)- 0. 2 0 3 x ( 0. 7 4 2 if 
fe mal e) x ( 1. 2 1 2 if Bl ac k). [ Scr: Sta n d ar diz e d s er u m creati ni ne]; 
ii. 
g.  H e mat ol o gic a b n or maliti es at Scree ni n g: 
i. H e m o gl o bi n < 1 0 g/ d L; or 
ii. W B C < 3. 0 x 1 0 3/ m m 3; or 
iii. Platel et c o u nt < 1 0 0, 0 0 0/ m m 3; or 
i v. 
/ m m3 
h.  H e m o gl o bi n A 1 C > 7. 5 %, c o nfir me d b y re p eat. 
i. Uri ne dr u g s cree n p ositi ve f or a dr u g of a b us e, f or w hic h t he p ati e nt d oes n ot h a ve a 
vali d pres cri pti o n a n d is s us pecte d of a b usi n g, i n t he j u d ge me nt of t he I n v esti gat or.  
N ote: uri ne dr u g s cr ee n p ositi ve f or ca n n a bis is e xcl usi o nar y u nless t he I n vesti gat or a n d 
M e dical M o nit or a gree t hat t he s u bje ct c a n a bstai n fr o m use f or t he d urati o n of t h e 
st u d y, or if t he s u bje ct has a v ali d me dic al prescri pti o n. 
j. H u ma n I m m u n o defici e nc y Vir us ( HI V) p ositi ve at S cree ni n g (i n dic ate d b y p ositi ve 
c o nfir mat or y West er n Bl ot);


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 6 4  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
k.
H Bs A g or H C V p ositi ve at Scre e ni n g;
l. F or W O C B P, p
- h C G w hic h is i n dicati ve of pre g na n c y a n d n ot fals e 
p ositi ve at Scree ni n g or a p ositi ve uri ne pr e g na nc y test at Bas eli ne. 
4.  Pr o hi bite d a n d R estricte d Tre at m e nts a n d/ or T her a pies (c a n be w as he d o ut d uri n g 
Scree ni n g) 
a. Partici p ati o n i n a n ot h er cli nical tri al f or a n i n vesti g ati o nal a g e nt a n d h a vi n g t a ke n at 
least o ne d ose of st u d y me di cati o n, u nless c o nfir m e d as ha vi n g bee n o n place b o, is 
e xcl u de d wit hi n 9 0 da ys or 5 half-li ves ( w hic h e ver is l o n ger) pri or t o 
Bas eli ne/ Ra n d o mizati o n. T h e e n d of a pre vi o us i n vesti gati o n al trial is defi ne d as t he 
date of t h e last d os e of a n i n vesti g ati o n al a g e nt.  
b.  D o pa mi ne a nta g o nists, i n cl u di n g met o cl o pra mi de a n d a nti ps yc h otic m e dicati o ns are 
e xcl u de d. 
i. Q uetia pi n e a n d cl oza pi n e are all o we d if t he d oses ar e sta ble f or at l east 3 0 da ys 
pri or t o Bas eli ne/ R a n d o mi zati o n
c. I n hi bit ors of C Y P 1 A 2 - Str o n g i n hi bit ors of C Y P 1 A 2 (i.e., ci pr ofl o xaci n, e n o xaci n, 
fl u v o xa mi n e, zafirl u kast) c o ul d p ote ntiall y i n crease B H V- 3 2 4 1 le vels a n d are e x cl u de d 
f or c hr o nic/l o n g-ter m ( > 2 wee ks) us e.  Str o n g i n hi bit ors of C Y P 1 A 2 f or ac ute/s h ort-
ter m us e s h o ul d be a v oi de d, if p ossi ble, or use d wit h ca uti o n, b ase d o n t he cli nical 
j u d ge me nt of t he i n vesti g at or.  M o derat e i n hi bit ors of C Y P 1 A 2 (i.e., met h o xs ale n) 
c o ul d p ote ntiall y i n creas e B H V- 3 2 4 1 le vels a n d s h o ul d be us e d wit h c a uti o n f or 
c hr o nic/l o n g-ter m us e, base d o n t he cli nical j u d ge me nt of t he i n v esti gat or.   
d.  I n d ucers of C Y P 1 A 2 - Str o n g i n d ucers of C Y P 1 A 2 (i.e., p he n yt oi n, rifa m pi n) c o ul d 
re d uce B H V- 3 2 4 1 le vels a n d s h o ul d be use d wit h c a uti o n, base d o n t h e cli nical 
j u d ge me nt of t he i n vesti g at or.  
e. I n hi bit ors of C Y P 3 A 4 - Str o n g i n hi bit ors of C Y P 3 A 4 (i.e., c o ni v a pta n, gr a pefr uit j uice, 
itrac o n az ol e, ket oc o n az ol e, p os ac o na z ole, tr olea n d o m yci n, v ori c o naz ole, 
clarit hr o m yci n, diltiaze m, i d elalisi b, nef az o d o ne, a n d a nti vir al a g e nts [c o bicistat, 
da n o pre vir, rit o na vir, el vite gra vir, i n di na vir, l o pi n a vir, parita pr e vir, o m bitas vir, 
dasa b u vir, s a q ui na vir, ti pr a na vir, nelfi na vir]) c o ul d p ote nti all y i ncre ase B H V- 3 2 4 1 
le vels a n d are e xcl u de d f or c hr o nic/l o n g-ter m ( > 2 wee ks) us e.  Str o n g i n hi bit ors of 
C Y P 3 A 4 f or ac ute/s h ort-ter m us e s h o ul d be a v oi d e d, if p ossi ble, or us e d wit h c a uti o n, 
base d o n t he cli ni cal j u d ge me nt of t he i n vesti g at or.  M o derate i n hi bit ors of C Y P 3 A 4 
(i.e., a pre pita nt, ci meti di ne, cl otri maz ole, criz oti ni b, c ycl os p ori ne, dr o n e dar o ne, 
er yt hr o m yci n, fl uc o n az ole, i mati ni b, t ofis o pa m, v era pa mil) c o ul d p ot e nti all y i ncreas e 
B H V- 3 2 4 1 le vels a n d s h o ul d be use d wit h ca uti o n f or c hr o nic/l o n g-ter m us e, base d o n 
t he cli nic al j u d g e me nt of t he i n v esti gat or.   


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 6 5  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
f.
I n d ucers of C Y P 3 A 4
Str o n g i n d ucers of C Y P 3 A 4 (i.e., car b a maz e pi ne, e nzal uta mi de, 
mit ot a ne, 
 c o ul d re d uce B H V- 3 2 4 1 le vels a n d 
s h o ul d be use d wit h ca uti o n, base d o n t h e cli nical j u d ge me nt of t he i n v esti gat or. 
g.  Dr u gs pri nci pall y met a b oli ze d b y C Y P 2 B 6 (i.e., b u pr o pi o n, c ycl o p h os p ha mi de, 
efa vire n z, if os p ha mi de, met ha d o ne, a n d s orafe ni b) s h o ul d be us e d wit h ca uti o n, b ase d 
o n t he cli nical j u d g e me nt of t he i n v esti gat or. 
h.
Dr u gs pri nci pall y met a b oli ze d b y C Y P 3 A 4 (i.e., clarit hr o m yci n, er yt hr o m yci n, 
et hi n yl estra di ol [ h or m o nal c o ntra ce pti ves], telit hr o m yci n, q ui ni di ne, t h e o p h ylli ne, 
tiza ni di ne, v era pa mil, w arfari n, zile ut o n, a n d z ol mitri pta n) s h o ul d be us e d wit h ca uti o n, 
base d o n t he cli ni cal j u d ge me nt of t he i n vesti g at or. N ote: h or m o nal c o ntr ace pti ve 
effecti ve ness ma y p ote nti all y b e re d uce d; t h us d os e a dj ust me nt, us e of alt er nati ve 
a n d/ or a d diti o nal met h o ds of birt h c o ntr ol is re q uir e d f or W O C B P.
i. C hr o nic/l o n g-ter m ( > 2 w ee ks) us e of i m m u n o m o d ul at or y me dicati o ns is e xcl u de d, 
i ncl u di n g t he f oll o wi n g: a zat hi o pri ne, c hl ora m b u cil, c ycl o p h os p ha mi de, fi n g oli m o d 
(a n d ot her S 1 P rece pt or m o d ul at ors), i b u dil ast, met h otre xat e, m o nt el u kast, 
m yc o p he n ol ate m ofetil, t acr oli m us, sir oli m us (ra p a m yci n), a n d m o n o cl o nal a nti b o dies 
or relat e d bi ol o gical a ge nts (i. e., a batac e pt, a d ali m u ma b, a na ki nra, basili xi ma b, 
beli m u ma b, ca na ki n u ma b, cert oli z u ma b, d acliz u m a b, eta ner ce pt, i nfli xi ma b, 
nataliz u m a b, ocreliz u m a b, t ocili z u ma b, rit u xi ma b, tr ast uz u ma b, a n d uste ki n u ma b).  
N O T E: As piri n, a n d n o nster oi d al a nti-i nfla m m at or y me dic ati o ns, ar e all o we d 
5. 4 
Pr o hi bit e d a n d R e stri ct e d C o n c o mit a nt M e di c ati o n 
D uri n g t he c o urse of t h e st u d y (fr o m Bas eli ne/ R a n d o mizati o n t o e n d of tre at me nt), patie nts 
s h o ul d sta y o n t heir us ual me dicati o n re gi mes (i.e. t h ose n ot e xcl u d e d b y t he pr ot oc ol) at 
relati vel y st a ble d os es. 
Use of t he f oll o wi n g m e dic ati o ns is pr o hi bite d or restrict e d as f oll o ws. S u bjects recei vi n g s uc h 
me dic ati o ns c hr o nic/l o n g-ter m at e nr oll m e nt s h o ul d u n der g o a 4 wee k was h o ut peri o d pri or t o 
Baseli ne/ Ra n d o mizati o n u nl ess ot her wise n ote d or m e dicall y c o ntrai n dicat e d: 
1.  A n y ot her i n vesti g ati o n al a g e nt is pr o hi bite d (re q uires mi ni m u m was h o ut of 9 0 d a ys or 5 
half-li v es [ w hic he ver is l o n ger], pri or t o B as eli n e/ Ra n d o mizati o n) 
2.  D o pa mi ne a nta g o nists, i n cl u di n g met o cl o pra mi de a n d a nti ps yc h otic m e dic ati o ns are 
pr o hi bite d. 
a. Q uetia pi n e a n d cl oza pi n e are all o we d if t he d os es ar e sta ble f or at l east 3 0 da ys pri or t o 
Bas eli ne/ Ra n d o mizati o n  


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 6 6  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
3. I n hi bit ors of C Y P 1 A 2 - Str o n g i n hi bit ors of C Y P 1 A 2 (i.e., ci pr ofl o xaci n, e n o xaci n, 
fl u v o xa mi n e, zafirl u kast) c o ul d p ote ntiall y i n creas e B H V- 3 2 4 1 le vels a n d are pr o hi bite d 
f or c hr o nic/l o n g-ter m ( > 2 wee ks) us e.  Str o n g i n hi bit ors of C Y P 1 A 2 f or ac ute/s h ort-ter m 
us e s h o ul d be a v oi de d, if p ossi ble, or us e d wit h ca uti o n, base d o n t he cli ni cal j u d ge me nt of 
t he i n vesti gat or.  M o der ate i n hi bit ors of C Y P 1 A 2 (i.e., met h o xs ale n) c o ul d p ote ntiall y 
i ncrease B H V- 3 2 4 1 le vels a n d s h o ul d be us e d wit h c a uti o n f or c hr o nic/l o n g-ter m us e, 
base d o n t he cli ni cal j u d ge me nt of t he i n vesti g at or.   
4.  I n d ucers of C Y P 1 A 2 - Str o n g i n d ucers of C Y P 1 A 2 (i.e., p he n yt oi n, rifa m pi n) c o ul d re d uce 
B H V- 3 2 4 1 le vels a n d s h o ul d be us e d wit h ca uti o n, b as e d o n t he cli ni cal j u d ge me nt of t he 
i n vesti gat or.  
5.  I n hi bit ors of C Y P 3 A 4 - Str o n g i n hi bit ors of C Y P 3 A 4 (i.e., c o ni v a pta n, gr a pefr uit j uic e, 
itrac o n az ol e, ket oc o n az ol e, p os ac o na z ole, tr olea n d o m yci n, v ori c o naz ole, cl arit hr o m yci n, 
dilti aze m, i delalisi b, nefaz o d o n e, a n d a nti vir al a g e nts [c o bicistat, da n o pre vir, rit o na vir, 
el vit e gra vir, i n di na vir, l o pi n a vir, parita pre vir, o m bitas vir, das a b u vir, s a q ui na vir, ti pr a na vir, 
nelfi na vir) c o ul d p ote ntiall y i ncre as e B H V- 3 2 4 1 le v els a n d are pr o hi bit e d f or c hr o nic/l o n g-
ter m ( > 2 wee ks) us e.  Str o n g i n hi bit ors of C Y P 3 A 4 f or ac ute/s h ort-ter m us e s h o ul d be 
a v oi de d, if p ossi bl e, or us e d wit h ca uti o n, base d o n t he cli nical j u d ge me nt of t he 
i n vesti gat or.  M o derat e i n hi bit ors of C Y P 3 A 4 (i.e., a pre pita nt, ci meti di ne, cl otri maz ole, 
criz oti ni b, c y cl os p ori ne, dr o ne d ar o ne, er yt hr o m yci n, fl uc o naz ole, i mati ni b, t ofis o pa m, 
vera pa mil) c o ul d p ote ntiall y i ncr eas e B H V- 3 2 4 1 le v els a n d s h o ul d be us e d wit h ca uti o n f or 
c hr o nic/l o n g-ter m us e, bas e d o n t he cli nical j u d ge me nt of t he i n v esti gat or.   
6.  I n d ucers of C Y P 3 A 4  Str o n g i n d ucers of C Y P 3 A 4 (i.e., car b a maz e pi ne, e nzal uta mi de, 
mit ot a ne, p he n yt oi n, rif a m pi n, St. J o h n's w ort) c o ul d re d uce B H V- 3 2 4 1 le vels a n d s h o ul d 
be use d wit h ca uti o n, bas e d o n t he cli nic al j u d g e me nt of t he i n v esti gat or.  
7.  Dr u gs pri nci pall y met a b oli ze d b y C Y P 2 B 6 (i.e., b u pr o pi o n, c ycl o p h os p ha mi de, efa vire n z, 
if os p ha mi de, met h a d o ne, a n d s orafe ni b) s h o ul d be us e d wit h ca uti o n, base d o n t h e cli nical 
j u d ge me nt of t he i n vesti g at or. 
8.  Dr u gs pri nci pall y met a b oli ze d b y C Y P 3 A 4 (i. e., clarit hr o m yci n, er yt hr o m yci n, 
et hi n yl estra di ol [ h or m o nal c o ntra ce pti ves], telit hr o m yci n, q ui ni di ne, t h e o p h ylli ne, 
tiza ni di ne, v era pa mil, w arfari n, zile ut o n, a n d z ol mitri pta n) s h o ul d be us e d wit h ca uti o n, 
base d o n t he cli ni cal j u d ge me nt of t he i n vesti g at or.  N ote: h or m o nal c o ntr ace pti ve 
effecti ve ness ma y p ote nti all y b e re d uce d; t h us d os e a dj ust me nt, us e of alt er nati ve a n d/ or 
a d diti o n al m et h o ds of birt h c o ntr ol is re q uire d f or W O C B P. 
 
 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 6 7 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
9.
C hr o nic ( > 2 wee ks) us e of i m m u n o m o d ul at or y m e di cati o ns, i n cl u di n g t he f oll o wi n g: 
azat hi o pri ne, c hl ora m b u cil, c ycl o p h os p ha mi de, fi n g oli m o d (a n d ot her S 1 P rece pt or 
m o d ulat ors), i b u dilast, met h otre xate, m o ntel u kast, m yc o p he n olate m of etil, tacr oli m us, 
sir oli m us (ra pa m yci n), a n d m o n ocl o nal a nti b o di es or relat e d bi ol o gical a ge nts (i. e., 
a batace pt, a dali m u ma b, a na ki nr a, basili xi m a b, beli m u ma b, ca n a ki n u m a b, cert oliz u ma b, 
dacli z u ma b, eta ner ce pt, i nfli xi ma b, n ataliz u ma b, ocr eliz u ma b, t o ciliz u m a b, rit u xi ma b, 
trast uz u m a b, a n d uste ki n u ma b) is pr o hi bite d.
N O T E: As piri n a n d n o nster oi d al a nti-i nfla m m at or y me dic ati o ns ar e all o we d.
T he a b o ve me di cati o ns, if us e d f or t he s h ort-t er m tr eat me nt of i nt erc urre nt ill n ess, are all o we d 
if nee de d, at t h e discreti o n of t he I n v esti gat or, pr o vi d e d t he y ar e n ot ot h er wise pr o hi bit e d as 
n ote d a b o ve.
T he ge neric na me ( w here p ossi ble), st art date, e n d d ate a n d d osi n g i nf or mati o n f or a n y 
me dic ati o n ( pr escri pti o ns or n o n- pres cri pti o n) ta ke n b y t he s u bject wit hi n 1 m o nt h pri or t o 
c o nc o mita nt me di cati o n ele ctr o ni c case r e p ort f or m.
5. 4. 1
Ot h er R e stri cti o n s a n d Pr e c a uti o n s
M e dicati o ns pres cri be d b y a n ot her p h ysicia n: I n or d er t o e ns ure t h at a p pr o pri ate c o nc o mita nt 
t hera p y is a d mi nist ere d, it is esse nti al t hat s u bjects be i nstr uct e d n ot t o ta ke a n y me di cati o n, 
eit her n o n- pr es cri pti o n or pres cri pti o n t her a p y prescri be d b y a n ot h er p h ysici a n, wit h o ut pri or 
c o ns ultati o n wit h t h e I n vesti g at or.
P h ysical re ha bilitati o n: Partici p ati o n i n p h ysical r e ha bilit ati o n pr o gr a ms is per mitt e d if t h es e 
ha ve bee n o n g oi n g pri or t o st arti n g t he st u d y a n d ar e pla n ne d t o c o nti n u e t hr o u g h o ut t he 
d urati o n o
partici pati o n s h o ul d be li mite d i n a n atte m pt t o mai nt ai n a sta ble re gi me n, w he ne v er p ossi ble, 
as cli ni call y a p pr o priate.
Electi ve me di cal pr oc e d ures: S u bje cts s h o ul d n ot u n der g o a n y el ecti ve me dical pr oce d ur es
wit h o ut pri or c o ns ultati o n wit h t h e I n vesti g at or. A n electi ve pr o ce d ure (e. g., mi n or s ur ger y, 
de ntal s ur ger y, ort h o pe di c s ur ger y) t hat mi g ht r e q uir e h os pitalizati o n or a n est hesia s h o ul d be 
deferre d u ntil after t he st u d y, w he n cli nicall y a p pr o priate.
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 6 8  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
5. 5
W o m a n of C hil d b e ari n g P ot e nti al ( W O C B P)
W O C B P i ncl u de a n y f e male w h o has e x peri e nce d m e narc he a n d w h o has n ot u n der g o ne 
s uccessf ul s ur gical st erilizati o n ( h ystere ct o m y, bilateral t u bal li g ati o n, or bilateral 
o o p h orect o m y) or is n ot p ost me n o p a us al. P ost me n o p a us al is defi n e d as: 
 A me n orr hea greater t h a n or e q ual t o 1 2 c o ns ec uti v e m o nt hs wit h o ut a n ot her c a use a n d a 
d oc u me nt e d s er u m f ollicle sti m ulati n g h or m o ne ( F S H) le vel > 3 5 mI U/ m L. A hi g h f ollicle 
sti m ulati n g h or m o n e ( F S H) le v el i n t he p ost m e n o pa us al ra n ge m a y be us e d t o c o nfir m a 
p ost me n o pa us al st ate i n w o me n n ot usi n g h or m o nal c o ntrac e pti o n or h or m o nal re plac e me nt 
t hera p y. H o we ver i n t he a bse nc e of 1 2 m o nt hs of a m e n orr hea, a si n gle F S H meas ure me nt is 
i ns ufficie nt. 
N O T E: F S H le vel testi n g is n ot re q uire d f or w o me n greater t ha n or e q ual t o 6 2 years ol d 
wit h a me n orr h ea of greater t h a n or e q ual t o o ne year. 
T he re q uisite dr u g i nteracti o n st u di es t o det er mi n e t h e i nter acti o n of B H V- 3 2 4 1 wit h oral 
c o ntrac e pti v es ha ve n ot be e n c o m plet e d t o date. It is t heref ore n ot p ossi ble t o d eter mi ne t h e 
effica c y of oral c o ntrac e pti v es as a n effe cti ve met h o d of c o ntrac e pti o n f or W O C B P w h o are 
partici pati n g i n t his st u d y. Si nce h or m o n al c o ntrace pti ve eff ecti ve ness ma y be r e d uce d, 
estr o ge n a n d pr o gest er o ne h or m o nal c o ntr ace pti ves as a s ole met h o d of c o ntra ce pti o n are 
t heref ore pr o hi bit e d.  
It is re q uire d t hat all W O C B P us e t w o met h o ds of c o ntrace pti o n t o a v oi d pre g na n c y f or t he 
d urati o n of t h e st u d y (i.e., b e gi n ni n g at 3 0 da ys pri or t o bas eli n e) t hr o u g h 3 0 da ys after t he l ast 
d os e of i n vesti gati o nal pr o d uct i n s uc h a ma n n er t hat ris k of pre g na nc y is mi ni mize d. T he t w o 
met h o ds s h o ul d i ncl u de o ne b arrier m et h o d (e. g., dia p hra g m wit h s per mici d al gel, c o n d o m wit h 
s per mici d al gel, cer vi cal ca p) a n d o n e ot her met h o d. T he ot h er met h o d c o ul d i n cl u de h or m o n al 
c o ntrac e pti v es (e. g., oral c o ntrac e pti v es, i nje cta ble c o ntrace pti ves, patc h, or c o ntr ace pti ve 
i m pla nt) us e d si nce at l east 4 w ee ks pri or t o se x u al i nterc o urs e.  
A n y male w h o has a fe male p art ner of W O C B P m ust a v oi d pre g na n c y w hile partici pati n g i n 
t his st u d y. If mal e s u bjects are se x uall y acti ve a n d n ot vasect o miz e d f or at l east 6 m o nt hs, a n d 
f oll o wi n g ac ce pt e d met h o ds of c o ntrac e pti o n s h o ul d be us e d t hr o u g h o ut t h e st u d y a n d f or 9 0 
da ys after t h e last st u d y dr u g a d mi nistrati o n: 
 Si m ulta n e o us use of mal e c o n d o m wit h s per mi ci dal gel, a n d f or t h e fe male part ner, 
h or m o nal c o ntrac e pti ves (e. g., birt h c o ntr ol pills, i m pla nts, pat c h, de p ot i nje cti o n, use d 
si nce at least 4 w e e ks) or i ntra- ut eri ne c o ntra ce pti ve de vice plac e d si nce at le ast 4 wee ks 
bef ore s e x ual i nterc o urs e; 
O R 
 Si m ulta n e o us use of mal e c o n d o m, a n d f or t he fe mal e part ner cer vical c a p or dia p hr a g m 
wit h i ntra v a gi nall y a p plie d s per mici d e. 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 6 9 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
5. 6
D e vi ati o n fr o m I n cl u si o n/ E x cl u si o n Crit eri a
A n y si g nifica nt e ve nt t hat d o es n ot c o m pl y wit h t he i ncl usi o n e xcl usi o n criteri a, st u d y c o n d uct, 
or st u d y pr oce d ures will b e d oc u me nte d as a d e viati o n. De viati o ns will be d oc u me nt e d a n d 
re p orte d t hr o u g h t he cli nic al m o nit ori n g of t he trial. De viati o ns will be re p orte d t o t he I R B/ E C 
at t he fr e q ue nc y re q uire d b y t h e I R B/ E C. N o pr ot o c ol e xce pti o ns rel ate d t o I ncl usi o n/ E xcl usi o n 
criteria will be gra nt e d b y t he S p o ns or.
6
S T U D Y C O N D U C T A N D D E S C RI P TI O N O F S T U D Y P R O C E D U R E S
6. 1
St u d y M at eri al s
Bi o ha ve n will pr o vi de t he I P, w hic h will i ncl u de B H V- 3 2 4 1 3 0 0 m g E R ta bl ets a n d m atc hi n g 
place b o ta bl ets.
Sites will als o be pr o vi de d wit h a Re g ulat or y bi n der, I W R S M a n ual, C S F c olle cti o n ma n ual 
a n d 
I ma gi n g M a n ual. S o urce d o c u me nt cre ati o n is t he res p o nsi bilit y of t h e site. 
I nstr ucti o ns o n all s peci me ns c ollect e d will b e pr o vi de d b y a ce ntral la b orat or y.
All sites will us e a n El ectr o nic D ata C a pt ure ( E D C) t o ol t o s u b mit st u d y d ata. Ele ctr o ni c Cas e 
Re p ort F or ms (e C R Fs) will be pre p are d f or all dat a c ollecti o ns.
Sites will be pr o vi de d wit h a st u d y pr ot oc ol a n d a n y a me n d m e nts.
T he I n vesti g at or will be re q uir e d t o ha v e a ce ntrif u g e ( prefera bl y r efri ger ate d), a sec ure l oc ke d 
ca bi net or si milar (f or dr u g st ora ge), as well as freez er (-2 0 C or -7 0 t o -8 0 C ; s ee 
la b 
ma n ual a n d C S F S ub -st u d y C oll ecti o n a n d Pr ocessi n g ma n ual f or s pecifi c i nstr ucti o ns 
re gar di n g st ora g e of la b sa m ples), a p pr o pri ate c o ntai ners a n d dr y ice f or s hi p me nt a n d st or a ge 
of bl o o d, plas ma a n d uri ne s a m ples. T he s a me c e ntrif u ge a n d freez er at a site s h o ul d b e us e d 
co nsiste ntl y f or pr e parati o n a n d st ora g e of s a m pl es fr o m st u d y s u bjects.  S ufficie nt dr y ice, 
w he n i n dicate d, s h o ul d be utilize d t o all o w sa m ples t o arri ve at t heir desi g nat e d la b or at or y i n a 
fr oze n stat e.
6. 2
Eli gi bilit y a n d S af et y A s s e s s m e nt s
6. 2. 1
M e di c al a n d P s y c hi atri c Hi st or y
A f ull me di cal hist or y will b e o btai ne d at Scr ee ni n g. T his will i n cl u de, b ut is n ot li mite d t o, 
s m o ki n g hist or y, car di o vas c ul ar disease, patie nt hist or y of M S A a n d ot her me dic al a n d 
ps yc hiatri c hist or y.
6. 2. 2
S af et y A s s e s s m e nt s
Safet y a n d t olera bilit y will b e e val u ate d b y r e p ort of A Es a n d b y e val uati o n of a b n or malities 
a n d cli nicall y si g nifica nt c ha n ges i n p h ysi cal e xa mi n ati o ns, E C Gs, vital si g ns, S hee ha n 
S uici dalit y Tr ac ki n g Sc ale ( S- S T S), a n d la b or at or y t ests.
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 7 0  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
6. 2. 2. 1
Vit al Si g n s a n d P h y si c al M e a s ur e m e nt s ( H ei g ht a n d W ei g ht)
Vital si g n m eas ure m e nts (te m perat ur e, bl o o d press ur e, a n d heart rate) will be r ec or de d at e v er y 
i n- pers o n visit as s pecifie d i n t he Sc he d ule of Assess me nts & E v e nts (Ta ble 1  a n d Ta ble 2 ). 
S u bjects s h o ul d be s eate d a n d r esti n g f or a p pr o xi mat el y 5 mi n utes pri or t o p erf or mi n g vital 
si g n meas ure m e nts (tilt t a ble ma y be use d, if a vaila bl e).  
H ei g ht will b e rec or d e d at Scre e ni n g a n d Wee k 4 8 a n d/ or earl y dis c o nti n u ati o n.  B o d y wei g ht 
will be re c or de d at S cree ni n g, B aseli n e, a n d W ee k 4 8 a n d/ or earl y dis c o nti n uati o n. I n t he O L E 
p hase, hei g ht a n d wei g ht will be re c or de d at Bas eli n e- E xte nsi o n a n d Wee k 4 8- E xte nsi o n/ Earl y 
Disc o nti n uati o n. T he f oll o wi n g g ui d eli n es will ai d i n t he sta n dar dizati o n of t hese 
meas ure m e nts: 
1.  T he s a me s cale s h o ul d b e us e d t o wei g h a gi ve n s u bj ect t hr o u g h o ut t he st u d y; 
2.  Scales s h o ul d be c ali br ate d a n d zer oe d p er site g ui deli nes. 
6. 2. 2. 2 
P h y si c al E x a m 
S u bjects will u n d er g o a c o m plete p h ysical e xa m at e ac h i n- pers o n st u d y visit. T he p h ysi cal 
e xa m s h o ul d i n cl u de at l east t he f oll o wi n g c o m p o ne nts: H E E N T ( hea d, e yes, ears, n os e, a n d 
t hr oat), nec k, l y m p h n o d es, l u n gs, car di o vasc ular, a b d o me n, s ki n, m us c ul os kelet al a n d 
ne ur ol o gic e val u ati o n b y t he Pri nci p al I n vesti gat or or a me di call y q ualifie d dele gate.  If a 
s u bject is dis c o nti n ue d f or a n y reas o n, a n atte m pt s h o ul d be ma d e t o c o n d u ct a fi n al p h ysic al 
e xa m.  
6. 2. 2. 3 
El e ctr o c ar di o gr a m ( E C G) 
A 1 2- Lea d E C G will b e rec or de d at Scre e ni n g, Bas eli ne, We e k 2, 4, 1 2, 2 4, 3 6, a n d 4 8, 
Bas eli ne- E xte nsi o n, Wee k 4- E xte nsi o n (if i n pers o n visit is c o n d ucte d), W ee k 8- E xt e nsi o n (if 
i n pers o n visit is c o n d u cte d), Wee k 1 2- E xte nsi o n, 2 4- E xte nsi o n, 3 6- E xte nsi o n a n d 4 8-
E xte nsi o n a n d/ or earl y dis c o nti n uati o n, as s pecifi e d i n t he Sc he d ul e of Ass ess me nts & E ve nts 
(Ta ble 1  a n d Ta ble 2 ) a n d as m e dic all y n ecess ar y.  If a s u bject is dis c o nti n u e d f or a n y reas o n, 
a n att e m pt s h o ul d b e ma d e t o c o n d uct a fi n al E C G.  
6. 2. 2. 4 
L a b or at or y A s s e s s m e nt s 
La b orat or y testi n g will be c o n d ucte d at Scre e ni n g, B aseli ne, a n d Wee ks 2, 4, 8, 1 2, 2 4, 3 6, a n d 
4 8, Bas eli ne- E xte nsi o n, Wee k 4- E xte nsi o n, Wee k 8- E xte nsi o n, W ee k 1 2- E xte nsi o n, Wee k 2 4-
E xte nsi o n, Wee k 3 6- E xte nsi o n, We e k 4 8- E xt e nsi o n a n d/ or earl y dis c o nti n uati o n, as s pecifi e d 
(a n d as me di call y necess ar y), t o i ncl u d e t he f oll o wi n g ( Refer t o Sc he d ule of Ass ess me nts & 
E ve nts [ Ta ble 1  a n d Ta ble 2 ]): 
a. H e mat ol o g y: he m o gl o bi n, he mat o crit, platelets, C B C wit h differe ntial a n d a bs ol ute 
ne utr o p hil c o u nt, R B C c o u nt a n d i n dices. At Scree ni n g a n d pri or t o l u m bar p u nct ure: 
I N R, P T a n d partial P T.   


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 7 1  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
b.
Ser u m C he mistr y: s o di u m, p ot assi u m, c hl ori de, calci u m, ma g nesi u m, A L T, A S T, L D H, 
A L P, G G T, p h os p h or us, bic ar b o nat e, C P K, t otal pr ot ei n, al b u mi n, t otal bilir u bi n (if 
greater t ha n 2 m g/ dl bilir u bi n will be fra cti o n ate d), gl uc os e, creati ni ne, B U N, uric aci d. 
T S H, free T 3 a n d free T 4. Als o, a nti- T P O a nti b o di es at Bas eli ne, W ee k 2, Wee k 4, 
Wee k 8, W ee k 1 2, We e k 2 4, Wee k 3 6, Wee k 4 8, Bas eli ne- E xte nsi o n, W ee k 4-
E xte nsi o n, Wee k 8- E xte nsi o n, We e k 1 2- E xt e nsi o n, Wee k 2 4- E xte nsi o n, Wee k 3 6-
E xte nsi o n, Wee k 4 8- E xte nsi o n a n d w he ne v er T S H is o utsi de of n or mal ra n ge.  
A d diti o nall y, at Scr ee ni n g: t ot al c h ol ester ol, L D L, H D L, tri gl yceri des, f ol ate, H b A 1c, 
P- A m ylase or Li pas e; Esti mat e d gl o m er ular filtrati o n rate (e G F R) 
c. Uri nal ysis (c oll ect uri ne s peci me n j ust pri or t o o bt ai ni n g wei g ht): macr osc o pic 
e xa mi n ati o n, p H, s pecific gra vit y, ket o nes, nitrites, ur o bili n o ge n, le u k oc yte est eras e, 
pr otei n, cr eati ni ne, gl uc os e, a n d oc c ult bl o o d. If bl o o d, pr otei n, or l e u k oc yt es are 
p ositi ve, micr os c o pi c e xa mi nati o n will be perf or m e d o n a b n or mal fi n di n gs; 
d.  S er u m pr e g n a n c y t est will b e c o n d u ct e d o n W O C B P ( p er s e cti o n 5. 5) at S cr e e ni n g, 
B as eli n e, a n d W e e ks 4, 1 2, 2 4, 3 6 a n d 4 8, B as eli n e- E xt e nsi o n, W e e k 4- E xt e nsi o n, 
W e e k 1 2- E xt e nsi o n, W e e k 2 4- E xt e nsi o n, W ee k 3 6- E xt e nsi o n, W e e k 4 8- E xt e nsi o n 
a n d e arl y dis c o nti n u ati o n.  Uri n e pre g na n c y tests will be p erf or me d ( as well as s er u m) 
at Bas eli ne a n d B as eli n e- E xte nsi o n ( pri or t o d osi n g) o n W O C B P a n d at t he discreti o n 
of t he I n vesti g at or. F S H is t o be c o n d ucte d o n p ost m e n o pa usal w o me n at Scree ni n g t o 
c o nfir m p ost m e n o pa us al st at us (s ee Secti o n  5. 5).  
e. At Scree ni n g O nl y: H Bs A g, H C V (refle x H C V- R N A after a p ositi ve H C V A b), HI V 
a nti b o d y detecti o n, a n d ra pi d plas m a rea gi n ( R P R).  Refle x t esti n g will be d o ne f or a n y 
p ositi ve R P R. 
f. At Scree ni n g, Bas eli ne a n d Bas eli n e- E xt e nsi o n O nl y: Uri ne Dr u g Scree n f or ca n n a bis 
( me dic al a n d r ecreati o nal), a m p h eta mi nes (i n cl u di n g M D M A/ecstas y), c ocai ne, 
bar bit urate, P C P, be nz o di aze pi n es, tric y cli c a nti de pr essa nts, a n d/ or o piates. Refl e x 
c o nfir mat or y testi n g will b e c o n d uct e d o n all p ositi v e uri ne dr u g scree n sa m ples.  
g.  At Scree ni n g O nl y: Uri n e al c o h ol le v el. 
h.  F or t h ose partici pati n g i n t h e o pti o n al C S F s u b-st u d y, a nal ysis c o n d ucte d b y l o cal la b of 
cell c o u nts ( w hite bl o o d cells a n d re d bl o o d cells [ wit h refle x e d differe ntial if eit her of 
t he c o u nts is a b n or mal], C S F pr otei n a n d C S F gl uc os e.  
If i niti al Scre e ni n g l a b sa m ple r es ults d o n ot m eet pr ot oc ol-s pecifie d eli gi bilit y criteri a a n d t h e 
I n vesti gat or d eter mi nes t hat a re p eat s a m ple ma y m e et eli gi bilit y crit eria, re p eat la b sa m ples 
ma y be c olle cte d ( o ne r e peat c ollecti o n/ a nal ysis all o we d).   


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 7 2 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
If la b sa m pl es are c ollecte d a n d a nal y ze d b y a l ocal l a b rat her t ha n 
 ce ntral la b, d u e t o 
C O VI D -1 9 restricti o ns pre ve nti n g a st u d y partici p a nt fr o m atte n di n g a n i n pers o n visit at t he 
st u d y site, t he f oll o wi n g s afet y la b a nal yses s h o ul d b e or dere d:
T S H
Free T 3
Free T 4
A nti- T P O a nti b o di es
H e mat ol o g y p a nel- H e mat ol o g y: he m o gl o bi n, he mat ocrit, pl atelets, C B C wit h differe ntial 
a n d a bs ol ute n e utr o p hil c o u nt, R B C c o u nt a n d i n dices
C he mistr y Pa nel- Direct Bili R E F L E X, I n dir ect Bili R E F L E X, Ser u m C he mistr y: s o di u m, 
p otassi u m, c hl ori de, c alci u m, m a g nesi u m, A L T, A S T, L D H, A L P, G G T, p h os p h or us, 
bicar b o nate, C P K, t otal pr otei n, al b u mi n, t otal bilir u bi n (if greater t h a n 2 m g/ dl bilir u bi n 
will be fra cti o n ate d), gl u c ose, cre ati ni ne, B U N, uric aci d
Uri nal ysis P a nel wit h Uri n e Creati ni n e- macr osc o pic e xa mi n ati o n, p H, s pecific gra vit y,
ket o nes, nitrites, ur o bili n o g e n, le u k oc yte ester as e, pr otei n, cr eati ni ne, gl uc ose, a n d oc c ult
bl o o d. If bl o o d, pr otei n, or le u k o c ytes are p ositi ve, micr os c o pi c e xa mi nati o n will be 
perf or me d o n a b n or mal fi n di n gs.
Ser u m pre g na nc y test f or all W O C B P.
Cli nic all y si g nifica nt l a b orat or y a b n or maliti es will b e i de ntifie d as Gra de 3 t o 4 la b or at or y t est 
res ults gra de d a cc or di n g t o n u meri c la b or at or y t est criteri a i n C o m m o n Ter mi n ol o g y Criteria 
f or A d vers e E ve nts ( C T C A E) V ersi o n 5. 0 ( 2 0 1 7)1 8.  F or t h ose n ot a vaila bl e i n C T C A E,
acc or di n g t o Di visi o n of AI D S ( D AI D S) Ta ble f or Gra di n g t he S e v erit y of A d ult a n d Pe diatric 
A d verse E ve nts C orrecte d V ersi o n 2. 1 ( 2 0 1 7) 1 9.
6. 2. 2. 5
S h e e h a n S ui ci d alit y Tr a c ki n g S c al e ( S h e e h a n- S T S)
T he S hee ha n S T S ( S- S T S) is a pr os pecti ve, cli nicia n a d mi nist ere d rati n g s cale t hat c o nt ai ns 1 6 
q uesti o ns t o tra c k b ot h tr eat me nt-e mer ge nt s uici d al i deati o n a n d be ha vi ors 2 0, 2 1. T he S- S T S will 
be c o m pl ete d o n a pa per f or m at t h e site at Scre e ni n g, Bas eli ne a n d eac h st u d y visit, i ncl u di n g 
Wee k 4 8, Bas eli ne- E xte nsi o n, W ee k 2- E xte nsi o n, W ee k 1 2- E xt e nsi o n, Wee k 2 4- E xte nsi o n, 
Wee k 3 6- E xte nsi o n, Wee k 4 8- E xt e nsi o n, or earl y wit h dra wal. At Scre e ni n g, t h e recall peri o d 
f or c o m pleti n g t h e S- S T S is 6 m o nt hs pri or; at all ot her visits, t he r ecall peri o d f or c o m pl eti n g 
t he S- S T S is si nce t he last visit (t w o s e parate versi o ns will be pr o vi de d). S u bj ects w h o ha ve a 
S- S T S s c ore > 0 s h o ul d be e val uate d b y t h e I n vesti g at or.  If t he I n v esti gat or deter mi nes t h at a 
s u bject is at ris k of s uici d e or s elf-
o btai n m e ntal healt h e val uati o n m ust be i m pl e me nte d a n d t he I n vesti gat or s h o ul d e val uate if 
t he patie nt s h o ul d b e disc o nti n ue d fr o m t he st u d y.
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 7 3  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
6. 2. 3
Cli ni c al O ut c o m e A s s e s s m e nt s
Eac h of t h e Cli nici a n Re p orte d O ut c o me ( Cli n R O) meas ures des cri b e d bel o w s h o ul d be 
perf or me d b y a n a p pr o priat el y q ualifi e d i n di vi d ual. S pecific q u alificati o n re q uir e me nts f or 
raters will b e d oc u m e nte d a n d a p pr o priate tr ai ni n g will be pr o vi de d t hr o u g h di dactic, vi de o 
certificati o n, a n d/ or o nli ne trai ni n g. W he n e ver p ossi ble, f or a n y i n di vi d ual s u bject, eac h of 
t hese ass ess me nts s h o ul d be perf or me d b y t he s a me r ater t hr o u g h o ut t he c o urse of t he st u d y. 
T he Pati e nt Re p orte d O utc o me ( P R O) meas ures des cri be d bel o w s h o ul d be directl y prese nt e d 
t o t he patie nt o n pa per.  As a bac k- u p o pti o n, e ac h of t he P R O meas ures ma y b e a d mi nistere d 
as Cli nicia n Re p orte d O utc o me meas ures w here all o w a ble b y t he assess me nt 
a ut h or/ de v el o per
mea ni n g t hat t he assess me nts will be pres e nt e d t o t h e patie nt ver b all y b y a 
q ualifi e d me m ber of t he site staff, w h o will rec or d t h e res p o ns es c olle cte d fr o m t he s u bje ct
i n 
or der t o pr o m ot e c o nsiste nt q ualit y, sta n dar dizati o n, a n d mi ni miz e b ur de n o n t h e st u d y s u bject. 
Care gi vers s h o ul d n ot c o m pl ete t he P R O meas ures o n be half of patie nts.  
F or a n y i n di vi d ual s u bject, ea c h of t he care gi v er assess me nts s h o ul d be c o m pl ete d b y t he sa m e 
care gi v er t hr o u g h o ut t he c o urse of t h e st u d y, w he n p ossi ble. Care gi v er faci n g s cales s h o ul d be 
directl y pres e nt e d t o t he care gi ver o n pa p er. As a bac k- u p o pti o n, ea c h of t he care gi v er 
meas ures ma y b e a d mi nistere d as Cli ni cia n R e p orte d O utc o me m eas ures w here all o wa ble b y 
t he ass ess me nt a ut h or/ de v el o per- m ea ni n g t hat t he ass ess me nts will be prese nte d t o t he 
care gi v er ver ball y b y a q ualifi e d me m ber of t h e site staff, w h o will rec or d t he res p o ns es 
c olle cte d fr o m t he care gi v er-i n or der t o pr o m ot e c o nsiste nt q ualit y, sta n d ar diz ati o n, a n d 
mi ni mize b ur d e n o n t he care gi v er.  Care gi vers m ust be willi n g t o si g n a n d date a n I R B/ E C-
a p pr o ve d writt e n i nf or m e d c o ns e nt f or m i n ac c or da n ce wit h re g ulat or y a n d i nstit uti o n al 
g ui deli n es, as a p pr o priate. Care gi ver i nf or mati o n will be rec or d e d o n t he C R F.   
T he U M S A R S s h o ul d be t he first Cli n R O c o m plet e d, w he ne ver p ossi ble.  T h e M S A- Q o L 
a n d/ or P GI- S s h o ul d be t h e first P R Os c o m plete d, w he ne ver p ossi ble.  
6. 2. 3. 1 
U nifi e d M ulti pl e S y st e m Atr o p h y R ati n g S c al e ( U M S A R S) 
T he U M S A R S is a cli nici a n-rat e d scale c o m prise d of f o ur parts 2 2.  Part I, Hist orical Re vie w, is 
a n assess me nt of f u ncti o ni n g acr oss vari o us areas.  Part II is a M ot or E x a mi n ati o n.  P art III is 
a n A ut o n o mic E xa mi nati o n, a n d i n cl u des s u pi ne a n d sta n di n g vit al si g ns, ort h ostatic c ha n ge, 
a n d ort h ostatic s y m pt o ms.  Tilt ta ble m a y be use d, if a vail a ble.  Part I V is a Gl o bal Dis a bilit y 
Scale. N ote: T he U M S A R S will be use d t o c olle ct data i n t his st u d y. H o we ver, t he pri mar y 
o utc o me v aria ble f or t he st u d y will be a m o difie d U M S A R S, c o m p ose d of a s u bs et of ite ms 
fr o m U M S A R S Part I a n d Part II, wit h t h e it e ms s electe d base d o n f ee d bac k fr o m Healt h 
A ut h orities, e x p ert o pi ni o n, a n d a nal ysis of data fr o m pre vi o us cli nical trials i n M S A. 
T he U M S A R S is ass esse d d uri n g t he Scree ni n g p has e t o det er mi n e eli gi bilit y f or st u d y e ntr y 
a n d will s u bs e q ue ntl y be a d mi nist ere d at Baseli n e, a n d Wee ks 4, 1 2, 2 4, 3 6 a n d 4 8, Bas eli ne-
E xte nsi o n, Wee k 1 2- E xte nsi o n, We e k 2 4- E xt e nsi o n, Wee k 3 6- E xte nsi o n, Wee k 4 8- E xt e nsi o n  
a n d/ or earl y dis c o nti n uati o n.  


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 7 4 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
If t he U M S A R S is a d mi nistere d re m otel y ( b y p h o ne/ vi de o) d ue t o C O VI D- 1 9 re m ot e visit 
all o w a nc es, o nl y P art I s h o ul d be c o n d ucte d a n d e nt ere d i n t he e C R F.
6. 2. 3. 2
Cli ni c al Gl o b al I m pr e s si o n of S e v erit y ( C GI- S) a n d Cli ni c al Gl o b al 
I m pr e s si o n of I m pr o v e m e nt ( C GI-I)
T h e C GI- S s cal e is a cli nicia n-rate d scale m eas uri n g t h e s e v erit y of
ill n ess. It is 
s c ore d o n a 7- p oi nt s cale ra n gi n g fr o m 1 ( n or mal, n ot ill at all) t o 7 ( a m o n g t h e m ost e xtre mel y 
ill patie nts). T h e C GI- S will b e a d mi nist er e d at B as eli n e a n d W e e ks 4, 1 2, 2 4, 3 6 a n d 4 8 
a n d/ or e arl y dis c o nti n u ati o n. T h e C GI- S will n ot be a d mi nist ere d d uri n g t he O L E.
T he C GI-I s cale is a cli nici a n-rat e d scal e me as uri n g
fr o m a s pecific p oi nt i n ti me. It is s c ore d o n a 7- p oi nt s cale, r a n gi n g fr o m 1 ( ver y m uc h 
i m pr o ve d) t o 7 ( v er y m uc h w orse), wit h a s c or e of 4 i n dicati n g n o c h a n ge. T he C GI-I s h o ul d be 
ass esse d relati v e t o t h e C GI- S at t he Wee k 0 ( Da y 1) visit as t he r efere nc e. T h e C GI-I will b e 
a d mi nist er e d at W ee ks 4, 1 2, 2 4, 3 6 a n d 4 8 a n d/ or e arl y dis c o nti n u ati o n. T he C GI-I will n ot 
be a d mi nistere d d uri n g t he O L E.
C GI rati n gs. F or a n y i n di vi d ual 
s u bject, t h ese ass ess me nts s h o ul d be perf or m e d b y t h e sa me rater t hr o u g h o ut t he st u d y.
6. 2. 3. 3
M S A Q u alit y of Lif e S c al e ( M S A- Q o L)
T h e M S A- Q o L is a p ati e nt-r at e d s cal e t h at w as d esi g n e d t o m e as ur e h e alt h-r el at e d q u alit y 
of lif e s p e cifi c all y i n M S A 2 3. It ass ess es a cti viti es of d ail y li vi n g a n d h as s u bs c al es f or 
m ot or, n o n m ot or, a n d e m oti o n al/s o ci al d o m ai ns.
T h e M S A- Q o L will b e a d mi nist er e d at B as eli n e,
W e e k 2 4 a n d 4 8, B as eli n e- E xt e nsi o n, 
W e e k 1 2- E xt e nsi o n, W e e k 2 4- E xt e nsi o n, W e e k 3 6- E xt e nsi o n, W e e k 4 8- E xt e nsi o n a n d/ or
e arl y dis c o nti n u ati o n.
6. 2. 3. 4
P ati e nt Gl o b al I m pr e s si o n of S e v erit y ( P GI- S)
T h e P GI- S is a p ati e nt-r at e d s c al e a n d will b e a d mi nist er e d at B as eli n e a n d W e e ks 4, 1 2,
2 4, 3 6 a n d 4 8 a n d/ or e arl y dis c o nti n u ati o n. T h e p ati e nt will r at e h o w t h e y p er cei v e t h e 
s e v erit y of t h eir ill n ess. T he P GI- S will n ot be a d mi nistere d d uri n g t he O L E.
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 7 5 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 7 6 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
6. 3
Ot h er A s s e s s m e nt s 
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 7 7 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 7 8 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 7 9 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
6. 4
E arl y Di s c o nti n u ati o n fr o m t h e St u d y
S u bjects M U S T dis c o nti n ue t he I P (a n d n o n-i n v esti g ati o nal pr o d uct at t h e dis creti o n of t he 
I n vesti gat or) f or a n y of t he f oll o wi n g reas o ns:
A n y cli nic al a d v ers e e ve nt ( A E), E C G, a n d la b or at or y a b n or maliti es (c o nfir me d b y r e peat 
if a p pr o priate) or i nterc urre nt ill ness w hic h, i n t h e o pi ni o n of t he I n v esti gat or or s p o ns or, 
i n dicates t hat c o nti n ue d partici p ati o n i n t he st u d y is n ot i n t he b est i nt erest of t h e s u bject.
T his ma y i n cl u de t he f oll o wi n g:
i.
Treat me nt- e mer ge nt E C G a b n or m alities
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 8 0  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Disease pr o gressi o n, w hic h, i n t h e o pi ni o n of t he I n v esti gat or or s p o ns or, i n di cat es t hat 
c o nti n ue d p arti ci pati o n i n t he st u d y is n ot i n t he best i nterest of t he s u bje ct 
 Pre g na nc y 
 Ter mi n ati o n of t he st u d y b y Bi o h a ve n P har mace utic als 
 L oss of a bilit y t o freel y pr o vi de c o nse nt t hr o u g h i m pris o n me nt or i n v ol u ntar y i ncarc erati o n 
f or treat me nt of eit her a ps yc hiatric or p h ysi cal ( e. g., i nfecti o us disease) ill ness 
All s u bjects w h o disc o nti n ue st u d y tr eat me nt earli er t ha n Wee k 4 8 or Wee k 4 8- E xt s h o ul d 
c o m pl y wit h pr ot oc ol s pecifi e d Earl y Dis c o nti n uati o n pr oce d ures as a p pr o priate, o utli ne d i n t he 
Sc he d ule of Ass ess me nts & E ve nts ( Ta bl e 1 , Ta bl e 2 ). De pe n di n g o n t he r eas o n f or t he earl y 
dis c o nti n uati o n (e. g., d ecli ni n g patie nt stat us), s o me pr oce d ures, f or e xa m ple, P K sa m ples, P D 
s a m ples, l u m b ar p u nct ur e, ma y n ot be c o n d ucte d at t his visit.  C o n d uct of all pr o ce d ures, if 
p ossi ble, is e nc o ura g e d. If p ossi ble, t h e s u bjects w h o disc o nti n ue fr o m st u d y me dicati o n pri or 
t o Wee k 4 8 s h o ul d b e c o nt acte d b y a f oll o w u p p h o n e call at t he a p pr o xi mat e ti me of t h eir 
Wee k 4 8 visit, t o c olle ct i nf or mati o n o n cli nical stat us (i ncl u di n g Ti me t o E ve nt me as ures of 
dis eas e pr o gressi o n a n d if a p plica ble, a d verse e v e nts, S A Es).  
A n e xce pti o n t o t he r e q uire m e nt f or E n d of Treat me nt pr oce d ures is w he n a s u bj ect wit h dr a ws 
c o nse nt f or all st u d y pr oce d ures or l oses t h e a bilit y t o c o ns e nt freel y (i.e., is i m pris o ne d or 
i n v ol u ntaril y i n carc erate d f or t he tr eat me nt of eit h er a ps yc hiatric or p h ysic al ill ness).  


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 8 1  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
7 
S T U D Y D R U G M A N A G E M E N T
7. 1 
D e s cri pti o n of St u d y Dr u g 
7. 1. 1
I n v e sti g ati o n al Pr o d u ct
A n I n vesti gati o n al Pr o d uct (I P), als o k n o w n as I n vesti gati o nal Me dici n al Pr o d uct i n s o me 
re gi o ns, is defi ne d as f oll o ws: 
A p har mace utical f or m of a n acti ve s u bsta nce or pla ce b o bei n g teste d or use d as a r efere n ce i n 
a cli nical st u d y, i ncl u di n g pr o d ucts alrea d y wit h a m ar keti n g a ut h ori zati o n b ut us e d or 
ass e m ble d (f or m ulat e d or pac ka g e d) i n a wa y differe nt fr o m t he a ut h ori ze d f or m, or use d f or a n 
u na ut h oriz e d i n di cati o n, or w he n us e d t o gai n f urt her i nf or mati o n a b o ut t he a ut h orize d f or m.
T he I P s h o ul d be st ore d i n a s ec ure ar ea a cc or di n g t o l ocal r e g ulati o ns. It is t h e res p o nsi bilit y of 
t he I n vesti g at or t o e ns ure t hat t he I P is o nl y dis pe ns e d t o st u d y pati e nts. T he I P m ust b e 
dis pe ns e d o nl y fr o m offi cial st u d y sites b y a ut h orize d pers o n nel ac c or di n g t o l oc al r e g ulati o ns. 
I n t his pr ot oc ol, t he I P is B H V- 3 2 4 1 3 0 0 m g ta bl ets a n d mat c hi n g pl ace b o ta blets.  
T he I P d uri n g t he O L E p hase of t he st u d y is B H V- 3 2 4 1 3 0 0 m g ta bl ets.
7. 1. 2
P a c k a gi n g, S hi p m e nt a n d St or a g e 
T he dr u g pr o d uct is pres e nte d as B H V- 3 2 4 1 E xte n d e d Releas e ( E R) Ta blets t hat are r e d dis h-
bei ge, fil m c o ate d a n d o v al ( 3 0 0 m g str e n gt h). T h e ta blets ea c h c o nsist of 3 0 0 m g of B H V-
3 2 4 1 dr u g s u bsta nce as free base, a n d ge ner all y r ec o g nize d as s afe ( G R A S) e xci pi e nts f or oral 
d os a ge f or ms i ncl u di n g h y dr o x y pr o p yl m et h yl cell ul ose, micr ocr yst alli ne cell ul os e, 
h y dr o x y pr o p yl cell ul os e, s o di u m st ear yl f u marat e a n d ora n ge c ol or. M atc hi n g place b o ta bl ets 
c o ntai n micr o cr ystalli ne c ell ul ose a n d s o di u m st ear yl f u marat e a n d are fil m- c oat e d wit h 
O P A D R Y ®  ( mi xt ure of h y pr o m ell os e, p ol yet h yle ne gl yc ol a n d tit a ni u m di o xi de) a n d ir o n 
o xi de t o gi v e re d dis h- bei ge c ol or.  T he t a blets are pa c ke d i n hi g h- d e nsit y p ol y et h yl e ne ( H D P E) 
b ottles.  T h e b ottles are i n d ucti o n seale d a n d cl os e d wit h c hil d r esista nt p ol y pr o p yle n e ( P P) 
s cre w ca ps.  
All i n vesti g ati o n al pr o d ucts s h o ul d be ke pt i n a sec ur e area wit h li mit e d acc ess u n der 
a p pr o priat e st ora ge c o n diti o ns. C o ntai ner(s) of i n v esti gati o nal pr o d u ct will bear a la bel 
c o ntai ni n g (at a mi ni m u m) t he na m e of t he st u d y dr u g, l ot a n d/ or b atc h n u m ber a n d a p pr o priat e 
st ora ge c o n diti o ns ( 1 5°- 2 5° C [ 5 9°- 7 7° F] i n a ti g htl y cl os e d c o nt ai ner, pr otect e d fr o m li g ht).   
St ora ge te m perat ure e xc ursi o ns s h o ul d be r e p orte d p er P har mac y M a n u al i nstr ucti o ns.  Te m p-
Tale U S B m o nit ors will be i ncl u d e d i n s hi p m e nts of i n vesti gati o nal me dicati o n t o st u d y sites 
a n d u p o n recei pt, st u d y pers o n nel m ust retrie ve, pri nt a n d e m ail t he T e m p- Tale m o nit or re p ort 
i n or d er t o c o nfir m t h at u nac ce pt a ble e xc ursi o ns di d n ot occ ur d uri n g s hi p me nt. 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 8 2  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
7. 2
D o s e a n d A d mi ni str ati o n
7. 2. 1
M et h o d of A s si g ni n g P ati e nt I d e ntifi c ati o n 
T he I n vesti g at or or desi g n ee will n ee d t o acc ess a n I nteracti ve We b- base d Res p o nse S yste m 
(I W R S) i n or der t o re gister eac h s u bject. I nitiall y, aft er i nf or me d c o ns e nt is o bt ai ne d at t he 
Scree ni n g Visit, t he I n vesti gat or or desi g n ee will e nt er t he s u bje ct i nt o t he st u d y a n d o btai n a 
s u bject n u m b er assi g n me nt. After c o m pleti o n of S cr ee ni n g e v al uati o ns, all eli gi ble s u bj ects 
will be ra n d o miz e d, i n a 1: 1 rati o t o rec ei ve eit h er B H V- 3 2 4 1 ( 6 0 0 m g BI D) or matc hi n g 
place b o. R a n d o mi zati o n will b e stratifie d b y dis eas e s u bt y pe of eit h er M S A- P vs. M S A- C, 
dia g n ostic cat e g or y of p ossi ble M S A vs. pr o ba ble M S A, a n d c o u ntr y.  C o ntai n er assi g n me nts 
will be o bt ai ne d b y t he I n vesti gat or ( or desi g n ee) vi a t he I W R S s yste m. 
I n vesti gati o nal sites will access t he I W R S at eac h sc he d ule d visit t hr o u g h o ut t he d o u bl e- bli n d 
p hase of t he st u d y (e x ce pt f or W ee ks 2, 8 a n d 4 8) t o trac k patie nt e nr oll me nt a n d dis pe ns e 
dr u g. St u d y me dic ati o n will be assi g ne d via t he I W R S s yste m; t he s yste m will assi g n s pecific 
c o ntai n er n u m bers f or all bli n d e d st u d y dr u g t o be dis pe nse d t o t he s u bje ct. O nce a c o ntai ner 
has bee n assi g ne d it ca n n ot be dis pe nse d t o a n ot her st u d y s u bject.  
After a s u bject has pr o vi de d i nf or me d c o nse nt t o partici p ate i n t he O L E p hase, t he I n v esti gat or 
 a n d at eac h 
s c he d ule d visit t hr o u g h o ut t he O L E p h as e of t he st u d y (e xce pt f or Wee ks 2- E xt, 4- E xt, 8- E xt 
a n d 4 8- E xt) t o trac k p atie nt e nr oll me nt a n d o bt ai n c o ntai ner n u m bers of o p e n-la b el B H V- 3 2 4 1 
t o be dis pe ns e d t o t he s u bject. O nce a c o ntai ner has bee n assi g ne d it ca n n ot be dis pe ns e d t o 
a n ot her st u d y s u bje ct.  
Sites will be r es p o nsi ble f or re c or di n g t he c o ntai ner n u m bers dis pe ns e d t o t h e s u bject o n t he 
Dr u g A cc o u nta bilit y F or m pr o vi d e d i n t h e Re g ulat or y Bi n der, as well as e ns ure a p pr o priate 
  
O nce a s u bject c o m pletes t h e st u d y, or if a s u bj ect is disc o nti n ue d earl y fr o m t he st u d y, t he 
I n vesti gat or or d esi g nee m ust acc ess t he I W R S t o d o c u me nt disc o nti n u ati o n of t he patie nt fr o m 
partici pati o n i n t h e st u d y. 
R escree ni n g:  If i nitial Scree ni n g la b s a m ple res ults d o n ot meet pr ot oc ol-s pecifie d eli gi bilit y 
criteria a n d t he I n vesti g at or deter mi nes t hat a re p eat sa m ple m a y me et t h e ra n ge re q uire d f or 
eli gi bilit y, a re p eat la b s a m pl e ma y b e c ollecte d ( o ne re peat c oll ecti o n/a nal ysis all o we d).  
After o btai ni n g S p o ns or a p pr o val, a s u bj ect w h o d o es n ot meet pr ot oc ol r e q uire d eli gi bilit y 
criteria d uri n g Scr ee ni n g b ut w h o m a y p ote ntiall y be c o me eli gi ble (e. g., l o gisti cal re as o ns s uc h 
as e xcee di n g s cree ni n g wi n d o w t o acc o m m o date ti m e re q uire d f or a dj ust me nt/sta bilit y of 
c o nc o mita nt me di cati o n, w as h o ut of pr o hi bit e d me di cati o n or r e peat pr oce d ures t o all o w f or 
rec hec k/c o nfir m ati o n of a n a b n or m alit y t hat ma y me et t he r e q uire d ra n g e i n a r eas o na bl e 
a m o u nt of ti me) ma y be e ntere d as a S cree n Fail ure i n I W R S a n d e C R F a n d res cree ne d o ne 
ti me ( e nter e d as a Res cree n i n I W R S a n d e C R F).  If t he S p o ns or a p pr o ves Rescree ni n g f or a 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 8 3  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
s u bject, i nstr u cti o ns will be pr o vi d e d t o t h e site re g ar di n g t he s pecific S cr ee ni n g 
pr oce d ures/e v al uati o ns t hat will ne e d t o be r e peate d f or Rescree ni n g, as t his is de pe n de nt o n 
t he a m o u nt of ti me ela ps e d. 
7. 2. 2
S el e cti o n a n d Ti mi n g of D o s e a n d A d mi ni str ati o n 
All s u bjects will be ra n d o mize d t o rec ei ve B H V- 3 2 4 1 6 0 0 m g BI D or matc hi n g pla ce b o BI D. 
S u bjects s h o ul d be a d mi nistere d t he D a y 1/first d os e of st u d y me dic ati o n ( 3 0 0 m g Q D or 
m atc hi n g pl ace b o Q D) w hil e i n t he offic e/cli nic o n t he d a y of t he B as eli ne visit. S u bjects 
s h o ul d st a y at t he office/cli nic f o r m o nit ori n g f or a p pr o xi m atel y 4 h o urs. 
T he t a blets s h o ul d be s w all o we d w h ol e wit h a dri n k of w ater. T he t a blets s h o ul d n ot be 
s plit, c he we d, or cr us h e d. 
St u d y me dic ati o n ca n be ta ke n wit h o ut re gar d t o meals.  
D os e titr ati o n peri o d - D o u ble- Bli n d P h ase:   
Fr o m t h e be gi n ni n g t o t h e e n d of W ee k 1 s u bjects s h o ul d i n gest eit her 3 0 0 m g Q D of B H V-
3 2 4 1 or matc hi n g pla ce b o Q D. Fr o m t he be gi n ni n g t o t he e n d of W ee k 2, s u bjects s h o ul d 
i n gest eit her 3 0 0 m g BI D of B H V- 3 2 4 1 or mat c hi n g place b o BI D.  S u bje cts s h o ul d ta k e t he 
st u d y dr u g t wice a d a y; d osi n g i n t he m or ni n g a n d e v e ni n g a p pr o xi mat el y 1 2 h o urs a part.   
At t he e n d of W ee k 2, a n ass ess me nt of c o m plia nc e a n d t oler a nce t o t his d ose titrati o n s c he d ul e 
will be c o n d u cte d.  Per I n v esti gat or j u d ge m e nt, a d diti o nal e v al uati o ns/ pr oc e d ures ma y be 
c o n d ucte d at t his ti m e p oi nt as a p pr o priat e.  If t ol era bilit y iss ues are e x perie nce d wit h 3 0 0 m g 
Q D or 3 0 0 m g BI D d osi n g, t he titrati o n sc he d ule m a y be m o difi e d (see S ecti o n 7. 2. 3). 
F ull d ose peri o d - D o u ble- Bli n d P h ase:  
Starti n g wit h t he be gi n ni n g of W ee k 3 a n d t hr o u g h o ut t he re mai n d er of t he st u d y, s u bje cts 
s h o ul d i n gest eit her 6 0 0 m g BI D of B H V- 3 2 4 1 or matc hi n g pl ace b o BI D. S u bje cts s h o ul d ta k e 
t he st u d y dr u g t wice a da y; d osi n g i n t h e m or ni n g a n d e ve ni n g a p pr o xi matel y 1 2 h o urs a part.  
At t he Wee ks 4, 1 2, 2 4, 3 6 a n d 4 8 st u d y visits, t h e m or ni n g d os e of st u d y me di cati o n s h o ul d be 
hel d o n t he d a y of t he st u d y visit a n d a d mi nistere d i n t he cli nic/ offic e d uri n g t he st u d y visit, s o 
t hat o ne pr e- d os e (tr o u g h) a n d o ne p ost- d os e P K s a m ple ca n b e c ollect e d a p pr o xi mat el y 2- 4 
h o urs p ost- d os e (see S ecti o n 6. 3. 2). 
D ose Titr ati o n Peri o d - O L E P h as e:
S u bjects e nt eri n g t h e O L E p has e of t h e st u d y will r e cei ve o p e n-la bel acti ve B H V- 3 2 4 1 a n d will  
f oll o w t he s a m e d os e titrati o n sc he d ule as t he titrati o n i n t he d o u bl e- bli n d p h ase of t he st u d y, t o 
e ns ure t hat all p artici pa nts s afel y c o nti n ue fr o m eit h er acti v e B H V- 3 2 4 1 or place b o t o o p e n-
la bel B H V- 3 2 4 1.  


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 8 4  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
S u bjects s h o ul d be a d mi nistere d t he D a y 1/first d os e of o pe n-l a bel B H V- 3 2 4 1 ( 3 0 0 m g 
Q D) w hile i n t he office/cli nic o n t h e d a y of t he B aseli ne - E xte nsi o n visit. S u bjects s h o ul d 
st a y at t h e office/cli nic f or m o nit ori n g f or a p pr o xi m atel y 4 h o urs.  
F or t he r est of We e k 1- E xte nsi o n of t he O L E p h as e, s u bjects will i n gest o ne ta bl et of B H V-
3 2 4 1 ( 3 0 0 m g) per da y i n t he m or ni n g f or o ne wee k.  Fr o m start t o e n d of Wee k 2- E xte nsi o n, 
s u bjects will i n gest 3 0 0 m g BI D of B H V- 3 2 4 1.  S u bjects s h o ul d ta k e o ne 3 0 0 m g ta bl et of 
B H V- 3 2 4 1 t wice a da y ( 6 0 0 m g p er da y); i n t he m or ni n gs a n d e ve ni n gs, a p pr o xi matel y 1 2 
h o urs a part. If t here is a del a y i n d osi n g, t h e i nt er val bet wee n t w o d oses s h o ul d be n o l ess t ha n 
6 h o urs.
A n e n d of Wee k 2- E xte nsi o n ass ess me nt of c o m pli a nce a n d t oler a nce t o t his d ose titr ati o n 
s c he d ule will be c o n d u cte d.  Per I n vesti gat or j u d ge m e nt, a d diti o nal e val uati o ns/ pr oce d ures 
ma y be c o n d u cte d at t his ti m e p oi nt as a p pr o priat e.  If t olera bilit y iss ues are e x perie nc e d wit h 
3 0 0 m g Q D or 3 0 0 m g BI D d osi n g, t he titr ati o n s c h e d ule ma y b e m o difie d (s ee Secti o n  7. 2. 3). 
F ull D ose Peri o d- O L E P h as e: 
Starti n g wit h Wee k 3- E xte nsi o n a n d f or t he re mai n d er of t he O L E p h as e of t he st u d y 
(a d diti o n al 4 6 w ee ks), s u bjects will i n gest 6 0 0 m g BI D of B H V- 3 2 4 1. S u bjects s h o ul d ta ke t w o 
3 0 0 m g ta bl ets of B H V- 3 2 4 1 t wice a d a y ( 1 2 0 0 m g per da y); i n t he m or ni n gs a n d e ve ni n gs, 
a p pr o xi matel y 1 2 h o urs a p art.  
S u bjects w h o w ere ta ki n g a re d uce d d os e of 3 0 0 m g BI D ( o ne ta blet t wice a da y) of t h e bli n d e d 
st u d y me dicati o n d u e t o t olera bilit y iss ues w he n t he y c o m plete d t h e d o u ble- bli n d p hase of t h e 
pr ot oc ol, m a y c o nti n ue t a ki n g t h at 3 0 0 m g BI D d uri n g t he O L E. 
7. 2. 3
D o s e M o difi c ati o n s 
S u bjects, al o n g wit h t heir care gi vers, will b e i nstr uct e d o n t he d osi n g re gi me n. 
If t olera bilit y iss ues are e x perie nc e d d uri n g t h e d ose titrati o n peri o d wit h t h e 3 0 0 m g Q D 
a n d/ or 3 0 0 m g BI D d oses ( or mat c hi n g pl ace b o), t h e titrati o n sc he d ule m a y be e xt e n de d (e. g., 
u p titrati o n t o t he ne xt d os e le v el del a ye d b y a n a d diti o nal wee k). P ot e nti al t olera bilit y iss u es 
ma y i ncl u de s u d de n, cli ni call y si g nific a nt c h a n ges fr o m bas eli n e i n s y m pt o ms of pres y nc o pe, 
s y nc o pe, ort h ostatic h y p ot e nsi o n, or falls t hat ar e n ot ot her wise e x pl ai ne d. T he I n vesti g at or 
m ust c o ns ult wit h t he Me di cal M o nit or if he or s he b elie v es t hat a c ha n ge t o t he d os e titr ati o n 
s c he d ule is w arra nte d; a n d, t he I n vesti gat or m ust d oc u me nt a n y s uc h c ha n ges t o t he d os e 
titrati o n sc he d ule.
D uri n g t he f ull d os e p eri o d of t h e st u d y, it is a nti ci pate d t hat all s u bjects will re cei ve eit h er 
B H V- 3 2 4 1 6 0 0 m g BI D or matc hi n g pl ace b o BI D. If s u bjects ha ve diffic ult y t olerati n g B H V-
3 2 4 1 6 0 0 m g BI D or matc hi n g pla ce b o BI D d osi n g, t he I n vesti g at or m a y per mit t he s u bject t o 
s witc h t o B H V- 3 2 4 1 3 0 0 m g BI D or matc hi n g pla ce b o BI D d osi n g (a n d d oc u me nt t his c ha n g e 
i n t he s u bj
P ote ntial t oler a bilit y iss ues ma y i ncl u de t h ose liste d a b o ve as well as 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 8 5  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
cli ni call y si g nifi ca nt la b orat or y a b n or malities (i.e., t h yr oi d a n d re nal f u ncti o n) t hat are n ot 
ot her wis e e x pl ai ne d. D o w n titrati o n t o B H V- 3 2 4 1 3 0 0 m g BI D or matc hi n g pla ce b o BI D will 
o nl y be all o we d t o a d dr ess t olera bilit y iss ues a n d o nl y wit h Me dical M o nit or a p pr o v al. If a 
s u bject is d o w n titrat e d t o t h e 3 0 0 m g BI D d ose, t he y ma y be all o we d t o r etr y t he 6 0 0 m g BI D 
d os e (re-c halle n ge), if d ee m e d a p pr o pri ate b y t he I n v esti gat or a n d M e dic al M o nit or. O nl y t w o 
re-c halle n ges are all o w e d. A n y s uc h c h a n ges m ust b e d oc u me nte d b y t h e I n vesti gat or. If a 
s witc h t o B H V- 3 2 4 1 3 0 0 m g BI D or matc hi n g pla ce b o BI D d osi n g d oes n ot res ult i n 
acce pta bl e t oler a bilit y, t h e n d osi n g s h o ul d be disc o nti n ue d.  
D ose m o dificati o n s h o ul d be c o nsi dere d if a patie nt e x perie n ces o ne of t he f oll o wi n g: 
a. Cli nic all y si g nific a nt c h a n ges i n fre q ue n c y a n d/ or s e verit y fr o m b as eli n e i n s y m pt o ms 
of pres y nc o pe, s y nc o pe, ort h ostatic h y p ote nsi o n, a n d/ or falls t h at ar e n ot e x plai ne d b y 
M S A disease pr o gressi o n or i nterc urre nt ill n ess a n d n ot a ble t o be a d e q uatel y treate d 
wit h s y m pt o matic p h ar ma c ol o gi cal a n d n o n- p h ar ma c ol o gical tr eat me nts, base d o n t h e 
j u d ge me nt of t he I n v esti gat or, 
b.  D e vel o p me nt of Gr a de 3 or Gr a de 4 h y p ot h yr oi dis m. Rec halle n ge ma y be atte m pte d, if 
w arra nte d, w he n i m pr o ve d t o l ess t ha n or e q ual t o Gra de 2 (i ncl usi ve of tre at m e nt wit h 
t h yr o xi ne re plac e me nt t hera p y. se e S ecti o n 8. 1. 8). 
c. D e vel o p me nt of a greater t h a n or e q ual t o Gra de 3 t o xicit y or a n i nt olera ble si de eff ect 
attri b ute d t o B H V- 3 2 4 1 base d o n t h e j u d ge me nt of t he I n vesti gat or. Rec h alle n g e ma y 
be att e m pt e d, if w arra nt e d, w he n s y m pt o ms i m pr o ve t o less t ha n or e q u al t o Gra d e 1. 
7. 3 
Bli n di n g a n d U n bli n di n g 
Bli n di n g is criti cal t o t he i nte grit y of t his cli nical st u d y. H o we ver, i n t he e v e nt of a m e dical 
e mer ge n c y or pre g na nc y i n a n i n di vi d ual s u bject, i n w hic h k n o wle d ge of t h e i n vesti gati o nal 
treati n g p h ysici a n. 
I n vesti gat or s h o ul d h a ve deter mi n e d t hat t he i nf or mati o n is nec ess ar y, i.e., t h at it will alter t he 
s clearl y 
n ot i n vesti g ati o n al pr o d uct rel ate d, t h e pr o ble m ma y be pr o perl y m a na ge d wit h o ut t he n ee d f or 
u n bli n di n g, b y ass u mi n g t hat t he s u bject is re cei vi n g acti v e pr o d uct. U n bli n di n g will be 
ma na ge d via t h e I W R S s yste m. T he cli nical s u p pl y ma na ger, p h ar mac o ki netic a n d 
p har mac o d y n a mi c ve n d ors, I W R S ve n d or, p har m ac o vi gila n ce a n d  D M C (if re q ueste d)  r oles 
ma y be u n bli n de d bef or e data are u n bli n de d f or t h e pri mar y e n d p oi nt a n d all s u bj ects c o m plet e 
t he st u d y. E xce pt as n ot e d a b o ve, ot h er me m bers of t he Bi o ha ve n r es earc h t ea m will re mai n 
bli n de d. I n c ases of acci d e ntal u n bli n di n g, c o nt act t h e M e dical M o nit or a n d e ns ure e ver y 
atte m pt is m a de t o pr es er ve t he bli n d. 
D uri n g t he O L E p has e, all p artici pa nts will n ot be bli n de d a n d will b e recei vi n g a cti v e B H V-
3 2 4 1. 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 8 6  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
7. 4
Tr e at m e nt C o m pli a n c e
Res p o nsi ble st u d y pers o n nel will dis pe ns e t he st u d y dr u g. Acc o u nta bilit y a n d c o m plia nc e 
verific ati o n s h o ul d b e d oc u me nte d i n t he 
st u d y rec or ds. S u bjects will be c o u ns ele d o n 
t he i m p orta nc e of ta ki n g t he st u d y dr u g as dir ect e d at all st u d y visits.   
O ver ni g ht s hi p me nt of st u d y me dicati o n u n der a m bi e nt c o n diti o ns ( via certifie d a n d trac k e d 
c o urier a n d f oll o wi n g Re m ote Visit W or kar o u n d G ui deli nes pr o vi d e d t o sit es), fr o m t he st u d y 
site t o st u d y partici pa nts is per missi ble w he n a n i n- p ers o n st u d y visit is n ot p ossi ble d u e t o t h e 
C O VI D-
. T he 
s p o ns or s h o ul d be c o ns ulte d pri or t o s hi p pi n g dr u g. C o nfir mati o n t hat t he st u d y dr u g s hi p me nt 
w as recei ve d b y t he st u d y partici p a nt s h o ul d be r etai n e d as d oc u me ntati o n, e. g., tra c ki n g 
c o nfir mati o n pri nt o ut fr o m t he c o uri er, writt e n d oc u me ntati o n of c o ntact wit h t h e s u bject ( b y 
p h o ne, e mail, t e xt), s u bject si g nat ure o n pac ki n g list, etc.
If p o or c o m pli a nce c o nti n ues, (i. e., ta ki n g st u d y dr u g differe ntl y t ha n p er I n vesti gat or 
i nstr ucti o ns, m ulti ple misse d d os es res ulti n g i n less t ha n 8 0 % o verall c o m plia nce), 
dis c o nti n uati o n of t h e s u bject fr o m t h e trial s h o ul d b e c o nsi dere d a n d disc usse d wit h t he 
S p o ns or. 
7. 5 
D e str u cti o n a n d R et ur n of St u d y Dr u g 
All u n us e d a n d/ or partiall y us e d st u d y dr u g ca n b e se nt bac k t o t he dr u g de p ot f or destr ucti o n 
desi g nee. If it
t o e ns ure t hat arra n ge me nts ha v e bee n ma de f or t he dis p osal, pr oce d ures f or pr o per dis p os al 
ha ve bee n esta blis he d acc or di n g t o t h e a p plica ble re g ulati o ns, g ui d eli n es a n d i nstit uti o n al 
pr oce d ures, a n d a p pr o pri ate r ec or ds of t he dis p os al h a ve bee n d o c u me nte d. T he u n use d st u d y 
dr u gs ca n o nl y be destr o y e d after b ei n g i ns pecte d a n d rec o ncile d b y t h e res p o nsi ble St u d y 
 
8 
A D V E R S E E V E N T S 
A n A d verse E ve nt ( A E) is defi ne d as a n y ne w u nt o w ar d me di cal o cc urre nc e or w orse ni n g of a 
pre-e xisti n g me di cal c o n diti o n i n a patie nt or cli nic al i n vesti gati o n patie nt a d mi nister e d a n 
i n vesti gati o nal ( me dici n al) pr o d uct a n d t hat d oes n ot necess aril y h a ve a c a us al relati o ns hi p 
wit h t his tre at m e nt. A n A E ca n t heref ore b e a n y u nfa v ora ble a n d u ni nte n d e d si g n (i ncl u di n g a n 
a b n or mal la b orat or y fi n di n g, f or e x a m pl e) s y m pt o m, or dis eas e te m p orall y ass ociat e d wit h t h e 
us e of t he i n vesti gati o nal pr o d u ct, w het her or n ot c o nsi dere d rel ate d t o t he i n v esti gati o nal 
pr o d uct.  
If a s pecifi c dia g n osis or s y n dr o me is i de ntifie d b y t h e I n vesti gat or, t his s h o ul d be r ec or de d as 
t he A E, rat h er t ha n re c or di n g as s e par ate A Es t h e i n di vi d ual si g ns/s y m pt o ms or cli nicall y 
si g nifica nt la b or at or y a b n or m alities k n o w n t o be ass ociat e d wit h, a n d c o nsi dere d b y t h e 
I n vesti gat or t o be a c o m p o ne nt of, t he dis eas e/s y n dr o me.   


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 8 7  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
A d verse e ve nts ca n be s p o nt a ne o usl y re p orte d or elicite d d uri n g o p e n-e n de d q u esti o ni n g, 
e xa mi n ati o n, or e val uati o n of a p ati e nt. I n or der t o pr e ve nt re p orti n g bi as, patie nts s h o ul d n ot 
be q uesti o ne d r e gar di n g t he s pecific occ urre nce of o ne or m ore A Es. 
T here ar e t w o t y pes of A Es, Seri o us A d verse E ve nts ( S A Es) a n d N o n- Seri o us A Es. 
8. 1 
S eri o u s A d v er s e E v e nt s 
8. 1. 1
D efi niti o n of S eri o u s A d v er s e E v e nt ( S A E) 
A S A E is a n y e ve nt t hat me ets a n y of t he f oll o wi n g criteri a at a n y d ose:
 D eat h; 
 Life-t hr eat e ni n g; 
 I n patie nt h os pitalizati o n or pr ol o n gati o n of e xisti n g h os pitali zati o n; 
 Persiste nt or si g nifi ca nt dis a bilit y/i nca p acit y; 
 C o n ge nital a n o m al y/ birt h def ect i n t he offs pri n g of a s u bject w h o recei ve d B H V- 3 2 4 1: 
 Ot her: I m p ort a nt m e dical e ve nts t hat ma y n ot r es ult i n deat h, be life-t hreat e ni n g, or re q uire 
h os pitali zati o n, ma y b e c o nsi dere d a n S A E w he n, bas e d u p o n a p pr o priat e me dical 
j u d g me nt, t he y m a y je o p ar dize t he s u bje ct a n d ma y r e q uire m e dic al or s ur gical i nt er ve nti o n 
t o pre ve nt o n e of t he o utc o mes liste d i n t his defi niti o n. E xa m pl es of s uc h e ve nts are ( b ut 
n ot li mite d t o): 
 I nte nsi ve tr eat me nt i n a n e m er ge nc y r o o m or at h o m e f or aller gi c br o nc h os pas m; 
 Bl o o d d yscrasias or c o n v ulsi o ns t h at d o n ot r es ult i n i n pati e nt h os pit ali zati o n; 
 D e vel o p me nt of dr u g de pe n de n c y or dr u g a b use; 
 
P ote ntial dr u g i n d uc e d li v er i nj ur y (s ee s ecti o n 8. 1. 7)  
8. 1. 2
D efi niti o n of T er m s 
Mil d: A mil d A E is us uall y tr a nsie nt a n d ma y r e q uir e o nl y mi ni mal treat m e nt or t her a pe utic 
i nter ve nti o n.  T h e e ve nt d oes n ot ge ner all y i nterf ere wit h us ual acti vities of dail y li vi n g. 
M o der ate: A m o derate A E is us uall y alle vi ate d wit h a d diti o n al s pecific t hera pe utic 
i nter ve nti o n. T h e e ve nt i nterf eres wit h us ual acti vities of dail y li vi n g, ca usi n g disc o mf ort b ut 
p os es n o si g nifica nt or p er ma n e nt ris k of har m t o t he s u bject. 
Se vere: A se vere A E i nterr u pts us ual acti vities of dail y li vi n g, si g nifi ca ntl y affe cts cli nical 
stat us, or ma y re q uire i nte nsi ve t hera pe utic i nter v e nti o n. 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 8 8  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
Life t hre ate ni n g: A n A E is lif e t hreate ni n g if t he s u bject was at i m me di ate ris k of de at h fr o m 
t he e ve nt as it o cc urre d; i.e., it d oes n ot i n cl u de a rea cti o n t h at if it ha d o cc urre d i n a m ore 
s eri o us f or m mi g ht h a ve ca us e d deat h. F or e x a m pl e, dr u g i n d uce d he p atitis t hat res ol ve d 
wit h o ut e vi d e nce of h e pati c fail ure w o ul d n ot b e c o nsi dere d lif e t hre ate ni n g e ve n t h o u g h dr u g 
i n d uce d he p atitis ca n be f atal. 
H os pit aliz ati o n: A Es re q uiri n g h os pitaliz ati o n s h o ul d be c o nsi dere d S A Es. H os pitalizati o n f or 
electi ve s ur ger y or r o uti ne cli ni cal pr o ce d ures t h at ar e n ot t he r es ult of a n A E (e. g., electi v e 
s ur ger y f or a pre-e xisti n g c o n diti o n t hat has n ot w orse ne d) nee d n ot be c o nsi der e d A Es or 
S A Es. If a n yt hi n g u nt o war d is re p ort e d d uri n g t he pr oce d ure, t h at occ urr e nce m ust be re p orte d 
as a n A E, eit h er 'seri o us' or ' n o n-s eri o us' a cc or di n g t o t he us ual criteria.  
I n ge neral, h os pitalizati o n si g nifies t hat t he s u bject h as bee n det ai ne d ( us uall y i n v ol vi n g at least 
a n o ver ni g ht st a y) at t he h os pit al or e m er ge nc y war d f or o bser vati o n a n d/ or treat me nt t hat 
w o ul d n ot ha ve be e n a p pr o priate i n t he p h ysicia n's office or o ut p ati e nt s etti n g. W he n i n d o u bt 
as t o w het her ' h os pitaliz ati o n' occ urr e d or was necess ar y, t he A E s h o ul d be c o nsi d ere d s eri o us.  
T he f oll o wi n g h os pitalizati o ns are n ot c o nsi dere d S A Es i n Bi o ha ve n cli ni cal st u dies ( b ut m a y 
be c o nsi dere d n o n-s eri o us A Es): 
 A visit t o t he e mer g e nc y r o o m or ot her h os pital de part me nt < 2 4 h o urs t h at d oes n ot r es ult 
 
t hreat e ni n g); 
 Electi ve s ur ger y, pla n ne d pri or t o si g ni n g c o nse nt; 
 A d missi o ns as per pr ot oc ol f or a pla n ne d me dic al/s ur gical pr o ce d ure; 
 R o uti ne healt h ass ess me nt re q uiri n g a d missi o n (i.e., r o uti ne c ol o n osc o p y); 
 A d missi o n e nc o u nter e d f or a n ot her life circ u msta nc e t hat carries n o beari n g o n healt h a n d 
re q uires n o me dical i nter v e nti o n (i.e., l ac k of h o usi n g, care- gi v er res pite, f a mil y 
circ u mst a nces).
Dis a bilit y/i n c a p acit ati n g:  A n A E is i nca pa cit ati n g or disa bli n g if t he e x p erie nc e res ults i n a 
s u bsta ntial a n d/ or per ma ne nt disr u pti o n of t he s u bject's a bilit y t o carr y o ut n or mal life 
f u ncti o ns.
8. 1. 3
Cl a s sifi c ati o n of A d v er s e E v e nt s 
T he s e verit y of all A Es m ust be rec or d e d i n t h e e C R F a n d o n t h e S A E F or m, if a p plica ble. T h e 
acti viti es. T he s e verit y of e ve nts s h o ul d be gra de d as mil d, m o d erat e or se vere.  
T
pr ocess b ut is n ot a fact or i n d eter mi ni n g w hat is or is n ot re p orte d i n t he st u d y. If t h ere is a n y 
d o u bt as t o w het her a cli nical o bs er vati o n is a n A E, t he e ve nt s h o ul d b e re p orte d. T he 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 8 9 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
relati o ns hi p or ass ociati o n of t h e st u d y dr u g i n ca usi n g or c o ntri b uti n g t o t h e A E will b e 
c haracteriz e d as n ot relat e d, u nli k el y relat e d, p ossi bl y relat e d or relate d f or n o n-s eri o us A Es 
a n d as n ot rel ate d or relat e d f or S A Es.
Dis eas e relate d si g ns a n d s y m pt o ms, i ncl u di n g t h ose t hat ar e part of t he dia g n ostic criteria f or 
M S A, ma y be re p orte d as A Es as f oll o ws:
Disease relate d si g ns a n d s y m pt o ms t hat meet t he defi niti o n of a n S A E as o utli n e d i n
Secti o n 8. 1. 1 s h o ul d be r e p orte d as S A Es.
Disease relate d si g ns a n d s y m pt o ms n ot meeti n g t he defi niti o n of a n S A E, b ut re pr ese nti n g 
u nt o w ar d me di cal o cc urre nc es or c ha n ges i n t he c o n diti o n t h at ar e 
me dic all y si g nific a nt s h o ul d be re p orte d as A Es.
Disease relate d si g ns a n d s y m pt o ms ma y be m e dic all y si g nifica nt if t h e y
o
are u nc o m m o n a n d u ne x pe cte d f or t he sta g e of t he disease,
o
c ha n ge si g nifica ntl y i n t heir fre q u e nc y or i nte nsit y,
o
lea d t o t he i niti ati o n of a ne w t hera p y or m o difi cati o n of a n e xisti n g t hera p y, or
o
are ass ociate d wit h mea ni n gf ul se q uel ae.
8. 1. 4
C oll e cti o n a n d R e p orti n g S eri o u s A d v er s e E v e nt s
w het her relate d or 
n ot relate d t o st u d y dr u g, m ust be c ollecte d, i n cl u di n g t h os e t h o u g ht t o b e ass ociate d wit h 
pr ot oc ol-s pecific pr oc e d ures. All S A Es m ust be c ollecte d t h at oc c ur d uri n g t he Scr ee ni n g 
peri o d a n d wit hi n 3 0 da ys of dis c o nti n uati o n of d osi n g. T he I n vesti g at or s h o ul d re p ort a n y 
S A E occ urri n g aft er t hes e ti me p eri o ds t hat is belie v e d t o be relat e d t o st u d y dr u g or pr ot oc ol-
s pecific pr o ce d ures. 
A n S A E re p ort s h o ul d be c o m pl ete d f or a n y e ve nt w here d o u bt e xists re gar di n g its stat us of 
s eri o us ness. 
If t he I n vesti g at or belie ves t h at a n S A E is n ot r elate d t o t he st u d y dr u g, b ut is p ote ntiall y 
relat e d t o t h e c o n diti o ns of t he st u d y (s uc h as a wit h dra wal of pre vi o us t h era p y or a 
c o m pli cati o n rel ate d t o st u d y pr oce d ure), t he relati o ns hi p s h o ul d be s pecifi e d i n t h e narrati ve 
s ecti o n of t h e S A E Re p ort F or m. 
S A Es ( w het her relat e d or n ot rel ate d t o st u d y dr u g), o ver d ose, p ote ntial dr u g i n d uce d li ver 
i nj ur y a n d pre g n a nci es m ust be re p ort e d i m me di atel y or n o l ater t h a n wit hi n 2 4 h o urs of
t he I n vesti g at or a w are n ess of t he e ve nt t o t h e 
 de part me nt. 
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 9 0 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
T he I n vesti g at or is res p o nsi bl e f or re p orti n g all S A Es a n d all Ot her I m p orta nt Me dical E ve nts 
t o
i m me diatel y u p o n o bser vi n g or lear ni n g of t h e e ve nt. 
 will t h e n i m me di atel y n otif y 
t he Bi o ha v e n M e dic al M o nit or of t he e ve nt. T he S A E f or m m ust t h e n be s u b mitte d t o
wit hi n o ne w or ki n g da y. 
If o nl y li mite d i nf or mati o n is i niti all y a vaila ble, f oll o w- u p re p orts are re q uire d. If a n o n g oi n g 
S A E c ha n ges i n its i nte nsit y or r elati o ns hi p t o st u d y dr u g or if ne w i nf or mati o n bec o mes 
a vail a ble, a f oll o w- u p S A E re p ort s h o ul d be s e nt wit hi n 2 4 h o urs of t he I n vesti g at or be c o mi n g 
a w are of t he u p date d i nf or mati o n usi n g t he s a me pr o ce d ure use d f or t he tra ns missi o n of t h e 
i niti al S A E a n d t h e s a me e ve nt ter m. 
All S A Es s h o ul d be f oll o w e d t o res ol uti o n or sta bili z ati o n.  
T he Seri o us A d verse E ve nt Re p ort F or m ( S A E R F) s h o ul d be s u b mitte d t o 
 b y 
facsi mile ( F A X). 
N ort h A meric a:
 
E U E M E A: 
 
If site pers o n nel d o n ot ha ve access t o a F A X mac hi ne d uri n g t he C O VI D-1 9 p u blic h ealt h 
e mer ge n c y, S A Es ma y be re p ort e d t o 
 b y e mail (e ncr y pt t h e d oc u m e nt bef ore e maili n g) t o
Re p orts ca n be ma de b y tele p h o n e via t he Safet y H otli ne N u m ber b el o w if a S A E R F ca n n ot be 
i m me diat el y s u b mitte d. 
N ort h A meric a:
 
E U E M E A: 
 
A d diti o nall y, t he I n v esti gat or, or desi g nate d staff, is res p o nsi ble f or e nt eri n g t h e S A E 
i nf or mati o n i n t h e El ectr o nic D ata C a pt ure ( E D C) s yste m (i.e.: e ve nt ter m, start st o p dates, 
ca us alit y, se verit y).  
re p orti n g re q uire m e nts. 
F or a n y q uesti o ns relati n g t o S A Es, ple ase c o nta ct t h e M e dical M o nit or vi a tele p h o ne:  
N ort h A meric a: Dr. 
E U E M E A : Dr. 
T he S p o ns or or s pecifie d d esi g nee/ a ut h ori ze d re pr es e ntati ve will re p ort s us pecte d u ne x pe cte d 
s eri o us a d verse reacti o ns ( S U S A Rs) i n a n e x pe dite d ma n ner ( wit h o ut del a y) t o t he Re g ulat or y 
A ut h orities a n d Et hi cs C o m mitte es c o ncer ne d, i n ac c or da nce wit h F o o d a n d Dr u g 
C CI
C CI
C CI
C CI
P P D
P P D
C CI
P P D
P P D
P P D
P P D
P P D
P P D
P P D


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 9 1 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
A d mi nistrati o n C o de of Fe der al Re g ulati o ns ( C F R) 2 1 C F R Parts 3 1 2 a n d 3 2 0, E ur o p ea n 
Directi v e 2 0 0 1/ 2 0/ E C a n d t h e D etaile d G ui da n ce o n c olle cti o n, v erifi cati o n a n d prese nt ati o n of
a d verse reacti o n re p orts arisi n g fr o m cli nical tri als o n I Ps f or h u ma n us e ( E N T R/ C T 3) a n d als o 
i n acc or d a nce wit h c o u ntr y-s pecific r e q uire me nts.
T he S p o ns or or s pecifie d d esi g nee/ a ut h ori ze d re pr es e ntati ve s hall n otif y t he I n vesti gat or of t h e 
f oll o wi n g i nf or m ati o n:
A n y A E t hat is b ot h seri o us a n d u n e x pecte d a n d is s us pecte d of bei n g relate d t o t he use of 
t he I P i n t his st u d y or i n ot her st u di es (i.e., S U S A R).
W here re q uire d b y l oc al l e gislati o n, t h e I n vesti g at or s hall n otif y his/ her I R B/ E C pr o m ptl y of 
t hese ne w seri o us a n d u ne x pe cte d A E(s) or si g nifica nt ris ks t o s u bjects.
8. 1. 5
O v er d o s e
A n o ver d ose is defi ne d as t h e acci de nt al or i nte nti o n al a d mi nistrati o n of a n y d os e of t he 
pr o d uct t hat is c o nsi der e d b ot h e xcessi ve a n d m e dic all y i m p orta nt. All occ urr e nces of 
me dic all y si g nifica nt o ver d os e (s us pect e d or c o nfir m e d a n d irres pe cti ve of w het her or n ot it 
i n v ol ve d B H V- 3 2 4 1) m ust be c o m m u ni cat e d t o Bi o h a ve n or a s pecifie d desi g n ee wit hi n 2 4 
h o urs of t he I n vesti gat or bec o mi n g a ware a n d be f ull y d oc u me nt e d as a n S A E. A n S A E is 
re p orte d f or o ver d ose w he n t h e i n vesti gat or f eels t h e o ver d os e was e xcessi ve a n d m e dic all y 
i m p orta nt. D etails of a n y si g ns or s y m pt o ms a n d t heir ma na g e me nt s h o ul d be rec or d e d 
i ncl u di n g d etails of a n y a nti d ot e(s) a d mi nist ere d.
8. 1. 6
Pr e g n a n c y
If, f oll o wi n g i nitiati o n of t h e I P, it is disc o v ere d t hat a st u d y s u bject is pre g na nt or ma y ha ve 
bee n pre g na nt at t he ti me of t h e I P e x p os ure, i ncl u di n g d uri n g at l east 6 half-li v es after I P 
a d mi nistr ati o n, t he I P will b e per m a ne ntl y disc o nti n u e d i n a n a p pr o priat e ma n ner (i.e., d os e 
ta peri n g, if nec ess ar y, f or patie nt safet y). Pr ot o c ol-re q uire d pr oce d ur es f or st u d y 
dis c o nti n uati o n a n d f oll o w u p will b e c o n d ucte d u nless c o ntrai n dic ate d b y t he pre g na n c y (i.e., 
x-ra y st u dies). Ot her a p pr o pri ate pr e g na nc y f oll o w- u p pr oce d ures s h o ul d be c o nsi d ere d if 
i n dicate d.
Sites s h o ul d i nstr uct p ati e nts t o c o ntact t he I n vesti gat or if t he y be c o me pre g n a nt d uri n g t he 
c o urs e of t he st u d y. T h e I n vesti gat or m ust i m me diat el y n otif y 
 of t he e v e nt wit hi n 2 4 h o urs 
of t he I n vesti g at or be c o mi n g a w ar e of t he i nf or mati o n a n d t he sit e m ust c o m plete a Pre g na n c y 
Re p ort F or m. F oll o w u p i nf or m ati o n r e gar di n g t he c o urs e of t he pre g na nc y, i ncl u di n g peri n atal 
a n d ne o nat al o ut c o me a n d, w her e a p plica ble, offs pri n g i nf or mati o n m ust als o be re p ort e d o n a 
Pre g na nc y Re p ort F or m.
A n y pre g na nc y t hat occ urs i n a f e male part ner of a m ale st u d y p arti ci pa nt s h o ul d als o be 
re p orte d t o 
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 9 2  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
8. 1. 7
P ot e nti al Dr u g I n d u c e d Li v er I nj ur y ( DI LI)
W here ver p ossi bl e, ti mel y c o nfir mati o n of t h e i nitial li ver-relat e d la b orat or y a b n or m alities 
s h o ul d occ ur pri or t o t he re p orti n g of a p ot e nti al dr u g i n d uce d li ver i nj ur y ( DI LI) e ve nt. All 
occ urre nces of p ot e nti al DI LIs, me eti n g t he defi ne d criteria, m ust b e re p orte d as S A Es as per 
Secti o n 8. 1. 4.  
P ote ntial dr u g i n d uc e d li v er i nj ur y is defi ne d as: 
 A mi n otra nsferases ( A L T or A S T) el e vati o n > 3 ti mes t he U L N; 
 
 T otal bilir u bi n ( T B L) > 2 ti m es U L N, wit h o ut i nitial fi n di n gs of c h olest asis (ele v ate d 
s er u m al kali ne p h os p hatas e); 
 
 N o ot her i m m e diatel y a p pare nt p ossi bl e ca us es of A L T or A S T ele v ati o n a n d 
h y per bilir u bi ne mia, i n cl u di n g, b ut n ot li mite d t o, vir al he patitis, pre-e xisti n g c hr o nic or 
ac ute li ver dis eas e, or t he a d mi nistrati o n of ot her dr u g(s) k n o w n t o be he pat ot o xic. 
If a n y p ote ntial DI LI is i de ntifie d a n d meets t he criteria a b o ve, t he Bi o h a ve n Me dic al M o nit or 
s h o ul d i m me diat el y be c o nta cte d f or f urt h er i nstr ucti o n o n d osi n g a dj ust me nts a n d w het her t he 
patie nt m ust disc o nti n ue fr o m t he trial a n d a p pr o pri ate f oll o w u p re q uire m e nts. 
8. 1. 8
A d v er s e E v e nt of S p e ci al I nt er e st- T h yr oi d F u n cti o n 
Re versi ble c ha n ges i n t h yr oi d f u ncti o n tests were o bs er ve d d uri n g t he pr ecli nical st u dies a n d 
cli ni cal st u dies wit h B H V- 3 2 4 1. P h ysical e x a mi n ati o n a n d la b orat or y m o nit ori n g of t h yr oi d 
f u ncti o n wit h s er u m trii o d ot h yr o ni n e (free T 3), t h yr o xi ne (free T 4), T S H, a n d a nti T P O 
a nti b o di es will be p erf or me d a n d d o c u me nte d t hr o u g h o ut t his st u d y. A n y si g nific a nt a b n or mal 
fi n di n gs s h o ul d be dis c uss e d wit h t h e st u d y Me dic al M o nit or a n d ma y b e f oll o we d u p as per 
l ocal pr actice (e. g., i n vesti g ati o ns a n d c o ns ultati o n wit h e n d ocri n ol o gist).  
I n cases of s us pecte d h y p ot h yr oi dis m, re pe at t h yr oi d f u ncti o n t ests s h o ul d be me as ure d a n d 
t h yr o xi ne re plac e me nt t hera p y s h o ul d b e c o nsi der e d. I nitiati o n of tr eat me nt is at t he discreti o n 
of t he I n vesti g at or. P ote ntial i nitiati o n of t h yr o xi ne r e place me nt t hera p y ma y be c o nsi dere d 
acc or di n g t o t he f oll o wi n g g ui d eli nes: 
 Mil d T S H i ncrease: 5. 0 t o 1 0 m U/ L (ass u mi n g a n or mal T S H ra n ge of 0. 4 t o 4. 9 m U/ L) a n d 
u nc ha n ge d free T 4 (a n d/ or fr ee T 3) 
 Wit h cli ni cal s y m pt o ms of h y p ot h yr oi dis m: C o nsi der t h yr o xi ne tr eat me nt if c o nfir m e d 
at 2 c o nsec uti ve o ccasi o ns a n d n ot e x plai ne d b y c o n c o mit a nt 
ill ness/fe v er/i nf ecti o n/s ur ger y 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 9 3  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
N o s y m pt o ms: C o nti n ue n or mal m o nit ori n g.
 T S H greater t h a n t he U L N a n d decrease d fr ee T 4 ( a n d/ or free T 3) b el o w n or mal r a n ge: 
 Re gar dless of s y m pt o ms, c o nsi d er i nitiati o n of t h yr o xi ne treat m e nt if c o nfir me d at 2 
c o nsec uti v e occasi o ns a n d n ot e x pl ai ne d b y c o nc o mita nt ill ness/fe v er/ i nf ecti o n/s ur ger y 
(if se vere s y m pt o ms, re peat sa m pli n g i n 2 wee ks). 
If si g ns/s y m pt o ms of h y p ot h yr oi dis m a n d/ or si g nific a nt c ha n g es i n t h yr oi d h or m o ne le v els 
(free T 3/free T 4/ T S H) de vel o p, c olle cti o n of f oll o w u p cli ni cal c he mistr y s a m pl es a n d/ or 
u ns c he d ule d st u d y visits ma y be w arr a nte d. 
Cli nic all y si g nifica nt l a b orat or y a b n or maliti es will b e i de ntifie d as Gra de 3 t o 4 la b or at or y t est 
res ults gra de d a cc or di n g t o n u meri c la b or at or y t est criteri a i n C o m m o n Ter mi n ol o g y Criteria 
f or A d vers e E ve nts ( C T C A E) V ersi o n 5. 0 ( 2 0 1 7)1 8.  F or t h ose n ot a vaila bl e i n C T C A E, 
acc or di n g t o Di visi o n of AI D S ( D AI D S) Ta ble f or Gra di n g t he Se v erit y of A d ult a n d Pe diatric 
A d verse E ve nts C orrecte d V ersi o n 2. 1 ( 2 0 1 7)
1 9.  
If t here are cli nicall y si g nifica nt iss ues wit h t ol era bilit y t hat are n ot a bl e t o be treat e d 
a de q uat el y wit h t h yr o xi ne re plac e me nt t her a p y, t he I n vesti gat or ma y c o nsi d er m o difi cati o ns t o 
t he d osa ge re gi me n. C o ns ultati o n wit h t h e Me dical M o nit or is re q uire d. M o dificati o ns ma y 
i ncl u de r e d uci n g t he d os e of B H V- 3 2 4 1/ mat c hi n g pl ace b o t o 3 0 0 m g BI D or ta ki n g a d os e 
h oli da y. A n y s uc h m o dificati o ns t o t h e d osa ge re gi m e n s h o ul d be n ote d i n t he C R F. 
8. 2 
N o n- s eri o u s A d v er s e E v e nt s 
A n o n-s eri o us a d verse e ve nt is a n A E n ot cl assifie d as a S A E.  
8. 2. 1
C oll e cti o n a n d R e p orti n g of N o n- S eri o u s A d v er s e E v e nt s 
T he c ollecti o n of n o n-s eri o us A E i nf or m ati o n s h o ul d be gi n at t he i niti ati o n of st u d y dr u g.  
N o n-s eri o us a d verse e ve nts s h o ul d be f oll o we d u ntil c o ncl usi o n or sta bili zati o n, or re p orte d as 
S A Es if t he y bec o m e s eri o us. F oll o w- u p is re q uir e d f or n o n-s eri o us A Es t hat ca us e i nterr u pti o n 
or dis c o nti n uati o n of st u d y dr u g or t h os e t hat are pres e nt at t h e e n d of st u d y tr eat me nt. 
8. 2. 2
L a b or at or y T e st A b n or m aliti e s 
T he f oll o wi n g la b orat or y test a b n or maliti es s h o ul d be ca pt ur e d o n t he n o n-s eri o us A E C R F 
pa ge or S A E Re p ort F or m ( pa p er or electr o ni c) as a p pr o priate: 
 A n y la b orat or y t est res ult t hat is cli nicall y si g nifi ca nt or meets t h e defi niti o n of a n S A E; 
 A n y la b orat or y a b n or malit y t hat re q uir e d t he p ati e nt t o ha ve t h e st u d y dr u g dis c o nti n ue d or 
i nterr u pt e d;
 A n y la b orat or y a b n or malit y t hat re q uir e d t he p ati e nt t o recei ve s pecific c orr ecti ve t h era p y. 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 9 4  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
9 
S T A TI S TI C S 
D etail e d pla ns f or a nal ysis are s u m m ariz e d i n a s e p arate Statisti cal A nal ysis Pla n ( S A P) 
d oc u me nt. A s u m m ar y of statistical as pects of t he desi g n a n d i nte n d e d a nal ysis is pr o vi de d 
here.
9. 1 
G e n er al Pr o c e d ur e s 
Cate g ori cal v aria bl es are t a b ulate d wit h c o u nts a n d p erce nt a ges. C o nti n u o us varia bles ar e 
s u m mariz e d wit h u ni v ariate statistics (e. g., n, mea n, sta n dar d err or, m e dia n, mi ni m u m a n d 
ma xi m u m).   
F or t he cal c ulati o n of descri pti ve st atistics of o bser v e d data, s u bj ects m ust h a ve a baseli ne 
val ue t o b e e val ua ble f or e n d p oi nts bas e d o n v al ues a n d c ha n ges fr o m bas eli ne o ver ti m e. 
Ta b ulati o ns of t he f oll o wi n g e n d p oi nts prese nt t he n u m ber of u ni q ue s u bj ects wit h a n e ve nt: 
pr ot oc ol de viati o ns; n o n-st u d y me dicati o ns; a d vers e e ve nts; a n d la b orat or y a b n or malities. 
T h us, f or t hes e e n d p oi nts, m ulti ple o cc urre nc es of t h e sa me e v e nt are c o u nte d o nl y o nce p er 
s u bject. 
9. 2 
S a m pl e Si z e 
T he s a m pl e size f or t his st u d y will b e a p pr o xi m atel y 3 2 5 ra n d o miz e d s u bjects.  Bas e d o n 
u n p u blis he d dat a fr o m t h e Pr o mesa st u d y, st u d yi n g E G C G (e pi g all o cat ec hi n gallate) vs 
place b o 2 6 wit h a tr eat m e nt d urati o n of 4 8 wee ks, t h e place b o gr o u p h a d a 4. 8 8 p oi nt i ncre ase 
wit h a sta n dar d d e viati o n of 4. 8 5 i n t he m o difie d U M S A R S Part I a n d Part II t ot al s c ore. Wit h 
a n e x pecte d i m pr o ve me nt of 4 0 % at Wee k 4 8 f or B H V- 3 2 4 1 c o m pare d t o pl ace b o, a t otal of 
2 6 0 s u bjects ( 1 3 0 per gr o u p) pr o vi d es 9 0 % p o wer base d o n a 2-s a m ple, t w o-si de d t-t est.  Wit h 
a dr o p- o ut rat e of ~ 2 0 %, t he st u d y will ra n d o mize a p pr o xi mat el y 3 2 5 s u bjects. 
9. 3 
P o p ul ati o n s f or A n al y si s 
T he p o p ulati o n of i nterest, f or all esti ma n ds, ar e s u bj ects dia g n ose d wit h p ossi ble or pr o ba ble 
M S A.  
T he f oll o wi n g a nal ysis s ets ar e defi ne d f or t his pr ot o c ol:  
E nr olle d s u bj ects: S u bj ects w h o si g ne d a n i nf or me d c o ns e nt f or m a n d were assi g ne d a 
Patie nt I d e ntificati o n n u m b er ( PI D). 
Ra n d o mize d s u bjects: E nr olle d s u bjects w h o recei v e d a treat me nt assi g n me nt fr o m t he 
I nteracti ve We b Res p o ns e S yste m (I W R S). 
Treat e d/ Safet y: E nr olle d s u bje cts w h o recei ve d at le ast 1 d os e of bli n de d st u d y t hera p y 
( B H V- 3 2 4 1 or place b o).  


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 9 5  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
M o difie d I nte nt t o Tr eat ( mI T T) s u bjects: Ra n d o mize d s u bjects t h at re cei ve d at l east o ne 
d os e of bli n de d st u d y t h era p y a n d pr o vi de d a bas eli n e a n d at least o n e p ost- baseli n e 
effica c y assess me nt.
O pe n- La bel E xte nsi o n Treat e d s u bjects: E nr olle d s u bjects i n t he e xte nsi o n p hase 
 
B H V- 3 2 4 1 Treate d Partici pa nts: E nr olle d s u bjects w h o recei v e d at least 1 d os e of B H V-
3 2 4 1 ( bli n de d or o pe n-la bel). 
9. 4 
St ati sti c al M et h o d s 
9. 4. 1
D e m o gr a p hi c a n d B a s eli n e C h ar a ct eri sti c s 
Ta b ulati o ns of de m o gr a p hic a n d b aseli n e c har act eristics will b e s u m marize d b y treat me nt 
gr o u p a n d f or all treate d s u bjects.  A se parate s et of t a b ulati o ns will be ma de f or s u bj ects 
e nr olle d b ut n ot ra n d o miz e d. 
9. 4. 2
Pri m ar y E n d p oi nt( s) 
T he pri m ar y e n d p oi nt is t he c ha n ge fr o m b as eli n e i n t he m o difie d U M S A R S sc ore meas ure d at 
t he Wee k 4 8 visit. T he ite ms i n t he m o difie d U M S A R S will c o ntai n t he f oll o wi n g Part I ite ms: 
S peec h, C utti n g F o o d a n d H a n dli n g Ut e nsils, Dressi n g, H y gie ne, Wal ki n g a n d Uri nar y 
F u ncti o n. T he f oll o wi n g Part II ite ms will als o be i ncl u de d: Arisi n g fr o m C h air, P ost ure, a n d 
Gait. I n t he a nal ysis of all ite ms, t h e res p o nse cat e g ories of 0 a n d 1 will b e c o m bi ne d i nt o a 
si n gle cate g or y bef ore s u m mi n g t h e i n di vi d ual ite ms t o deri ve t he m o difie d U M S A R S.  
T he pri m ar y esti ma n d, f or t he pri mar y e n d p oi nt, will p urs ue a h y p ot hetical strate g y of 
esti mati n g t h e effect of B H V- 3 2 4 1 relati ve t o place b o ha d all s u bj ects sta y e d o n treat me nt.  
Usi n g t he mI T T p o p ulati o n, t he s u m mar y will be t h e differe nc e bet wee n plac e b o a n d B H V-
3 2 4 1 treat e d s u bjects at t he Wee k 4 8 visit. T h e s u m mar y will b e c o m p ute d usi n g a Mi x e d 
M o del f or Re peate d Meas ures ( M M R M) t hat will i n cl u de fi x e d effect fact ors f or treat me nt 
gr o u p, ra n d o mizati o n str ata ( M S A- C or M S A- P, P ossi ble or Pr o ba ble M S A dia g n osis, a n d 
c o u ntr y), visit, a n d t he treat me nt gr o u p b y visit i nter acti o n. B aseli n e m o difie d U M S A R S s c ore 
will e nt er t he m o del as a c o vari ate, a n d s u bject will b e a ra n d o m effect. I nterc urr e nt e v e nts t hat 
lea d t o disc o nti n u ati o n, or lac k of data, will be ha n dl e d b y o nl y usi n g t he- o n treat me nt data.  
M M R M- base d esti mates (i. e., least-s q uares mea n [ L S M] wit h c orres p o n di n g S D a n d 9 5 % CI) 
of val ues a n d c h a n ges fr o m bas eli ne will be pres e nte d b y treat me nt gr o u p a n d wee k. I n 
a d diti o n, t he L S M differ e nce i n c ha n ge fr o m bas eli n e bet wee n treat me nt gr o u ps ( B H V- 3 2 4 1  
place b o) at We e k 4 8 wit h c orr es p o n di n g S D, 9 5 % CI, a n d p- val ue fr o m M M R M will als o be 
pres e nte d.  Si nc e t he esti mate is c alc ulat e d usi n g a li keli h o o d- base d a p pr oac h, t h e a nal ysis is 
base d o n a Missi n g at Ra n d o m ( M A R) ass u m pti o n. Se nsiti vit y a nal ys es will i ncl u de m ulti ple 
i m p utati o n of missi n g data usi n g a c o p y i n cre me nt fr o m refere n ce met h o d.  


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 9 6 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
O bser ve d val ues a n d c ha n g es fr o m baseli ne i n t he m o difie d U M S A R S s c ores will als o be 
s u m mariz e d usi n g descri pti ve st atistics o ver ti me b y treat me nt gr o u p d uri n g t he R a n d o mizati o n 
P hase.
D etails of t h es e a nal yses are pr o vi de d i n t he S A P.
9. 4. 3
S e c o n d ar y E n d p oi nt( s)
T he s ec o n dar y e n d p oi nts, M S A- Q o L m ot or s u bscale a n d n o n- m ot or s u bscal e s c ores, U M S A R S 
Part I a n d P art II t otal s c ore, P GI- S, C GI- S, U M S A R S P art III, a n d U M S A R S Part I V are
c ha n ge-fr o m- baseli ne e n d p oi nts a n d will be a nal y ze d f or mI T T s u bje cts usi n g t he s a me 
strate g y as des cri be d f or t he pri mar y esti m a n d as t he pri mar y e n d p oi nt. T h e U M S A R S Part I 
a n d Part II t ot al sc ore will e xcl u de ite m 1 1 fr o m Part I (s e x ual f u ncti o n).
T he ot her s ec o n dar y e n d p oi nt, t he C GI-I, d oes n ot h a ve a bas eli ne val ue. T h e esti ma n d f or t his 
e n d p oi nt will p urs ue a h y p ot h eti cal strate g y of esti m ati n g t h e effe ct of B H V- 3 2 4 1 relati ve t o 
place b o h a d all s u bjects sta y e d o n tre at m e nt. T h e a nal ysis will us e t he mI T T p o p ulati o n.  T he 
p o p ulati o n s u m mar y will be t h e differe n ce i n t he C GI-I bet wee n pl ace b o a n d B H V- 3 2 4 1
treat e d s u bjects at t he Wee k 4 8 visit. T h e s u m mar y will be c o m p ute d usi n g a n a nal ysis of 
varia nce, t hat will i ncl u de fi xe d eff ect f act ors f or tr e at me nt gr o u p, baseli ne C GI- S s c ore, a n d 
ra n d o miz ati o n str ata ( M S A- C or M S A- P, P ossi ble or Pr o ba ble M S A dia g n osis a n d c o u ntr y).
I nterc urre nt e ve nts will be ha n dle d b y o nl y usi n g t he o n-treat me nt d ata.
F urt her d etails o n t he se c o n dar y a nal ys es are pr o vi d e d i n t he S A P.
9. 4. 4
E xt e n si o n P h a s e A n al y si s
9. 4. 5
A dj u st m e nt f or M ulti pli cit y
T y pe- 1 err or will be c o ntr olle d f or t he pri mar y a n d k e y s ec o n dar y effi cac y e n d p oi nts b y t esti n g 
t he m wit h a gat e- kee pi n g pr o ce d ure. T he pri mar y e n d p oi nt will b e test e d at a t w o-si de d al p ha 
le vel of 0. 0 5. If t his test is si g nific a nt, t h e n t he ke y s ec o n dar y efficac y e n d p oi nts will be t este d 
u na dj uste d p- val ues f or t he ke y s ec o n dar y e n d p oi nts will be pres e nte d o nl y f or d escri pti v e 
p ur p os es.
N o atte m pt will b e ma d e t o a dj ust f or m ulti plicit y w he n testi n g t he n o n -ke y se c o n dar y or 
 e n d p oi nts. A n y e n d p oi nts s u bjecte d t o si g nifica n ce t esti n g are e val u ate d at a n 
u na dj uste d t w o -si de d al p ha le vel of 0. 0 5.
9. 4. 6
Mi s si n g D at a
If m ore t ha n 1 0 % of t he s u bjects dis c o nti n u e, t he n t h e missi n g dat a will b e m ulti pl y i m p ut e d 
f or t he pri m ar y e n d p oi nt usi n g a c o p y i n cre m e nt fr o m refere n ce met h o d. 
C CI
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 9 7  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
9. 4. 7
A n al y si s of S af et y
T he I n vesti g at ors det er mi ne t he i nte nsit y of A Es a n d t he rel ati o ns hi p of A Es t o st u d y t hera p y. 
T he I n vesti g at o
of t he M e dic al Dicti o nar y f or Re g ulat or y Acti vities ( Me d D R A) a vaila bl e. A Es will be 
pres e nte d b y s yste m or g a n class a n d pref erre d t er m, or dere d b y t he o v erall fr e q ue nc y of e ve nts.  
If a s u bject h a d a n a d verse e ve nt wit h differ e nt i nte nsities o ver ti me, t he n o nl y t he greatest 
i nte nsit y is re p orte d. 
A Es are ta b ul ate d i n all treate d s u bje cts.  All de at hs a n d S A Es are liste d f or e nr olle d s u bjects 
wit h o ut re gar d t o o ns et. 
T he fre q ue n cies of t he f oll o wi n g safet y e ve nts are s u m mari ze d b y tr eat me nt gr o u p a n d o v erall 
f or treat e d s u bjects:  S A Es; all A Es, n o n-s eri o us A Es; A Es b y i nte nsit y; A Es b y relate d ness 
a n d cli nicall y rele va nt la b orat or y a b n or m alities. 
Gra p hi cal a n d ta b ular dis pla ys of o n-tr eat me nt li ver f u ncti o n t est res ults ar e pr o vi de d. 
Safet y will b e prese nt e d s e parat el y f or t h e d o u ble- bli n d p hase a n d f or t he o p e n-la bel e xt e nsi o n 
p hase, o verall a n d b y ra n d o mize d ar m. 
9. 5 
S c h e d ul e of A n al y s e s 
T he first s c he d ule d u n bli n de d a nal ysis will be t he pri mar y a nal ysis, w hic h will b e c o n d uct e d 
after t h e last s u bj ect c o m pletes t heir We e k 4 8 visit a n d t he dat a base has bee n l oc ke d.  T his will 
s u m mariz e all effic ac y, safet y, la b or at or y a n d ot her data c olle cte d t hr o u g h t he e ntire st u d y. I n 
a d diti o n, d ata ma y be l oc ke d, bli n de d a n al yses c o n d ucte d, a n d r e p orts pr o d uce d as re q uire d t o 
s u p p ort safet y m o nit ori n g or re g ulat or y re q uire m e nts. 
I n a d diti o n t o t he a b o ve, a D at a M o nit ori n g C o m mitt ee (s ee Secti o n 1 0. 2) will re vie w effica c y 
a n d s afet y data o n a peri o dic b asis, wit h acti vities f ull y des cri be d i n a D M C C harter. 
A fi nal a nal ysis will be c o n d ucte d at t h e e n d of t h e o pe n-la bel e xt e nsi o n p has e.
1 0 E T HI C S A N D R E S P O N SI BI LI TI E S
1 0. 1 
G o o d Cli ni c al Pr a cti c e 
T his st u d y will be c o n d uct e d i n c o m pli a nce wit h t he pr ot oc ol, G o o d Cli nical Practice ( G C P), 
G o o d La b or at or y Practice ( G L P), I nt er nati o nal C o nf ere nce o n Har m o nizati o n g ui d eli n es , a n d 
all a p plic a ble re g ulati o ns, i ncl u di n g t he Fe d eral F o o d, Dr u g a n d C os metic Act, U. S. a p plica ble 
C o de of Fe d eral R e g ulati o ns (title 2 1), a n y I E C re q uire me nts relati ve t o cli nical st u dies. T he 
st u d y will als o be c o n d uct e d i n c o m pli a nce wit h t he rec o m m e n dati o ns lai d d o w n i n t he m ost 
rece nt v ersi o n of t he D eclarati o n of Helsi n ki, wit h t h e e xce pti o n t h at re gistrati o n of s uc h P hase 
1 trials i n a p u bli cl y accessi ble d ata b ase is n ot m a n d at or y. 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa ge 9 8  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
T his st u d y will be c o n d uct e d i n c o m pli a nce wit h t he pr ot oc ol. T h e pr ot oc ol, a n y a m e n d me nts 
a n d t he i nf or me d c o nse nt f or m(s) will re cei v e I nstit uti o nal R e vie w B oar d/I n de pe n de nt Et hics 
C o m mittee (I R B/I E C) a p pr o v al/f a v ora ble o pi ni o n pri or t o i nitiati o n of t h e st u d y. 
All s eri o us breac h es m ust be re p ort e d t o Bi o h a ve n ( or desi g nee) i m me diatel y. A seri o us br eac h 
is a breac h of t he c o n diti o ns a n d pri n ci pl es of G C P i n c o n necti o n wit h t h e st u d y or pr ot oc ol, 
w hic h is li kel y t o aff ect, t o a si g nifica nt d e gree, t he s afet y or p h ysic al or m e ntal i nte grit y of t h e 
patie nts of t he st u d y or t h e s cie ntific v al ue of t he st u d y. 
St u d y pers o n nel i n v ol v e d i n c o n d u cti n g t his st u d y will be q ualifi e d b y e d ucati o n, trai ni n g, a n d 
e x perie n ce t o perf or m t heir res pecti ve tas k(s). 
T his st u d y will n ot use t he ser vi ces of st u d y pers o n n el w here s a ncti o ns ha ve be e n i n v o ke d or 
w here t here has be e n scie ntifi c mis c o n d u ct or fra u d ( e. g., l oss of me dic al lice ns ure, 
de bar me nt). 
1 0. 2 
D at a M o nit ori n g C o m mitt e e
A n i n de pe n de nt D ata M o nit ori n g C o m mitt ee ( D M C) will be est a blis he d f or t his st u d y a n d its 
acti viti es, pr ocess es a n d g ui da nce f or t he o v ersi g ht a n d a d here nc e t o D M C practi ces will b e 
descri be d i n a se parat e D M C C harter. T h e D M C will be c o m p os e d of at least 2 i n de pe n d e nt 
p h ysicia ns a n d 1 i n d e pe n de nt statisticia n. I n t his st u d y, t he maj or res p o nsi biliti es of t he D M C 
will be t o m o nit or t he be n efit/ris k of B H V- 3 2 4 1, t o ass ess w het her t here are u na cce pta bl e 
s afet y fi n di n gs after a d mi nistrati o n of B H V- 3 2 4 1 t hat re q uire m o dif yi n g or st o p pi n g t he st u d y 
a n d p ote ntiall y t o a dj u dicate st u d y dr u g-relat e d ness of S A Es a n d deat hs t hat are u ne x pecte d 
a n d/ or at y pical f or parti ci pa nts wit h M S A. 
1 0. 3 I n stit uti o n al R e vi e w B o ar d/I n d e p e n d e nt Et hi c s C o m mitt e e 
T he I n vesti g at ors a gree t o pr o vi de t he I E C wit h all a p pr o priate d o c u me nts, i ncl u di n g a c o p y of 
t he pr ot oc ol/a me n d m e nts, I C Fs, a d v ertisi n g te xt (if a n y), I n vesti gat or br o c h ure (if a n y) a n d a n y 
ot her writt e n i nf or m ati o n pr o vi de d t o st u d y s u bj ects. T he tri al will n ot be gi n at a site u ntil t he 
I n vesti gat ors ha v e o btai ne d t he I E C fa v ora ble writte n a p pr o vals f or t he a b o ve- me nti o ne d st u d y 
d oc u me nts. A pr o perl y e xec ut e d writt e n I C F s hall be rea d, si g ne d a n d d ate d b y e ac h s u bje ct 
pri or t o e nt eri n g t h e tri al or pri or t o p erf or mi n g a n y st u d y pr oce d ure.  
I n t he e ve nt t hat t he pr ot oc ol is a me n de d, t he re vis e d pr ot oc ol m ust b e a p pr o ve d b y t he I E C 
pri or t o its i m ple me nt ati o n, u nless t he c h a n ges i n v ol ve o nl y l o gistical or a d mi nistrati ve as pe cts 
of t he tri al. If a re vise d I C F is i ntr o d uc e d d uri n g t h e st u d y, t he ne w versi o n of t h e I C F m ust be 
be o btai n e d.  
a me n d m e nts (if a n y) b ef ore i nitiati n g t h e st u d y.  
I C Fs t o re g ul at or y a ut h orities w he n necessar y. 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa ge 9 9 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
1 0. 4
I nf or m e d C o n s e nt
I n vesti gat ors m ust e ns ure t hat patie nts, or, i n t h os e sit uati o ns w here c o nse nt ca n n ot be gi v e n b y 
patie nts, t heir le gall y ac ce pt a ble r e prese nt ati v es, are clearl y a n d f ull y i nf or me d a b o ut t h e 
p ur p os e, p ote nti al ris ks, a n d ot h er critical iss ues re gar di n g cli nical st u dies i n w hi c h t he y 
v ol u nteer t o partici p ate.
Bi o ha ve n ( or desi g n ee) will pr o vi de t h e I n vesti g at or wit h a n a p pr o pri ate (i.e., Gl o bal or L ocal) 
s a m ple i nf or me d c o ns e nt f or m w hic h will i ncl u de all ele m e nts re q uir e d b y I C H, G C P a n d 
a p plic a ble r e g ulat or y r e q uire me nts. T h e s a m pl e i nf or me d c o ns e nt f or m will a d here t o t he 
et hic al pri n ci pl es t hat ha v e t heir ori gi n i n t he Declar ati o n of Helsi n ki.
Bef ore t he p ote ntial s u bj ect has u n der g o n e a n y st u d y-relat e d Scree ni n g pr o ce d ures, t h e nat ur e 
of t he st u d y a n d t h e p ote ntial ris ks ass ociate d wit h it will be e x plai n e d t o t h e s u bject, a n d t he 
s u bject will be gi v e n a n o p p ort u nit y t o as k q uesti o ns t o his or her s atisfacti o n. Aft er t he 
q uesti o ns are a ns w ere d, b ut bef ore pr ocee di n g f urt her, t he s u bject m ust rea d, si g n a n d dat e a n 
I R B/I E C a p pr o ve d writte n i nf or me d c o ns e nt f or m. T he si g ne d a n d date d I C F will b e retai ne d at 
A n y re visi o ns t o t he pr ot o c ol or I C F will b e re vi e we d a n d a p pr o ve d b y t h e I R B/I E C a n d 
s u bjects will b e i nf or m e d of I C F c ha n ges a n d d oc u m e nt c o nti n ui n g c o ns e nt b y si g ni n g a n d 
dati n g t h e re vise d v ersi o n of t he I C F.
di a n or le g all y acce pta bl e 
re pres e ntati ve, a n d t he patie nt s u bse q ue ntl y b ec o m es ca pa bl e of ma ki n g a n d c o m m u nic ati n g 
t heir i nf or me d c o ns e nt d uri n g t he st u d y, t he n t h e c o nse nt m ust a d diti o nall y be o btai n e d fr o m 
t he patie nt.
T he i nf or m e d c o ns e nt f or m m ust als o i ncl u de a stat e me nt t h at Bi o h a ve n a n d its re pres e nt ati v es 
a n d re g ulat or y a ut h orities ma y ha ve direct access t o patie nt rec or ds.
T he ri g hts, s afet y, a n d w ell- bei n g of st u d y patie nts are t he m ost i m p ort a nt c o nsi d erati o ns a n d 
s h o ul d pre vail o v er i nt erests of s cie nc e a n d s oci et y.
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa g e 1 0 0 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
1 0. 5
C a s e R e p ort F or m s
A n I n vesti gat or is re q uire d t o pre p are a n d mai ntai n a de q uate a n d acc ur ate case hist ories 
desi g ne d t o re c or d all o bs er vati o ns a n d ot her data perti ne nt t o t h e i n vesti g ati o n of eac h st u d y 
patie nt. D ata r e p orte d o n t h e C R F t hat are deri ve d fr o m s o urce d oc u m e nts m ust be c o nsiste nt 
wit h t he s o urce d o c u me nts or t he dis cre p a nci es m ust be e x plai ne d.
Electr o nic C R Fs will b e pre pare d f or all d ata c oll ecti o ns fiel ds w he n E D C is bei n g us e d.
T he c o nfi d e nti alit y of rec or ds t hat c o ul d i de ntif y pati e nts m ust be pr ot ect e d, res pecti n g t he 
pri vac y a n d c o nfi de ntialit y r ul es i n ac c or da nc e wit h t he a p pli ca bl e re g ulat or y re q uir e me nt(s).
T he I n vesti g at or m ust r etai n a c o p y of t h e C R Fs, i n cl u di n g rec or ds of c ha n ges a n d c orrecti o ns. 
If E D C is bei n g use d, si g nat ur es will be o btai ne d ele ctr o nic all y a n d a c o p y of t h e el ectr o nic 
C R Fs will be pr o vi de d ( or t h e dat a fr o m t h e C R Fs) f or f ut ure refere n ce.
1 0. 6
R e c or d s M a n a g e m e nt a n d R et e nti o n
I n acc or da nce wit h t h e pri nci ples of G C P a n d G L P, t he st u d y ma y be i ns pect e d b y re g ulat or y 
a ut h orities, t he S p o ns or a n d C R O. T he S p o ns or ( or s pecifi e d desi g ne e) is e ntitle d t o ac cess 
i nf or mati o n a b o ut t he stat us of t he st u d y a n d t o re vie w t he ori gi nal d oc u m e nts of t he st u d y.
T he I n vesti g at or m ust r etai n all st u d y rec or ds a n d s o urce d oc u m e nts f or t he ma xi m u m re q uir e d 
b y t he a p plica ble re g ul ati o ns a n d g ui deli nes, or i nstit uti o n pr oce d ur es or f or t he peri o d of ti m e 
s pecifie d b y t he s p o ns or, w hic he ver is l o n g er. T he I n vesti gat or m ust c o nt act t he S p o ns or pri or 
t o destr o yi n g a n y r ec or ds ass ociat e d wit h t his st u d y if n ot wit hi n t h ese g ui deli nes.
Bi o ha ve n will n otif y t he I n vesti gat ors w he n t he st u d y files f or t his st u d y ar e n o l o n ger n ee de d.
If t he I n vesti g at or wit h dr a ws fr o m t he st u d y (i.e., r etire me nt, r el oc ati o n), t h e rec or ds s hall be 
tra nsferre d t o a m ut uall y a gr ee d u p o n desi g n ee.  N oti ce of s uc h tra nsfer will be gi v e n i n writi n g 
t o Bi o ha ve n.
It is t he res p o nsi bilit y of t he I n vesti gat or t o e ns ure t h at t he c urre nt dis p ositi o n rec or d of 
i n vesti gati o nal pr o d uct (t h ose s u p plie d b y t he s p o ns or) is mai nt ai ne d at eac h st u d y site w her e 
t he st u d y dr u g is i n ve nt orie d a n d dis pe ns e d. Rec or ds or l o gs m ust c o m pl y wit h a p plica ble 
re g ulati o ns a n d g ui deli nes a n d s h o ul d i ncl u de:
A m o u nt of st u d y dr u g recei ve d a n d place d i n st ora ge area;
La bel I D n u m b er or batc h n u m ber or Kit n u m ber as s pecifie d f or t he pr ot o c ol;
C CI


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa g e 1 0 1  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
 A m o u nt dis pe ns e d t o a n d r et ur ne d fr o m eac h patie nt; 
 A m o u nt tra nsferre d t o a n ot her area or site f or dis pe nsi n g or st ora ge if a p plic a ble;
 A m o u nt of dr u g l ost or w aste d; 
 A m o u nt destr o ye d at t he site if a p plica ble; 
 A m o u nt ret ur ne d t o s p o ns or, if a p plica ble; 
 Retai n e d s a m pl es f or bi oa vaila bilit y/ bi oe q ui val e nce, if a p pli ca bl e;
Rec or d of dat es a n d i nitials of pers o n nel res p o nsi ble f or I M dis pe nsi n g a n d acc o u nta bilit y.
1 0. 7 
S o ur c e D o c u m e nt ati o n 
A n I n vesti gat or is re q uire d t o pre p are a n d mai ntai n a de q uate a n d acc ur ate case hist ories 
desi g ne d t o re c or d all o bs er vati o ns a n d ot her data perti ne nt f or all s u bj ects o n st u d y.  
If s o urce d oc u me nts are cre ate d t o s u p p ort t he c oll ecti o n of st u d y i nf or m ati o n, t his m ust be 
retai n e d wit h t h e ot her perti ne nt me dical rec or d f or e ac h patie nt f or v erific ati o n of d ata p oi nts, 
u nless ot her wise i nstr ucte d b y t h e S p o ns or ( or s pecifie d desi g ne e) t o e nter dat a dire ctl y o n t he 
C R F. 
1 0. 8 
St u d y Fil e s a n d R e c or d R et e nti o n 
T he S p o ns or d oes n ot re q uire ori gi nal d oc u me nts t hat ha ve alrea d y be e n s ca n ne d a n d e nt ere d 
i nt o t he e T M F s yste m be f or w ar de d t o t he S p o ns or. A n y ori gi nal d oc u me nts (i. e., 1 5 7 2, si g ne d 
fi na nci al discl os ure, si g ne d I C F, etc.) will be r etai ne d i n t he re g ulat or y bi n der at t he st u d y site. 
T he C R O will d o a fi nal T M F rec o nciliati o n t o e ns ur e all st u d y files a n d r e g ulat or y d oc u me nts 
ha ve bee n c orrectl y u pl oa d e d t o t h e T M F pri or t o t h e cl ose or ter mi nati o n of t h e st u d y. A n y 
materials or d oc u me nts t o s u p p ort t he cli nical trial o utsi de of t he e T M F (i.e., rater trai ni n g 
ta pes) s h o ul d be m ai nt ai ne d b y t he C R O. T he S p o ns or will be c o ntacte d t o deter mi ne w het h er 
t he st u d y d oc u m e nts/ m aterials t h at are r etai ne d o utsi de of t he T M F will b e f or war de d t o t he 
S p o ns or, destr o ye d or ke pt at t he C R O or at a n ot her facilit y f or a l o n ger peri o d of ti m e at t he 
S p o ns or's e x pe nse. 
1 1 A M E N D M E N T S 
Pr ot oc ol m o dificati o ns, e xce pt t h os e i nte n de d t o re d uce i m me di ate ris k t o st u d y s u bjects, ma y 
be ma de o nl y b y t he S p o ns or ( or s pecifie d desi g nee). A pr ot oc ol c ha n g e i nt e n de d t o eli mi nat e 
a n a p pare nt i m me diate ha zar d t o s u bj ects m a y be i m ple me nte d i m me diat el y, pr o vi de d t he 
I R B/I E C is n otifie d wit hi n 5 da ys. 
 
 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa g e 1 0 2  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
A n y per ma ne nt c ha n ge t o t he pr ot o c ol m ust b e ha n dl e d as a pr ot oc ol a m e n d me nt. T he writte n 
a me n d m e nt m ust b e s u b mitte d t o t he I R B/I E C a n d t h e I n vesti gat or m ust a wait a p pr o val bef ore 
i m ple me nti n g t he c ha n ges. T he S p o ns or will s u b mit pr ot oc ol a me n d m e nts t o t h e a p pr o priate 
re g ulat or y a ut h orities f or a p pr o val. 
If i n t he j u d g me nt of t he I R B/I E C, t he I n vesti gat or, a n d/ or t he S p o ns or, t he a me n d m e nt t o t he 
pr ot oc ol s u bsta ntiall y c ha n g es t he st u d y desi g n a n d/ or i ncreas es t h e p ote ntial ris k t o t he s u bj ect 
a n d/ or has a n i m pact o n t he s u bje ct's i n v ol ve me nt as a st u d y parti ci pa nt, t he c urre ntl y a p pr o ve d 
writte n i nf or me d c o ns e nt f or m will re q uire si mil ar m o dificati o n. I n s uc h c ases, i nf or me d 
c o nse nt will b e re ne we d f or s u bje cts e nr olle d i n t he st u d y bef ore c o nti n ue d p artici pati o n. 
1 2 S T U D Y R E P O R T A N D P U B LI C A TI O N S 
T he S p o ns or ( or s pecifie d d esi g nee) is res p o nsi bl e f or pre pari n g a n d pr o vi di n g t h e a p pr o priate 
re g ulat or y a ut h orities wit h cli nical st u d y r e p orts acc or di n g t o t he a p pli ca bl e re g ulat or y 
re q uire m e nts.  
T he p u bli cati o n p oli c y of t he S p o ns or is disc uss e d i n t he I n vesti g at or's Cli ni cal R es earc h 
A gree me nt. 
1 3 S T U D Y DI S C O N TI N U A TI O N 
B ot h t he S p o ns or a n d t he Pri n ci pal I n vesti g at or reser ve t he ri g ht t o t er mi n ate t he st u d y at t he 
Pri nci pal I
t h e S p o ns or ( or s pecifie d 
desi g nee) will i nf or m t he a p pr o pri ate r e g ulat or y a ut h orities of t h e ter mi nati o n of t h e st u d y a n d 
t he reas o ns f or its t er mi n ati o n, a n d t he Pri nci pal I n v esti gat or will i nf or m t he I R B/I E C of t he 
s a me. I n ter mi nati n g t h e st u d y, t he S p o ns or a n d t he Pri nci pal I n v esti gat or will ass ure t hat 
i nt erests. 
1 4 C O N FI D E N TI A LI T Y 
All i nf or mati o n ge n erate d i n t his st u d y is c o nsi dere d hi g hl y c o nfi d e nti al a n d m ust n ot be 
dis cl os e d t o a n y p ers o n or e ntit y n ot dir ectl y i n v ol v e d wit h t he st u d y u nl ess pri or writte n 
c o nse nt is gai n e d fr o m t h e S p o ns or ( or s pecifie d desi g nee). H o we ver, a ut h ori ze d re g ulat or y 
officials, I R B/I E C pers o n nel, t he S p o ns or a n d its a ut h orize d re pr es e ntati ves are all o we d f ull 
access t o t h e rec or ds. 
I de ntifi cati o n of s u bjects a n d C R Fs s hall be b y S u bje ct n u m bers o nl y. If r e q uire d, t he s u bject's 
f ull na m e ma y b e ma de k n o w n t o a n a ut h orize d r e g ulat or y a g e nc y or ot h er a ut h ori ze d offi cial.  
T he S p o ns or ma y a p pr o ve t he s hari n g of de-i de ntifie d data fr o m t his st u d y t o be ma de 
a vail a ble t o res earc h ers f or t he p ur p ose of a d v a nci n g t he u n dersta n di n g of ne ur ol o gic or 
ps yc hiatri c ill ness, rati n g s c ales, or tri al m et h o d ol o g y f or t he affecte d p o p ul ati o n. I n a n y 
p u blicati o n of t his data, c o nfi de ntialit y of i n di vi d ual s u bjects will b e pr ote cte d. 
 
 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa g e 1 0 3 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
1 5
A P P E N DI C E S
1 5. 1
A P P E N DI X I - N a m e s of St u d y P er s o n n el
S p o ns or:
Bi o ha ve n P h ar mace uticals, I n c.
2 1 5 C h urc h Stre et
Ne w Ha ve n, C T 0 6 5 1 0
M e dical M o nit ors a n d M e dical 
M o nit or B ac k- u p:
E U/ E M E A:
E m ail: 
P h o n e: 
N o rt h A m eric a:
E m ail: 
P h o n e: 
Ba c k- u ps:
Bi o ha v e n P h ar mac e uticals, I nc. 
Ne w Ha ve n, C o n nectic ut 0 6 5 1 0 
U S A
E m ail :
P h o n e: 
Bi o ha ve n P h ar mac e uticals, I nc.
Ne w Ha ve n, C o n ne ctic ut 0 6 5 1 0
U S A
E m ail: 
P h o n e: 
Cli nical R esearc h
Or ga nizati o n:
P P D
P P D
P P D
P P D
C CI
P P D
P P D
P P D
P P D
P P D
P P D
P P D
C CI
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
C CI
P P D


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa g e 1 0 4  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
1 6 R E F E R E N C E S CI T E D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7 
C o nfi de nti al  
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y 
Pa g e 1 0 5  of 1 0 6  
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


B H V 3 2 4 1- 3 0 1; Cli nical Pr ot o c ol V 0 7
C o nfi de nti al
B H V- 3 2 4 1 i n A d ult S u bje cts wit h M ulti ple S yste m Atr o p h y
Pa g e 1 0 6 of 1 0 6
 
A p pr o v e d Versi o n 0 7; 2 0 J a n 2 0 2 1
C LI NI C A L P R O T O C O L A P P R O V A L F O R M
Pr ot o c ol Title: A R a n d o mize d, D o u ble- Bli n d, Pl a ce b o C o nt r olle d, P ar allel- Gr o u p St u d y t o E v al u ate t he 
Effic ac y a n d S af et y of B H V- 3 2 4 1 i n S u bjects wit h M ulti ple S yste m Atr o p h y ( M S A)
St u d y N o: B H V 3 2 4 1- 3 0 1
Dr aft O ri gi n al Pr ot o c ol D ate: 1 8 D ec 2 0 1 8
Pr ot o c ol Versi o n N o: V 0 7
Pr ot o c ol Ve rsi o n D ate: 2 0 J a n 2 0 2 1
T his st u d y pr ot oc ol w as s u bje ct t o critical re vie w a n d has bee n a p pr o ve d b y t he a p pr o pri ate 
pr ot oc ol re vie w c o m mittee of t h e s p o ns or.  T he i nf or mati o n c o ntai ne d i n t his pr ot oc ol is 
c o nsiste nt wit h:
-
T he c urre nt ris k- be nefit e val uati o n of t he i n vesti g ati o nal pr o d uct.
-
T he m oral, et hical a n d s cie ntifi c pri nci ples g o ver ni n g cli ni cal r esearc h as s et o ut i n t h e 
D eclarati o n of Helsi n ki, a n d pri nci ples of G C P as des cri be d i n 2 1 C F R parts 5 0, 5 4, 5 6 
a n d 3 1 2 a n d ac c or di n g t o a p plic a ble l ocal re q uir e me nts.
-
T he I n vesti g at or will be s u p pli e d wit h details of a n y si g nifica nt or ne w fi n di n gs, 
i ncl u di n g a d verse e v e nts, relati n g t o treat me nt wit h t he i n vesti g ati o n al pr o d uct.
N a m e a n d Title
Si g n at ure A p pr o v al
D ate
A ut h or/ Pr ot oc ol Writer:
 
 
Bi o ha v e n P h ar mac e uticals
(I c o nfir m, Q C c o m plete d f or re q uire d ele me nts)
Cli nical O perati o ns:
Bi o ha v e n P h ar mac e uticals
Bi ostatistics:
Bi o ha v e n P h ar mac e uticals
M e dical Lea d:
Bi o ha v e n P h ar mac e uticals
Re g ulat or y Affairs:
Bi o ha v e n P h ar mac e uticals
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D
P P D

SAP_001.pdf: 




PPD
PPD
CCI
PPD
PPD
PPD
PPD
PPD
PPD
PPD


CCI
CCI


CCI


CCI
CCI




CCI
CCI
CCI
CCI


CCI
CCI
CCI
CCI
CCI
















CCI


CCI
CCI


CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI








CCI


CCI


CCI


CCI


CCI




CCI




CCI












CCI


CCI
















CCI


CCI


CCI


CCI


CCI


CCI


CCI


CCI










CCI








CCI




CCI
CCI
CCI


CCI
CCI


CCI
CCI








CCI


CCI


CCI


CCI